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RÉSUMÉ 
 
 La tolérance immunitaire dépend de la distinction entre le soi et le non soi par 
le système immunitaire. Un bris dans la tolérance immunitaire mène à l'auto-
immunité, qui peut provoquer la destruction des organes, des glandes, des 
articulations ou du système nerveux central. Le diabète auto-immun, également 
connu sous le nom diabète juvénile et diabète de type 1, résulte d'une attaque auto-
immune sur les cellules β pancréatiques sécrétrices d’insuline, localisées au niveau 
des îlots de Langerhans du pancréas. Bien que le diabète auto-immun soit traitable 
par une combinaison d’injections quotidiennes d’insuline d’origine exogène, de 
régime et d'exercices, beaucoup de complications chroniques peuvent se manifester 
chez les patients, y compris, mais non limitées à, la cécité, les maladies 
cardiovasculaires, l’insuffisance rénale et l'amputation. En raison des nombreuses 
complications liées au diabète auto-immun à long terme, la recherche continue afin 
de mieux comprendre tous les facteurs impliqués dans la progression de la maladie 
dans le but de développer de nouvelles thérapies qui empêcheront, renverseront et/ou 
traiteront cette maladie.  
  
 Un rôle primordial dans la génération et l'entretien de la tolérance immunitaire 
a été attribué au nombre et à la fonction des sous-populations de cellules régulatrices. 
Une de ces populations est constituée de cellules T CD4-CD8- (double négatives, 
DN), qui ont été étudiées chez la souris et  l'humain pour leur contribution à la 
tolérance périphérique, à la prévention des maladies et pour leur potentiel associé à la 
thérapie cellulaire. En effet, les cellules de T DN sont d'intérêt thérapeutique parce 
qu'elles montrent un potentiel immunorégulateur antigène-spécifique dans divers 
cadres expérimentaux, y compris la prévention du diabète auto-immun. D’ailleurs, en 
utilisant un système transgénique, nous avons démontré que les souris prédisposées 
au diabète auto-immun présentent peu de cellules T DN, et que ce phénotype 
contribue à la susceptibilité au diabète auto-immun. En outre, un transfert des cellules 
T DN est suffisant pour empêcher la progression vers le diabète chez les souris 
prédisposées au diabète auto-immun. Ces résultats suggèrent que les cellules T DN 
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puissent présenter un intérêt thérapeutique pour les patients diabétiques. Cependant, 
nous devons d'abord valider ces résultats en utilisant un modèle non-transgénique, qui 
est plus physiologiquement comparable à l'humain.     
  
 L'objectif principal de cette thèse est de définir la fonction immunorégulatrice 
des cellules T DN, ainsi que le potentiel thérapeutique de celles-ci dans la prévention 
du diabète auto-immun chez un modèle non-transgénique. Dans cette thèse, on 
démontre que les souris résistantes au diabète auto-immun présentent une proportion 
et nombre absolu plus élevés de cellules T DN non-transgéniques, lorsque comparées 
aux souris susceptibles. Cela confirme une association entre le faible nombre de 
cellules T DN et la susceptibilité à la maladie. On observe que les cellules T DN 
éliminent les cellules B activées in vitro par une voie dépendante de la voie perforine 
et granzyme, où la fonction des cellules T DN est équivalente entre les souris 
résistantes et prédisposées au diabète auto-immun. Ces résultats confirment que 
l'association au diabète auto-immun est due à une insuffisance en terme du nombre de 
cellules T DN, plutôt qu’à une déficience fonctionnelle. On démontre que les cellules 
T DN non-transgéniques éliminent des cellules B chargées avec des antigènes d'îlots, 
mais pas des cellules B chargées avec un antigène non reconnu, in vitro. Par ailleurs, 
on établit que le transfert des cellules T DN activées peut empêcher le développement 
du diabète auto-immun dans un modèle de souris non-transgénique. De plus, nous 
observons que les cellules T DN migrent aux îlots pancréatiques, et subissent une 
activation et une prolifération préférentielles au niveau des ganglions pancréatiques. 
D'ailleurs, le transfert des cellules T DN entraîne une diminution d'auto-anticorps 
spécifiques de l'insuline et de cellules B de centres germinatifs directement dans les 
îlots, ce qui corrèle avec les résultats décrits ci-dessus. Les résultats présentés dans 
cette thèse permettent de démontrer la fonction des cellules T DN in vitro et in vivo, 
ainsi que leur potentiel lié à la thérapie cellulaire pour le diabète auto-immun.      
 
Mots-clés : Cellules T double négatives, diabète auto-immun, immunorégulation, 
souris transgénique, souris non-transgénique, antigène-spécifique. 
 iii 
ABSTRACT 
 
 Immune tolerance is dependent on the immune system discriminating between 
self and non-self. A break in immune tolerance results in autoimmunity, which can 
lead to the destruction of healthy organs, glands, joints or the central nervous system. 
Any disease that results from such an aberrant immune response is termed an 
autoimmune disease. Autoimmune diabetes, which is also referred to as juvenile 
diabetes and type 1 diabetes, results from an autoimmune attack on the insulin-
producing β cells located within the islets of Langerhans of the pancreas. Although 
autoimmune diabetes is treatable through a combination of insulin therapy, diet and 
exercise, many chronic complications may arise in patients, including, but not limited 
to, blindness, cardiovascular disease, kidney failure and amputation. Due to the many 
complications associated with long-term autoimmune diabetes, research continues to 
better understand all the factors implicated in disease progression in order to develop 
new therapies that will prevent, reverse and/or cure this disease.  
  
 A prominent role in the generation and maintenance of immune tolerance has 
been attributed to the number and function of regulatory cell subsets. One of these 
regulatory cell populations, namely CD4-CD8- (double negative, DN) T cells, have 
been studied in both mice and humans for their contribution to peripheral tolerance, 
disease prevention and their potential for use in cellular therapy. DN T cells are of 
particular therapeutic interest because they exhibit an antigen-specific 
immunoregulatory potential in various experimental settings, including the 
prevention of autoimmune diabetes. Indeed, using a transgenic system, we have 
shown that autoimmune diabetes-prone mice carry fewer DN T cells and that this 
phenotype contributes to autoimmune diabetes susceptibility, where a single transfer 
of DN T cells is sufficient to prevent diabetes progression in otherwise autoimmune 
diabetes-prone mice. These results suggest that DN T cells may be of therapeutic 
interest for diabetic patients. However, we must first validate these results using a 
non-transgenic setting, which is more physiologically relevant to humans.  
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 The main objective of this thesis is to determine the immunoregulatory 
function of the DN T cells as well as the therapeutic potential of these cells in the 
prevention of autoimmune diabetes in the non-transgenic setting. Here, we show that 
diabetes-resistant mice present with a higher proportion and cell number of DN T 
cells than diabetes-susceptible mice in the non-transgenic setting, which associates a 
deficiency in DN T cell number with disease susceptibility. We determine that DN T 
cells eliminate activated B cells in vitro via a perforin/granzyme-dependent pathway, 
where the function of DN T cells is equal between the diabetes-resistant and -
susceptible mice, demonstrating that the association to autoimmune diabetes is due to 
a deficiency in DN T cell number rather than function. Interestingly, we show that 
non-transgenic DN T cells eliminate B cells loaded with islet antigen, but not B cells 
loaded with an irrelevant antigen, in vitro. Importantly, we establish that the transfer 
of activated DN T cells could prevent autoimmune diabetes development in the non-
transgenic setting. Interestingly, we reveal that DN T cells migrate to the pancreatic 
islets and undergo preferential activation and proliferation within the pancreatic 
lymph nodes. Moreover, the transfer of DN T cells results in a decrease in both 
germinal center B cells directly within the pancreatic islets as well serum insulin 
autoantibody levels, which correlates with the aforementioned findings. Altogether, 
the results presented in this thesis have allowed us to enhance our understanding of 
the function of DN T cells both in vitro and in vivo as well as demonstrate the 
therapeutic potential for DN T cells as a novel cellular therapeutic for autoimmune 
diabetes.  
 
Keywords : Double negative T cells, autoimmune diabetes, immunoregulation, 
transgenic mouse, non-transgenic mouse, antigen-specific. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Autoimmunity 
 A low level of autoreactivity is physiologic and crucial to normal immune 
function, where autoantigens helps to form the repertoire of mature lymphocytes and 
promote the survival of naive T cells and B cells in the periphery1. Contrary to this 
physiological low level of autoreactivity, autoimmunity results from the failure of the 
immune system to discriminate self from non-self, leading to an immune response 
against cells and tissues. Any disease that results from such an aberrant immune 
response is termed an autoimmune disease. Autoimmune diseases are typically 
defined as either systemic, in which the autoimmune reaction occurs against various 
organs, tissues and cells of the body, such is the case for systemic lupus 
erythematosus, or organ-specific, in which the autoimmune reaction targets a single 
organ as the name implies, as in the case of autoimmune diabetes. 
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1.2 Autoimmune diabetes 
 
 Autoimmune diabetes, which is also referred to as juvenile diabetes and type 
1 diabetes, results from the destruction of the insulin-producing β cells located within 
the islets of Langerhans of the pancreas. 
 
1.2.1 The pancreas 
 
 The pancreas is made up of exocrine and endocrine tissues (Figure 1). The 
exocrine is made up of cellular clusters called acinus, which consist of acinar cells 
that secrete digestive enzymes into the intestine, including proteases, amylases, 
lipases and nucleases2. The endocrine cells, which secrete hormones, are contained 
within the islets of Langerhans, which are compact spheroidal clusters embedded in 
the exocrine tissue2. There are four major cell types of endocrine cells, namely α, β, δ 
and PP cells, where the β cells make up approximately 70% of the islet mass. 
Together the and  cells regulate blood glucose levels, where the cells secrete 
glucagon, which promotes the conversion of stored glycogen in the liver into glucose 
that can be released into the bloodstream, and the  cells secrete insulin, which is 
necessary for glucose uptake from the blood into cells. The  cells secrete 
somatostatin, and the PP cells secrete pancreatic polypeptide (PP), both of which are 
implicated in modulating the secretory properties of the other cell types2.  
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Figure 1. Schematic representation of islet and pancreas cell types. Adapted from 3. 
 
1.2.2 Insulin 
 During insulin synthesis, preproinsulin is first secreted from the β cells of the 
pancreas with an A-chain, a connecting peptide (C-peptide), a B-chain, and a signal 
sequence, which, once cleaved, gives rise to proinsulin. Subsequently, the C-peptide 
is removed, leaving the A-chain and B-chain that constitute the mature insulin 
molecule. The mature insulin is stored in the β cells of the islets of Langerhans and its 
release is controlled by the level of glucose within the blood. Following insulin 
release, insulin binds to its receptor on the cell surface2. The signal transduction 
subsequently induces various physiological effects, including but not limited to the 
influx of glucose into cells, glycogen synthesis and lipid synthesis. As a result, insulin 
is a vital requirement for life2.  
 Autoimmune diabetes was considered a fatal disease until the early 1920s 
when doctors Banting and Best, who were positioned in Toronto, demonstrated that 
the injection of concentrated pancreatic extracts, namely insulin, from dogs into 
human diabetic patients could maintain blood glucose homeostasis4. In 1923, this 
discovery would result in Dr. Banting being awarded the Nobel Prize at the age of 
325. Today, diabetic patients use human biosynthetic insulin to treat their disease. 
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1.2.3 Clinical signs and diagnosis 
 The classical symptoms associated with autoimmune diabetes include 
polyuria (excessive production of urine), polydipsia (excessive thirst), glucosuria 
(excretion of sugar in the urine) and tiredness, which are all connected to 
hyperglycemia, or high blood glucose/sugar levels. The average plasma glucose 
concentration over a 3-4 month period can be established by measuring haemoglobin 
A1c (HbA1c) levels, where HbA1c is the glycated haemoglobin which forms due to the 
haemoglobin's exposure to plasma glucose.   
 
 At the time of the diagnosis, the mass of β cells is estimated to represent 10 to 
33% of its initial value based on a glucose tolerance test that measures your blood 
glucose levels following glucose stimulation, which is insufficient to provide the 
insulin contribution necessary following glucose ingestion6. The insulin response 
continues to decline following diagnosis, where two years after diagnosis, the insulin 
response now represents 28 ± 8.4% of the response at diagnosis7. Indeed, there is a 
significant inverse relationship between the insulin secretory response and glucose 
control, which is reflected by the HbA1c levels
7. Therefore, increased HbA1c levels 
are indicative of a decrease in the insulin secretory response. 
 
 The insulin secretory response following a glucose tolerance test assesses β 
cell function by measuring either insulin or C-peptide levels found in the plasma6, 
where lower insulin levels would indicate a decrease in β cell function, thus the 
progression to diabetes. However, insulin is known to have a short half-life and an 
unpredictable hepatic extraction as well as peripheral clearance, making it difficult to 
assess insulin secretion based on insulin plasma levels following glucose 
stimulation8. On the contrary, C-peptide plasma levels are a more accurate 
measurement of insulin secretion as C-peptide, which is co-secreted with insulin from 
β cells at an equimolar concentration, does not undergo significant hepatic extraction, 
maintains a constant metabolic clearance rate and exhibits a longer half-life6, 8. 
Altogether, plasma C-peptide levels, and to a lesser extent plasma insulin levels, are 
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used to measure β cell function, where a decrease in β cell function is an indicator of 
autoimmune diabetes progression.  
 Another factor used to identify autoimmune diabetes development is the 
presence of autoantibodies to insulin (IAA) and other islet antigens, including 
autoantibodies targeting the 65-kDa isoform of glutamic acid decarboxylase,  
(GAD65) and autoantibodies targeting the phosphatase-related insulinoma-
associated-2 (IA-2) molecule9. Moreover, the presence of these autoantibodies can 
also be used to predict the onset of disease10, 11, 12, 13. Indeed, IAA, GAD65 and IA-2 
autoantibodies may arise before any signs of hyperglycemia, where the time interval 
between the emergence of autoantibodies and disease onset can range from a few 
months to several years14.  Notably, not everyone who presents with autoantibodies 
progresses to autoimmune diabetes. However, as the number of  autoantibody types 
increases, the risk of developing the disease is also amplified, where an individual 
who presents with three to four autoantibody types has a 60–100% risk of progressing 
to autoimmune diabetes14. Autoantibodies to the zinc transporter ZnT8, which is a 
member of the large cation efflux family, were recently discovered to be present in 
pre-diabetic and new-onset diabetic patients, where ZnT8 antibodies generally 
emerged later than IAA and GAD65 antibodies in pre-diabetic patients11. Indeed, the 
inclusion of ZnT8 autoantibody with IAA, GAD65 and IA2 autoantibody detection 
can increase the prognostic value to 98% rather than the previous 90%11. With the 
combination of these 4 autoantibodies, we are closer to detecting pre-diabetes in a 
general pediatric population with a family history of disease11.  
 Altogether, the symptoms of autoimmune diabetes development include a 
decrease in insulin and C-peptide plasma levels that correlates with an increase in 
blood glucose levels and its associated symptoms as well as the potential presence of 
insulin and islet antigen autoantibodies. 
 
1.2.4 Prevalence 
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 Currently, there are 347 million people worldwide living with diabetesi. Of 
these diabetic patients, an estimated 5–10% constitute people living with autoimmune 
diabetes15, which amounts to approximately 17-35 million people worldwide. In 
Canada alone, more than 300,000 people are living with this diseaseii. Importantly, it 
is believed that the worldwide rate of diabetes incidence among children under the 
age of 14 will increase by three per cent annually16. Therefore, until a cure is 
discovered, this disease will continue to burden an increasing number of children and 
adults all over the world. 
 
1.2.5 Risk factors 
 
 Importantly, both genetic and environmental factors have been implicated in 
disease susceptibility. Studies involving twins have helped to reveal the relative 
importance of environmental and genetic factors with regards to autoimmune 
diabetes. Indeed, in comparison to dizygous (non-identical) twins, who express a 
disease concordance of 6%–10%, monozygous twins (genetically identical) express 
an increased disease concordance of approximately 30-50%17, 18 and a concordance of 
at least 66% for the presence of persistent islet cell autoantibodies and/or disease17. 
These results clearly demonstrate that genetic factors contribute to autoimmune 
diabetes development. However, as there is a significant fraction of monozygous 
twins that do not show disease concordance, it is also clear that environmental factors 
play an important role in disease development, as well. For instance, a study has 
revealed a higher prevalence of autoimmune diabetes ( ≥ 20/ 100,000 per year) for 
many developed countries, such as the United Kingdom, Sweden, and Canada, 
whereas a very low prevalence (<1/100,000 per year) can be detected for various 
underdeveloped countries, such as Peru, Paraguay and Venezuela19. An additional 
indication of an environmental factor is the north–south gradient of disease 
frequency, where the incidence of disease decreases from north to south in the 
Northern Hemisphere20. Altogether, these results demonstrate that both genetic and 
                                                 
i WHO website 
ii Canadian Diabetes Association. The prevalence and costs of diabetes. December 2009 
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environmental factors are implicated in autoimmune disease susceptibility. Although 
the genetic factors involved in disease development have been very compelling, the 
precise environmental causes have remained rather controversial. 
 
1.2.5.1 Genetics 
 The major histocompatibility complex (MHC), also called human leukocyte 
antigen (HLA) in humans, remains the greatest genetic contributor to autoimmune 
diabetes susceptibility. Indeed, the genes located within the MHC region account for 
approximately 45% of the genetic component implicated in autoimmune diabetes21. 
The function of these genes is well known such that they are involved in the 
presentation of antigenic peptides to T lymphocytes. More specifically, MHC class I 
is expressed on all nucleated cells and presents peptides derived from cytosolic 
proteins, or extracellular proteins that have undergone cross-presentation, to CD8+ T 
cells. On the other hand, the expression of MHC class II is limited to antigen-
presenting cells (APCs) and presents peptides from the extracellular medium to CD4+ 
T cells. The MHC class II region actually encodes the strongest genetic contribution 
to autoimmune diabetes21. More specifically, the HLA-DQ β chain in humans is 
directly associated with autoimmune diabetes susceptibility.  Accordingly, the lack of 
the aspartic amino acid residue at position 57 of the β chain22, which is responsible 
for the HLA-DQ conformational stability23, affects antigen presentation. However, 
there exist HLA class II genes in humans that also protect from autoimmune diabetes, 
such as the DQB1*0602 haplotype, which confers dominant protection even in the 
presence of islet autoantibodies24. Overall, certain HLA haplotypes provide 
protection (ex. DQA1*0102, DQB1*0602, DRB1*1501) while others form 
susceptibility (ex. DQA1*0301, DQB1*0302, DRB1*0401) for disease 
development25. 
 Multiple non-MHC genes also clearly contribute to disease susceptibility26, 27, 
28. These include the insulin gene (INS) on chromosome 11p1529, the cytotoxic T-
lymphocyte-associated protein 4 (CTLA4) gene on chromosome 2q3330, the protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) gene on chromosome 1p1331, 
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and the interleukin 2 receptor, alpha (IL2RA, also known as CD25) gene on 
chromosome 10p1528. Moreover, a meta-analysis of 3 distinct genome-wide 
association studies uncovered over forty non-MHC candidate genes associated with 
autoimmune diabetes, which, in addition to those mentioned above, include CD69 
and interleukin-10 (IL-10)26, 28, 32. Altogether, although the MHC, or HLA in humans, 
represents the greatest genetic contributor to autoimmune diabetes susceptibility, a 
multitude of non-MHC factors also play an important role in disease development. 
1.2.5.2 Environment 
 
 Several environmental risk determinants, in addition to those mentioned 
above have been investigated for their potential role in autoimmune diabetes 
development, including early infant diet, vitamin D, social mixing and viral 
infections.  
 
1.2.5.2.1 Dietary influence 
 
 As mentioned above, countries located further from the equator, such as the 
United Kingdom and Canada, express a higher incidence of autoimmune diabetes20. 
Due to the association between sun exposure and vitamin D synthesis, a lack of the 
daily requirement of vitamin D has also been implicated as a risk factor for disease 
development. Indeed, two studies have demonstrated that vitamin D supplementation 
during infancy was associated with a decreased risk of autoimmune diabetes33, 34. In 
addition to the role of vitamin D during infancy, various Finnish reports have 
suggested that breastfeeding during infancy and early exposure to cow's milk have a 
respective beneficial and negative outcome on autoimmune diabetes development in 
children35, 36, 37. In contrast, both the DAISY study performed in the United States of 
America38 and the BABYDIAB study performed in Germany39 have not documented 
any significant outcomes of the aforementioned factors. Therefore, a dietary influence 
on autoimmune diabetes development remains controversial.   
 
1.2.5.2.2 Hygiene hypothesis  
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 In 1989, David P. Strachan published an article demonstrating that both hay 
fever and eczema were less common in children from larger families, which would 
suggest a greater likelihood of exposure to more infectious agents through increased 
interactions with siblings40. This article was the first to corroborate the 'hygiene 
hypothesis', which suggests that a lack of early childhood exposure to infectious 
agents increases susceptibility to disease development by suppressing natural 
development of the immune system. The hygiene hypothesis can also be applied to 
autoimmune diabetes as studies have demonstrated that daycare attendance and social 
mixing during the first year of life, which facilitates the exposure to multiple 
infections, is associated with a significantly reduced risk of autoimmune diabetes41, 42.  
Moreover, both the number of children in the daycare setting and the number of 
sessions attended were significantly associated with protection from disease41. 
Altogether, these studies suggest that an increase in exposure to infections at an early 
age correlates with a reduced risk of developing autoimmune diabetes. Interestingly, 
an inverse association between the incidence of prototypical infectious diseases and 
the incidence of immune disorders has been observed between 1950 to 2000 in the 
United States20. Accordingly, the hygiene hypothesis may help to clarify why over 
the years, while standards of sanitation have continued to improve, disease incidence 
has continued to increase as well.  
 
1.2.5.2.3 Viral infections 
 
 As explained by the hygiene hypothesis, exposure to viral infections may help 
to prevent the development of autoimmune diabetes. This hypothesis has been 
supported by studies using mouse models. Indeed, infecting young, diabetes-
susceptible mice with either Mycobacteria avium 43 or lymphocytic choriomeningitis 
virus44 results in autoimmune diabetes inhibition. The coxsackie B virus (CBV) is 
another example of this theory as the exposure to this virus can help to prevent 
autoimmune diabetes development in young diabetes-susceptible mice which have 
yet to undergo pancreatic islet infiltration45. However, in the presence of islet 
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infiltration, the CBV virus will not inhibit, but rather accelerate the onset of disease45. 
The association of CBV with autoimmune diabetes has been further suggested from 
studies involving diabetic patients. Indeed, CBV proteins could be found within the 
islets of patients46, 47, while CBV RNA has been detected in the blood48, of newly 
diagnosed autoimmune diabetes patients. In addition to CBV,  a diabetogenic variant 
of the picornavirus encephalomyocarditis virus (EMCV) induces autoimmune 
diabetes in otherwise diabetes-resistant mice49. These studies demonstrate that viruses 
can either promote or inhibit autoimmune diabetes as well as suggest that the timing 
of viral exposure can have opposing consequences on disease development. 
 
 Although it remains controversial which environmental aspects play a clear 
role in autoimmune diabetes development, it is incontrovertible that both genetic and 
environmental factors contribute to disease susceptibility.  
 
1.2.6 Pathogenesis  
 
Autoimmune diabetes results from the destruction of the pancreatic β cells. As 
illustrated in Figure 2, β cell-derived antigens, such as preproinsulin (PPI), are taken 
up by APCs in the islets resulting in their maturation and subsequent migration to the 
draining pancreatic lymph nodes (PLNs). Within the PLN, the APCs will present the 
β cell-derived antigens to naive β cell-reactive T cells, thus activating them. 
Following their activation, the autoreactive T cells acquire the ability to migrate to 
the islets where they will encounter cognate antigen expressed by the β cells, leading 
to the destruction of the insulin-producing β cells50.  
 
The source of islet antigen is believed to be the wave of physiological 
pancreatic β cell death that occurs during pancreatic tissue remodelling. Indeed, in 
mice 51, 52, pigs53 and humans54, this wave of β cell death is evident early in life. In 
mice, this neonatal wave of β cell death peaks at about 2 weeks of age51, 52, which 
correlates with the initiation of insulitis, which describes the infiltration and 
inflammation of the pancreatic islets, in diabetes-susceptible mice50. In humans, a 
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decrease in β cell proliferation is observed starting at 17-32 weeks of gestation up 
until 6 months of age, while the frequency of β cell apoptosis increases up to 6 
months of age and subsequently decreases54. Evidence that this wave in β cell death is 
implicated in disease development is demonstrated through the removal of the PLNs 
from NOD mice prior to 3 weeks of age, when insulitis onset occurs, which results in 
protection from T1D55. Moreover, it has recently been shown that β cell death in 
young, female NOD mice induces the recruitment and activation of various innate 
immune cells to the pancreas56. This was not observed, however, when 1 week-old 
NOD mice were treated with a pan-caspase inhibitor to block β cell death, a treatment 
that also prevented T1D development up to 30 weeks of age56. Altogether, these 
results suggest that the onset of insulitis and subsequent progression of T1D is related 
to the wave of β cell death that occurs in the islets. However, as β cell death does not 
appear to be unique to the diabetes-susceptible NOD strain and is also apparent in 
diabetes-resistant strains 52, 57, 58, it cannot be said that this wave of β cell death is the 
trigger that leads to T1D onset despite its importance in the process. 
 
 
 
Figure 2. Model for the development of autoimmune diabetes. Adapted from 59 
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During the first stage of autoimmune diabetes, the pancreatic islets are 
invaded by a mix of leukocytes, including dendritic cells, macrophages, NK cells, B 
cells, and T cells. 
1.2.6.1 T cells  
 
 The utilization of mouse models has greatly enhanced our understanding of 
autoimmune diabetes pathogenesis. Accordingly, the non-obese diabetic (NOD) 
mouse model, which develops spontaneous autoimmune diabetes comparable to 
disease progression in humans (refer to Section 1.3), has become an important tool 
for researchers. Using this mouse model, it has been shown that T cell-enriched 
splenocytes from diabetic mice, contrary to T cell-depleted splenocytes, are able to 
transfer disease to young NOD mice60, demonstrating that T cells are involved in 
disease development. Moreover, T cell-modulating therapies, such as anti-CD3 
antibody61 and cyclosporin62, inhibit disease development. Altogether, these results 
demonstrate that autoimmune diabetes is a T cell-mediated disease.  
 
 The role of the diverse T cell subsets in disease development has been 
investigated. Accordingly, it was shown that a CD4+ T cell clone required the co-
transfer of CD8+-enriched T cells in order to induce autoimmune diabetes in 
immunodeficient NOD.SCID (severe combined immunodeficient) mice, which lack 
both T cells and B cells63. Because of these results, some believed that CD8+ T cells, 
and not CD4+ T cells, were essential for autoimmune diabetes development. 
However, it is now clear that both CD4+ and CD8+  T cells play a role in the 
development of disease. Indeed, autoimmune diabetes is impeded in the absence of 
CD4+ T cells, as shown by the treatment of NOD mice with a monoclonal antibody 
targeting CD4+ T cells64, 65 as well as in mice that lack CD4+ T cells66, demonstrating 
that CD4+ T cells are involved in disease progression. In addition, autoimmune 
diabetes is inhibited in mice that are deficient in CD8+ T cells, either by anti-CD8 
antibody injection into young mice67 or of β2 microglobulin-deficient mice, in which 
few CD8+ T cells develop68. Altogether, these studies demonstrate that autoimmune 
diabetes development is a function of the action of both CD4+ and CD8+  T cells.  
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 On the contrary, another T cell population, the CD4+CD25+Foxp3+ regulatory 
T cells (Tregs), have been shown to play a role in autoimmune diabetes prevention 
rather than induction. Indeed, patients with IPEX (immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked) syndrome, which is caused by mutations 
in the transcription factor FOXP3 (forkhead box P3), which is important for the 
development of Tregs, can also develop autoimmune diabetes69. Moreover, CD28-
deficient NOD mice, which exhibit a drastic decrease in Tregs, develop accelerated 
disease70. In addition, the transfer of splenocytes from diabetic CD28-deficient mice, 
thus lacking Tregs, to NOD.SCID mice induced autoimmune diabetes, while the co-
transfer of the Treg-deficient splenocytes and Tregs resulted in the prevention of 
disease transfer70. Therefore, these results demonstrate that Tregs play a role in 
autoimmune diabetes prevention. 
 
 Altogether, these results demonstrate that while CD4+ and CD8+  T cells are 
involved in the promotion of autoimmune diabetes, Tregs are involved in the 
prevention of disease. 
 
1.2.6.2 B cells 
 
 While T cells are implicated in the destruction of pancreatic islets, B cells are 
also implicated in disease development. Indeed, diabetes incidence is much reduced 
in NOD mice lacking B cells 71, 72, 73, 74, 75, and similarly, the elimination of most B 
cells using anti-CD20 treatment reverses or delays diabetes progression in both mice 
and humans76, 77. Interestingly, diabetes susceptibility was restored in irradiated B 
cell-deficient NOD mice that were reconstituted with syngeneic bone marrow mixed 
with NOD B lymphocytes, but not in mice reconstituted with syngeneic bone marrow 
only78. Therefore, B cells contribute to disease progression. 
 Importantly, the antigen-presenting function of B cells is believed to play a 
role in autoimmune diabetes development. Accordingly, NOD mice for which the 
class II MHC molecule I-Ag7 expression was specifically deleted in B cells are 
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resistant to the development of disease, despite the presence of peri-insulitis, which 
describes infiltration surrounding the islets, of the pancreas79. Moreover, T cells from 
GAD65-primed B cell-deficient NOD mice failed to respond upon antigenic 
restimulation in vitro in the presence of either B cell-sufficient or -deficient APCs78. 
However, the reconstitution of irradiated B cell-deficient NOD mice with syngeneic 
bone marrow mixed with NOD B lymphocytes, but not with syngeneic marrow alone, 
restored T cell responses to GAD65 autoantigen78. These results suggest that antigen-
presenting B cells are required for the initial in vivo priming of GAD65-reactive T 
cell responses in NOD mice. B cells are also activated in the presence of another 
autoantigen, the insulin antigen, where the costimulatory molecule, CD86, which is 
important for T cell crosstalk, is upregulated on autoreactive B cells following insulin 
autoantigen exposure80. When anti-insulin B cells are specifically eliminated by anti-
insulin monoclonal antibody therapy, diabetes incidence is inhibited in NOD mice80. 
Altogether, B cells can present β cell autoantigens to autoreactive T cells, which 
overcomes a checkpoint in T cell tolerance to islet β cells and promotes autoimmune 
diabetes development.  
 
 H2-O (HLA-DO in humans) expression can influence the 
participation of B cells in the germinal centers, which are the site of B cell 
maturation 81. More specifically, H2-O is a MHC class II-like protein that inhibits 
peptide loading onto MHC II by inhibiting the function of the MHC class II-like 
protein H2-M (HLA-DM in humans) 82. Recent publications have demonstrated that 
germinal center B cells exhibit a decreased H2-O expression 83. Moreover, it has been 
shown that H2-O-deficient antigen-specific B cells preferentially populate germinal 
centers in comparison to H2-O-sufficient B cells due to their enhanced ability to 
obtain antigen-specific T cell help, where T cell help is dependent upon antigen 
presentation by B cells 84. Interestingly, H2-O expression is cell maturation-
dependent as both mature B cells and DCs express H2-M and H2-O whereas 
developing immature B cells and DCs express very little H2-O 85, 86. These results 
suggest that, as H2-O limits peptide exchange on MHC class II, loss of function of 
H2-O might lead to autoimmunity as presentation of self-peptides by antigen-
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presenting cells such as B cells would not be attenuated. Although it has been shown 
that H2-O-deficient mice do produce higher titers of autoantibodies 87, H2-O 
expression on B cells and its direct association with autoimmune diabetes has not 
been evaluated. 
  
 B cells also contribute to autoimmune diabetes through the production of 
autoantibodies. Indeed, it has been demonstrated that maternally transmitted 
autoantibodies contribute to the disease onset in NOD offspring88, 89. Accordingly, the 
NOD progeny from B cell–deficient NOD mothers that were mated with a NOD 
males, as well as the NOD progeny of diabetes-resistant mothers that were implanted 
with the NOD embryos, displayed a reduction in autoimmune diabetes incidence88. 
Thus, the maternal transmission of antibodies is implicated in disease development.  
 
 Altogether, it is clear B cells play a role in autoimmune diabetes development. 
 
1.2.6.3 Macrophages 
 
 Macrophages are present in the pancreatic islet infiltrates of NOD mice prior 
to T cell infiltration64, 90, suggesting that macrophages are involved in autoimmune 
diabetes progression. Macrophages are believed to participate in disease pathogenesis 
through the production of various pro-inflammatory cytokines, such as tumor 
necrosis factor alpha (TNF-α) and interleukin-1 (IL-1), which contribute to β cell 
dysfunction90, 91, and interleukin-12 (IL-12), which promotes the differentiation of 
diabetogenic CD8+ cytotoxic T cells in the diabetes-prone setting92. Interestingly, the 
injection of a monoclonal blocking antibody that is specific for the myelomonocytic 
adhesion-promoting type-3 complement receptor (CD11b/CD18), which targets 
macrophages but not T cells, prevented islet infiltration by both macrophages and T 
cells and inhibited disease onset93. Interestingly, TNF-α and IL-1β-producing 
macrophages have also been observed in pancreatic islet infiltrates from patients with 
recent-onset autoimmune diabetes in humans 94. Therefore, these studies demonstrate 
a pathogenic role for macrophages in autoimmune diabetes. 
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1.2.6.4 Natural killer cells  
 
Natural killer (NK) cells are composed of effector lymphocytes, known to 
play a crucial role in the control of viral infection and the prevention of cancer95, as 
well as regulatory cells95. Indeed, while NK cells can kill immature DCs in humans 
and mice thereby influencing DC homeostasis 96, 97, the interaction between NK cells 
and immature monocyte-derived DCs in humans can also promote cytokine 
production by DCs 96. Similarly, it has been shown that NK cells can both promote 
the priming of CD4+ T cells through the secretion of IFN-γ98 or kill activated T cells 
that express insufficient amounts of classical or non-classical MHC class I molecules 
99. Moreover, IL-10-secreting NK cells inhibit antigen-specific T cell proliferation 
while maintaining their natural cytotoxic activity 100. Therefore, NK cells are not a 
homogenous subset and are composed of both effector and regulatory subsets.  
 
NK cells are another cell population implicated in autoimmune diabetes. 
Indeed, similar to macrophages, NK cells also infiltrate the pancreas before T cells in 
NOD mice101 and can be found directly within the islets of diabetic patients47. 
Moreover, the depletion of NK cells using an anti-asialo-Gm1 antibody prevented 
autoimmune diabetes in NOD mice 102. Interestingly, NK cells from diabetes-
susceptible NOD mice have impaired immune functions compared with NK cells 
from diabetes-resistant mouse strains103, 104. Accordingly, NK cells isolated from the 
pancreas of NOD mice are hyporesponsive such that they produce significantly less 
interferon gamma (IFNγ) and express less CD107a, which is a marker of 
degranulation101. Interestingly, NOD mice congenic for the NK cell surface marker 
NK1.1, which is expressed in the diabetes-resistant C57BL/6 strain but not in the 
NOD strain, exhibit a reduced disease incidence105. This protection from diabetes 
development also correlates with improved NK cell performance, as compared with 
wild-type NOD mice105. Thus, it is possible that the functional deficiency of NK cells 
from diabetes-susceptible mice, rather than an efficient NK cell function, contributes 
to autoimmune diabetes progression. Altogether, these results demonstrate that NK 
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cells infiltrate the pancreas and play a role in autoimmune diabetes. However, 
whether NK cells promote or protect from autoimmune diabetes remains 
controversial.  
 
1.2.6.5 Dendritic cells 
 
 Antigen-presenting dendritic cells (DCs) play an important role in 
autoimmune diabetes pathogenesis. Accordingly, DCs are able to capture 
autoantigens released after β cell death, which occurs physiologically in NOD mice at 
2 weeks of age during tissue remodelling52, as described earlier in section 1.2.6. 
Subsequently, the autoantigen-specific DCs migrate to the PLN where they can 
present the autoantigen to islet antigen-specific T cells, which initiates the 
diabetogenic response52. Indeed, a large frequency of DCs presenting β cell antigens 
can be found within the PLNs of NOD mice52. Interestingly, in diabetes-susceptible 
NOD mice that constitutively overexpress human HLA-DO in DCs, where, as 
previously explained, the association of HLA-DO with HLA-DM modulates the 
peptide loading function of HLA-DM thus hampering the presentation of self-
antigens and the inappropriate activation of T cells 82, 106, disease development is 
completely blocked107. This inhibition of autoimmune diabetes occurred despite a 
comparable diabetogenic T cell repertoire and level of peri-insulitis to control NOD 
mice 107, suggesting that HLA-DO expression dampens the presentation of islet-
derived autoantigens by DCs to T cells and can consequently promote T cell 
tolerance. Altogether, it is clear that the antigen-presenting function of DCs plays a 
key role in disease initiation. 
 
 DC involvement in autoimmune diabetes has been demonstrated via the in 
vivo treatment using Fms-like tyrosine kinase 3 ligand (FLT-3L), which expands DC 
populations. Indeed, FLT-3L treatment can accelerate autoimmune diabetes 
development in NOD mice108. Nevertheless, the contribution of DCs to autoimmune 
diabetes development seems to depend on the timing of FLT-3L treatment and the 
presence of autoreactive T cells such that FLT-3L treatment can prevent autoimmune 
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diabetes in NOD mice at early stages of autoimmune diabetes progression109, whereas 
it can also accelerate disease development at later stages when islet antigen-specific 
CD8+ T cells are already detectable in the blood108. Altogether, the contribution of 
DCs to autoimmune diabetes development seems to depend on both the stage of 
disease development and the presence of autoreactive T cells. 
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1.3 The non-obese diabetic mouse model  
 
 Murine models are a useful tool for research as they allow for the 
characterization of the cellular mechanisms involved in the progression of 
autoimmune disease. Autoimmune diabetes can be experimentally induced with 
various chemicals, such as streptozotocin110 and cyclophosphamide111, or by genetic 
manipulation, which is observed for transgenic mice. However, spontaneous murine 
models of autoimmune diabetes also exist. In particular, the non-obese diabetic 
(NOD) mouse strain is a key tool for investigating the aetiology of human 
autoimmune diabetes112. Indeed, the NOD mouse strain spontaneously develops 
autoimmune diabetes, which shares many similarities to disease development in 
humans, such as the presence of autoreactive CD4+ and CD8+ T cells as well as 
pancreas-specific autoantibodies. Moreover, the broadly immunosuppressive anti-
CD3 therapy, which has been successful in the treatment of new-onset type 1 diabetic 
patients during clinical trials, is a protocol initially developed in the NOD mouse 113, 
114, further demonstrating a parallel in disease development between humans and 
mice.  
 Investigation of the genetic control of autoimmune diabetes in the NOD 
mouse has revealed an interesting parallel with genetic susceptibility to disease in 
humans28, 32, 115, 116. First, the MHC haplotype H-2g7 expressed by the NOD mouse 
does not express an MHC class II I-E molecule because of a defective Eα locus. In 
addition, similar to the human autoimmune diabetes-associated HLA-DQ β chain 
(HLA-DQB1*0302) 22, 117, 118, NOD mice have a unique MHC class II I-A molecule 
containing a non-aspartic acid substitution at position 57 of the β chain119, which 
substantially alters the repertoire of MHC binding peptides presented by this allele120. 
Furthermore, autoimmune diabetes is multigenic in both mice121, 122  and humans123 
with the MHC being the major locus contributing to disease development123. 
Accordingly, NOD.B10-H-2b mice, for which the H-2g7 is replaced by the H-2 region 
from the diabetes-resistant C57BL/10SnJ (B10) strain, do not develop autoimmune 
diabetes124. However, in B10.NOD-H-2g7 mice, for which the H-2 region from the 
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diabetes-resistant B10 strain is replaced by the NOD H-2g7, diabetes development 
does not ensue105, 108, demonstrating that non-MHC genes are also implicated in 
disease susceptibility122, 125. Indeed, in the NOD mouse, over 20 insulin-dependent 
diabetes (Idd) loci have been identified with the MHC composing the Idd1 locus126. 
Accordingly, most of the human and mouse alleles conferring risk for autoimmune 
diabetes reveal common candidate genes that are concordant between humans and the 
NOD mouse, including the aforementioned INS ( within the Idd2 locus) and CTLA-4 
(within the Idd12 locus) genes115, 116, 127. Hence, the NOD mouse represents a useful 
tool for the study of the genetic factors influencing autoimmune diabetes 
susceptibility.  
  In terms of autoimmune diabetes pathogenesis in the NOD mouse, 
infiltration begins around 3-4 weeks of age such that few immune cell infiltrates 
surround the islet (peri-insulitis). By 10 weeks of age, the cell infiltrates progress and 
invade the islets (insulitis). Overt diabetes is observed beginning at 12-14 weeks of 
age in females and slightly later in males. By 30 weeks of age, the incidence of 
disease observed in NOD mice is 80% in females and less than 20% in males128. 
Moreover, the pathological examination of the pancreas in NOD mice revealed a high 
frequency of lymphocyte infiltration around and/or into the pancreatic islets as well as 
a reduction in the number and size of pancreatic islets in the overt diabetic mice128. 
Finally, the NOD mouse also displays key diabetic symptoms that also arise in 
diabetic patients, such as polyuria, polydipsia, hyperglycemia, and glucosuria128. 
Because of these many similarities, the NOD mouse is a key tool for autoimmune 
diabetes research. 
 
 Nevertheless, it must be noted that there also exists various differences 
between NOD mice and humans. Firstly, there exists various differences between the 
innate and adaptive immunity of mice and humans, including variances in the balance 
of leucocyte subsets, γ T cells, cytokines and cytokine receptor expression, to name 
a few 129. Moreover, additional differences have been noted between NOD mice and 
humans with respect to autoimmune diabetes manifestation. For instance, the islet 
infiltration in NOD mice is characterized by peri-insulitis followed by insultis. In 
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contrast to what is observed in NOD mice, few leukocytes are detectable within the 
inflamed islets of human patients 130. Furthermore, while CD4+ T cells are the 
predominant T cell subset found in the NOD mouse islet infiltrate131, CD8+ T cells are 
the most abundant cell population detected during insulitis in human patients 132.  In 
addition, the presence of maternal islet autoantibodies in the offspring of diabetic 
mice has been identified as a diabetogenic factor in mice 88, as described in Section 
1.2.6.2. However, children of mothers with autoimmune diabetes who were 
autoantibody positive at birth had significantly lower risks for developing the disease 
than children of mothers with autoimmune diabetes who were islet autoantibody 
negative at birth 133, suggesting that fetal exposure to islet autoantibodies may be 
protective against disease development in humans. Lastly, the gender bias observed 
for autoimmune diabetes development in NOD mice, which is described above, is not 
observed in humans134. Therefore, despite many similarities, the NOD mouse does 
not fully mimic all aspects of autoimmune diabetes observed in humans. 
 
Altogether, because of its many similarities to autoimmune diabetes in human 
patients, the NOD mouse has been used extensively in autoimmune diabetes research 
and as a pre-clinical tool for the development of new therapeutic strategies for the 
treatment of this disease. 
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1.4 Autoimmune diabetes therapy 
 
 Due to the many complications associated with long-term autoimmune 
diabetes, the life expectancy of people living with the disease may be shortened by as 
much as 15 yearsiii. As a result, research continues to better understand all the factors 
implicated in autoimmune diabetes progression in order to develop new therapies that 
will prevent, reverse and/or cure the disease. The main therapeutic avenues that are 
discussed in this section include the transplantation of pancreatic islets or of whole 
pancreas as well as immunotherapy.  
1.4.1 Transplantation  
 Some patients who have experienced severe complications associated with 
autoimmune diabetes have seeked an alternative therapy, namely either pancreatic or 
islet transplantation, in an attempt to cure their disease and achieve glucose tolerance 
and an alleviation of their complications. 
1.4.1.1 Pancreas transplantation  
 
 A pancreas transplant involves implanting a healthy pancreas from a recently 
deceased individual, or a partial pancreas from a living donor, into the diabetic 
patient. As mentioned above, the majority of pancreas transplant recipients have 
complicated autoimmune diabetes. Since 75% of diabetic patients with kidney failure 
do not survive longer than 5 years while receiving dialysis135,  approximately 90% of 
pancreas transplant recipients are either uremic (in kidney failure) or post-uremic. 
Importantly, mortality rate was decreased by approximately 50% when patients with 
autoimmune diabetes and end-stage renal failure received a simultaneous pancreas 
and kidney transplant135.  
 
                                                 
iii Canadian Diabetes Association. An economic tsunami: the cost of diabetes in Canada. December 2009 
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 In patients who receive a pancreas transplant alone, the actual patient and 
pancreas survivals at 5 years is 98.6% and 73.2%, respectively136. Long-term follow-
up of transplant recipients has demonstrated that pancreas transplants are successful 
in returning normal glycemia to diabetic patients for periods as long as 1-2 
decades137. Indeed, the half-life of the pancreas graft currently averages at 16.7 
years138. Additional benefits of successful pancreatic transplant are improved 
retinopathy, blood pressure, as well as neuropathic and cardiac function139. The 
inability to maintain insulin-independence following transplantation is mostly 
explained by technical failure in the postoperative phase and rejection in the long-
term period138, where graft rejection remains the leading cause of pancreas loss140. 
Autoimmunity is also increasingly recognized as a cause of graft loss141. 
Nevertheless, improvements in graft preservation, surgical techniques, 
immunosuppression, and prophylactic treatments are expected to further improve the 
results of pancreas transplantation138. 
 
 Altogether, pancreas transplantation consistently induces insulin-
independence in diabetic patients, however this is at the cost of major surgery and its 
associated complications as well as life-long immunosuppression138, hence the reason 
why only patients who have severe complications associated with the disease, and 
thus have no other options, consider this means of treatment. 
1.4.1.2 Islet transplantation 
 Islet transplantation is similar to pancreas transplantation in that it entails the 
transplantation of isolated islets from a donor pancreas into a diabetic patient. 
However, this transplantation is considered to be a more attractive alternative to 
pancreas transplantation since the islets can simply be infused into the liver of the 
patient through a catheter. Once transplanted, the islets will begin to produce insulin 
leading to glucose regulation. 
 In 1988, Ricordi and colleagues first reported on the semi-automated method 
for human pancreatic islet isolation making it feasible to consistently reproduce the 
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difficult process of separating insulin-producing β cells from the rest of the 
pancreas142. In 2000, a group in Edmonton developed a steroid-free 
immunosuppressive regime termed the Edmonton protocol, which promoted long-
term islet survival and function in patients143. With the development of the Edmonton 
protocol, 100% of patients, in comparison to the previous 8%, did not require insulin 
therapy 1 year after transplantation143. The initial success of the “Edmonton Protocol” 
quickly created an international passion and many centers adopted this technique. 
Unfortunately, 5 years after transplantation, more than 90% of the patients were again 
dependent on exogenic insulin144. Although much work is left to be done with regards 
to islet transplantation, researchers are still confident that this form of therapy will 
prove to be a success. 
 Indeed, both pancreas and islet transplantations result in the restoration of 
proper insulin production and, consequently, blood glucose regulation. Therefore, 
both methods have the potential to cure autoimmune diabetes, at least for a given 
amount of time. Nevertheless, both surgeries are accompanied by a lifelong regimen 
of immunosuppressive drugs to prevent graft rejection, where both the surgery itself 
and permanent immunosuppression is considered to be far more dangerous than 
continued insulin replacement therapy.  
1.4.2 Immunotherapy  
 Several immunosuppressive agents have been tested for their ability to 
prevent/delay/reverse autoimmune diabetes development due to their ability to target 
either T cells or B cells, both of which are involved in disease progression. 
1.4.2.1 Cyclosporine A  
 Cyclosporine A is an immunosuppressive agent that is widely used to prevent 
graft rejection due to its ability to interfere with T cell activity145. As T cells are 
directly involved in the destruction of pancreatic β cells, cyclosporine A was studied 
as a preventative therapy for autoimmune diabetes in mice and humans. NOD mice 
between the ages of 4 and 9 weeks that were treated with cyclosporine every 2 days 
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until 23 weeks of age demonstrated a significant reduction in disease incidence in 
comparison to control mice62. These results also correlated with a decrease in blood 
glucose levels, islet infiltration and islet destruction62. However, when cyclosporine 
treatment was started after development of glucose intolerance, the treatment 
appeared to have little therapeutic effect on disease development62. In humans, 
approximately 50% of patients who were treated with cyclosporine within 6 weeks of 
diagnosis and for a duration of 2 to 12 months became insulin-independent and 
showed C-peptide plasma concentrations in the normal range as well as decreasing 
titres of islet cell antibodies146. Nevertheless, this agent demonstrated multiple side 
effects, including nephrotoxicity, making it unsuitable for the treatment of disease147. 
1.4.2.2 Anti-CD3 monoclonal antibodies 
 Anti-CD3 antibodies, including teplizumab and otelixizumab, target T cells 
by binding to the CD3 molecule located on their cell surface. The ability of a CD3-
specific antibody to reverse autoimmune diabetes onset in 64-80% of female NOD 
mice61 paved the way for clinical trials in diabetic patients.  Recent-onset diabetic 
patients who received the anti-CD3 antibody otelixizumab showed a sustained 
remission of the disease for up to four years148. Success of the treatment correlated 
with the initial residual β cell function where patients presenting with a higher 
functional β cell mass before starting the treatment responded better. Indeed, 18 
months post-treatment, nearly 75% of patients in this subgroup were clinically 
insulin-independent148. Disease remission following anti-CD3 treatment is believed to 
be a result of the simultaneous action of the antibody on effector T cells, a fraction of 
which was deleted by apoptosis, and on Tregs, whose function was preserved and 
even increased149, 150. Therefore, anti-CD3 antibodies can be used to reverse and delay 
autoimmune diabetes progression.  
1.4.2.3 Anti-CD20 monoclonal antibody 
 The anti-CD20 monoclonal antibody, rituximab, is a chimeric monoclonal 
antibody, incorporating human immunoglobulin heavy-chain sequences and murine 
immunoglobulin variable regions151, that eliminates B cells by binding to the 
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extracellular portion of CD20 molecules, which are expressed on the cell surface of 
all B cells except for plasma cells. More specifically, rituximab depletes B cells via 
three mechanisms of action152, 153 (Figure 3). The first mechanism is via the 
modulation of the apoptotic signal transduction pathway resulting in direct 
cytotoxicity. The second mechanism is via antibody-dependent cell-mediated 
cytotoxicity, in which NK cells and macrophages bind to the Fc portion of the anti-
CD20 antibody by means of their Fcγ receptor and subsequently release effector 
molecules such as perforin leading to cell lysis. The third mechanism is via 
complement-dependent cytotoxicity, for which complement binds to the Fc portion of 
the anti-CD20 antibody thereby activating the complement cascade and formation of 
the membrane attack complex154. Although the mechanism by which B cell depletion 
ameliorates disease is not completely understood, the effect on antibody production 
and antigen presentation to T cells are thought to be important. 
 
 
Figure 3. Mechanisms of action of anti-CD20 antibodies inducing B cell depletion. 
Adapted from 151. 
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 As B cells are implicated in autoimmune diabetes development, rituximab 
treatment has been studied as a potential therapeutic agent for the disease in mice and 
humans. In mice, a 9 day cycle of 4 injections results in almost complete B cell 
depletion within 1 week after the last injection, where B cells begin to repopulate 3 
weeks after the last injection and reach normal levels by 12 weeks after the last 
injection77. Using a transgenic NOD mouse expressing human CD20 on B cells, Hu 
and colleagues demonstrated that anti-CD20 treatment can significantly delay and 
reduce the onset of autoimmune diabetes in 4 week-old mice77. Furthermore, 
treatment of mice presenting with hyperglycemia resulted in a decrease in blood 
sugar levels in over one-third of diabetic mice77. In addition, the beneficial outcome 
of the anti-CD20 treatment was shown to be a result, at least in part, of a Treg 
expansion77. Altogether, anti-CD20 treatment was able to delay, inhibit and reverse 
autoimmune diabetes in mice.    
 In humans, anti-CD20 treatment leads to a transient depletion in B cells, 
which gradually recover over the course of 12 months76. New-onset diabetic patients 
that received a four-dose course of anti-CD20 demonstrated a significantly higher 
level of plasma C-peptide as well as a significantly lower level of HbA1c over a 
period of 1 year in comparison to the placebo group76. These results correlated with a 
decrease in required insulin and, altogether, demonstrate a preserved β cell function 
in anti-CD20 treated patients76. Moreover, 40% of anti-CD20-treated patients who 
were IAA positive became IAA negative versus 0% of placebo-treated patients, 
where these results were ameliorated the sooner the patient begun treatment 
following diagnosis155. Therefore, anti-CD20 treatment in both mice and humans has 
a beneficial outcome for autoimmune diabetes. 
 Although these immunosuppressive agents have proven to impede further β 
cell destruction, thus preserving natural insulin production, the duration of this 
beneficial effect as well as the possible long-term negative effects have not been fully 
evaluated or completed for each of these therapies. Indeed, the most common side 
effect of immunosuppressive drugs is global immunodeficiency, resulting in 
increased susceptibility to infections and decreased cancer immunosurveillance. The 
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risk that accompanies global immunosuppression is the basis for the ongoing search 
for an antigen-specific cellular therapy for the treatment of autoimmune diabetes. 
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1.5 Immunoregulatory CD4-CD8- (DN) T cellsiv 
 
 Immune tolerance is dependent on the immune system discriminating between 
self and non-self. As explained earlier, a break in immune tolerance results in 
autoimmunity, which can lead to the destruction of healthy organs, glands, joints or 
the central nervous system. The triggers that cause T or B lymphocytes to aberrantly 
recognize and mount an immune response against self-antigens remain to be fully 
elucidated. However, a prominent role in the generation and maintenance of immune 
tolerance has been attributed to the number and function of regulatory cell subsets. 
Indeed, several populations belonging to the T cell or B cell compartment carry the 
ability to inhibit immune responses and promote peripheral tolerance, including 
CD4+CD25+FoxP3+ naturally occurring T cells, IL-10-producing CD4+ Tr1 cells, 
TGF--producing CD4+ Th3 cells, CD8+CD28- T cells, CD4-CD8- (DN, double 
negative) T cells, CD4+CD8+ (DP, double positive) T cells, and Natural Killer-like T 
(NKT) cells 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, as well as B10 regulatory B cells 167, 
168. These various regulatory cell populations express diverse mechanisms of action, 
which may also vary depending on the experimental model being studied 158, 
suggesting that the contribution to immune tolerance, as well as to disease prevention, 
differ amongst these various cell populations. Hence, there is a need to further 
examine the contribution of various T cell subsets to autoimmune predisposition. One 
of these regulatory T cell populations, namely CD4-CD8- (double negative, DN) T 
cells, have been studied in both mice and humans for their contribution to peripheral 
tolerance, disease prevention and their potential for use in cellular therapy. 
 
 DN T cells are of particular interest because they have demonstrated the 
ability to inhibit immune responses in an antigen-specific manner169, 170, 171. This has 
major implications, since the use of DN T cells in immunotherapy should therefore 
                                                 
iv Most of the text in section 1.5, 1.5.1, 1.5.2 and 1.5.3 was recently accepted for publication as a review article: 
Reference 156. Hillhouse EE, Lesage S. A comprehensive review of the phenotype and function of antigen-
specific immunoregulatory double negative T cells. Journal of autoimmunity 2012.. Hillhouse, E.E. & Lesage, 
S. A comprehensive review of the phenotype and function of antigen-specific immunoregulatory double 
negative T cells. Journal of autoimmunity (2012). 
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lead to fewer side-effects along with a decreased risk of infections, which remains a 
major concern in the application of broad immunosuppressive regimens172.  
 
1.5.1 Challenge associated with the specific identification of 
immunoregulatory DN T cells 
 
 CD4-CD8- T cells are defined by exclusion (i.e., as CD3+ non-CD4 non-CD8 
T cells) and, as a consequence, the term refers to three T cell populations that are 
infrequent in the peripheral blood and lymphoid organs, including γδ T cells 173, 174, a 
subset of NKT cells 175, and DN T cells 171. As a result, other markers besides CD4, 
CD8, and CD3 must be used in order to distinguish these three subsets. The 
expression of the γδ T cell receptor (TCR) separates γδ T cells from both NKT and 
DN T cell subsets, which both express an αβ TCR. Unfortunately, there are currently 
no known phenotypic markers which readily allow the discrimination between NKT 
and DN T cells, therefore their distinction is often ambiguous and is based on 
imprecise or incomplete characterization. To grasp the complexity of this challenge, 
the known phenotypic and functional characteristics of NKT and DN T cells must be 
understood (refer to Table 1 for phenotypical comparison of CD3+CD4-CD8- T cell 
populations). 
 
 DN T cells NKT I cells NKT II cells γδ T cells 
T cell receptor αβ αβ  αβ γδ 
Repertoire Polyclonal 169, 
176 
Oligoclonal 177 
 
Polyclonal 178 Oligoclonal 179, 
180, 181 
Restriction MHC CD1d 182, 183 CD1d 184 Rare MHC 
restriction 179, 
185 
Antigen 
recognition 
Peptides186 Glycolipids 187, 188, 
189, 190 
Glycolipids 184, 191 Protein and 
non-protein 179, 
192 
NK1.1 
expression 
+/- * +/- 193 +/-194 +/- 195, 196 
CD49b 
expression 
+/- 193 +/- 193, 197 +/- 159, 197 N/A 
 
Table 1. Properties of the various CD3+CD4-CD8- T cell populations. Adapted from 
156. *Manuscript in preparation, refer to Chapter 3, Supplementary Figure 1. 
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1.5.1.1 Distinguishing DN T cells from NKT cells 
 
 NKT cells can be categorized into two main subpopulations, namely type I 
and type II NKT cells, both of which express an αβ TCR and are either CD4+ or CD4-
CD8- in mice 175, 198, 199 or CD4+, CD8+ or CD4-CD8- in humans 159, 200. Thus, similar 
to DN T cells, a subset of both type I and type II NKT cells exhibit a CD4-CD8-
TCRαβ+ phenotype, making other markers of NKT cells essential for their 
discrimination. Accordingly, NKT cells are known to express CD56 or CD161 in 
humans and CD49b or NK1.1 in mice 159, 200, 201, 202. However, in mice, expression of 
the NK1.1 surface antigen is dependent on the expression of the C57BL/6 NK gene-
complex haplotype as well as the genetic background. Consequently,  NK1.1 
expression on NKT cells is limited to just a few mouse strains, including C57BL/6, 
FVB/N, and NZB, whereas it is not expressed in other commonly used mouse strains, 
such as BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. More 
importantly, CD49b and NK1.1 in mice, as well as CD56 and CD161 in humans, are 
neither exclusive to NKT cells, nor are they expressed by all NKT cells 159, 193, 200, 203, 
204, 205. Furthermore, a fraction of immunoregulatory DNT cells found in CD1d-
deficient mice, which lack type I and II NKT cells (further discussed below), also 
express CD49b 193. Therefore, these NK cell surface markers cannot be used to 
effectively distinguish NKT cell subsets from DN T cells.  
 
 Alternatively, type I NKT cells can be distinguished from both DN T and type 
II NKT cells by the distinct selectivity of their TCR repertoire. Indeed, while both 
DN T and type II NKT cells express a polyclonal TCR Vβ repertoire 169, 189, 199, 200, 
type I NKT cells, also referred to as invariant NKT (iNKT) cells, express an 
oligoclonal TCR repertoire. In mice, type I NKT cells express an invariant Vα chain 
(Vα14) and one of three possible Vβ chains (Vβ2, Vβ7, Vβ8.2) 198 while in humans, 
type I NKT cells are specified by the expression of the Vα24 chain and the Vβ11 
chain, which are respectively homologous to mouse Vα14 and Vβ8.2 159, 200, 206, 207. 
Therefore, in both mice and humans, type I NKT cells can be specifically separated 
from both DN T and type II NKT cells based on their TCR repertoire. 
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 With regards to CD4-CD8-CD3+ T cell subsets, both  T cells and type I 
NKT cells can be specified through their TCR. However, type II NKT cells and DN T 
cells both express a polyclonal αβTCR repertoire 169, 189, 199, 200 and thus their specific 
identity must be resolved through other means. Type II NKT cells, as for type I NKT 
cells, differentiate in the thymus and are positively selected on an MHC class I-like, 
β2m-dependent, CD1d molecule 175, 183, 194. Based on their TCR restriction to CD1d 
molecules, molecular tools have been developed to specifically identify both type I 
and type II NKT cells. More specifically, the invariant TCR of type I NKT cells 
recognizes the α-galactosyl ceramide (α-GalCer)-loaded CD1d tetramer 189, 190, while 
type II NKT cells bind to the sulfatide (I3SO3-GalCer)-loaded CD1d tetramer 184. 
Similarly, human type II NK T cells recognize sulfatide presented by group I CD1 
molecules 184, 208. Nevertheless, not all type II NKT cells are reactive with sulfatide 
loaded CD1 molecules 209, further stressing the point that DN T and type II NK T 
cells cannot be readily distinguished. To circumvent this issue, one can resort to 
CD1d-deficient mice, which are fully devoid of both type I and type II NKT cells, as 
both subsets are fully dependent on CD1d for thymic positive selection 182, 183, 210, 211. 
Therefore, using CD1d-deficient mice, immunoregulatory DN T cells, void of any 
contaminating NK T cells, may be successfully isolated. 
 
1.5.2 DN T cell phenotype 
 
 Immunoregulatory DN T cells compose approximately 1-3% of total T cells 
in non-transgenic mice 212, 213, 214 and in humans 169 making them difficult to isolate 
and subsequently study. To circumvent these issues of scarcity, as well as their 
similarity in phenotype to NKT cells, DN T cells have been mostly investigated in 
TCR transgenic mice, where the insertion of various TCR transgenes increases the 
proportion of immunoregulatory DN T cells in the lymphoid organs of mice, as 
observed in the HY-TCR, the 4E3-TCR, the 1H3.1, the 2C-TCR and the 3A9 TCR 
transgenic mice. Moreover, these TCR transgenes are not restricted to CD1d and 
are thus incompatible with NKT cell differentiation. Similarly, most of these 
transgenes also preclude γδ T cell differentiation 171, 175, 214, 215, 216, 217, 218, 219, 220, 221. In 
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other words, using an αβTCR transgene not only increases the number of DN T cells 
thereby facilitating the study of this otherwise rare T cell subset, the insertion of a 
given αβTCR transgene also facilitates the isolation of a pure DN T cell population 
void of other contaminating CD4-CD8- T cell subsets, namely both NKT cells and γδ 
T cells. 
 
1.5.2.1 Phenotype of TCR transgenic DN T cells  
 
 TCR transgenic DN T cells are a distinct regulatory T cell population as they 
do not express NKT cell markers, NK1.1 and CD49b 222 as well as the Treg marker, 
Foxp3 214, 223. Interestingly, DN T cells from TCR transgenic models generally 
exhibit a naive phenotype, in that they express low levels of CD44, are negative for 
CD25, CD28, CD69, CD122, and B220 expression and show high levels of Ly-6A 
171, 214, 216, 218, 222, 224, 225, 226. Additional phenotypic characterization demonstrates that 
TCR transgenic DN T cells express low levels of CD5 and express other T cell 
markers such as CD3, CD62L and CD45RB at levels comparable to naive CD4 T 
cells from TCR transgenic mice 214, 216, 222. Altogether, TCR transgenic DN T cells 
express a phenotype comparable to that of naive T cells. However, in TCR transgenic 
mice where the cognate antigen is also expressed, TCR transgenic DN T cells express 
an activated phenotype such that they are CD44hiCD122hiCD45RB+ 218, 226, but they 
do not express acute activation markers CD69 and CD25 218.  
 
 In terms of cytokine production, 2C DN T cells have been shown to produce 
IFNγ 226 and perforin 222 whereas they do not produce IL-10, IL-2 or IL-4 171. In terms 
of anergy, in the three TCR transgenic models tested, namely 2C, IH3.1 and 3A9, DN 
T cells were shown to be anergic and, similar to CD4+FoxP3+ Tregs 214, 227, 228, this 
anergic phenotype was reversed following the addition of IL-2 170, 214, 216, 218, 226, 229. In 
summary, immunoregulatory DN T cells from TCR transgenic mice are anergic 
and exhibit a naive T cell phenotype. 
 
1.5.2.2 Phenotype of non-transgenic DN T cells 
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 With the goal to move towards a more clinical setting, the study of DN T cells 
using a non-transgenic system, which is more physiologically relevant to humans, is 
essential. Despite their scarcity in non-transgenic mice 212, 213, 214, as well as their lack 
of a specific marker, both of which present a challenge for their isolation, 
characterization and manipulation, various groups have studied DN T cells using non-
transgenic mice. 
 
 Similar to TCR transgenic DN T cells, non-transgenic DN T cells express 
markers of T cells such as CD3 and CD5, but do not express Foxp3 or CD49b and do 
not stain with the CD1d-αGalCer tetramer 214, 230. Contrary to TCR transgenic DN T 
cells, non-transgenic DN T cells do not exhibit a naive T cell phenotype, but rather 
show a CD69lowCD25lowCTLA-4-CD44+ profile 230. However, a note of caution must 
be taken in the interpretation of these data, as neither  T cells nor NKT cells were 
specifically excluded in defining the phenotype of the non-transgenic DN T cells 230. 
Nonetheless, and similarly to DN T cells from TCR transgenic mice expressing their 
cognate antigen, an activated DN T cell phenotype was also observed in other non-
transgenic settings. Indeed, in CD4, CD8, MHC I and MHC II quadruple-deficient 
non-TCR transgenic mice (referred to as quad-deficient mice) DN T cells are found 
to exhibit a CD5hiCD69+CD62LlowCD44hi phenotype 231. Interestingly, DN T cells 
from AND TCR transgenic quad-deficient mice express a more naive phenotype 
similar to other TCR transgenic models, such that they are CD5lowCD69-
CD62L+CD44-. From these observations, the authors were led to suggest that 
endogenous TCRs expressed by non-transgenic DN T cells in quad-deficient mice 
receive a signal from self-ligands whereas, in the absence of cognate antigen, TCR 
transgenic DN T cells do not231. Admittedly, the quad-deficient mouse model is a 
highly complex system and the phenotype of the resulting non-transgenic DN T cells 
from these mice must again be interpreted with caution, if only for the fact that the 
thymic selection process of these cells is limited to non-MHC molecules. Finally, 
non-TCR transgenic DN T cells have also been isolated from mice homozygous for 
the lymphoproliferation (lpr) spontaneous mutation, namely lpr/lpr mice, wherein a 
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mutation in Fas leads to an abnormal accumulation of DN T cells232, 233, 234, 235, 236. 
Interestingly, non-TCR transgenic DN T cells from lpr/lpr mice again exhibit a 
similar activated T cell phenotype, in addition to abnormally expressing the B220 B 
cell antigen236. Again, the severe lymphoproliferative disorder observed in the lpr/lpr 
mouse model must be noted as a limitation in defining the activation status of non-
transgenic DN T cells. Although all of these models present with some limitations 
towards identifying the exact phenotype of immunoregulatory DN T cells, the 
phenotypic characterization of DN T cell in non-TCR transgenic mice, quad-deficient 
mice and lpr/lpr mice all suggest that immunoregulatory DN T cells exhibit an 
activated phenotype. If these findings consistently hold true in more physiological 
settings, the activated DN T cell phenotype may suggest that, similar to Tregs237, the 
TCR repertoire of DNT cells is partial to the preferential recognition of self-antigens.  
 
1.5.2.3 Phenotype of human DN T cells 
 
 Similar to non-transgenic DN T cells, human DN T cells compose 
approximately 1-3% of total T cells 169 making them difficult to isolate and 
subsequently study. Nevertheless, human DN T cells have been isolated from whole 
blood and, as for mouse DN T cells, have been shown to express a polyclonal TCR 
repertoire 176 and to lack the expression of the Treg marker, FoxP3, as well as the 
NKT cell marker, CD56 169, 238. In humans, DN T cells consist of both 
CD45RAbrightCCR7+ naive cells and CD45RAlowCCR7- Ag-experienced cells 169, 238. 
Moreover, human DN T cells are negative for CD28, CD25, CTLA-4 and CD16, but 
they do express Fas 169, 238. However, as is observed for lpr/lpr mice, DN T cells 
isolated from patients presenting with a lymphoproliferative disorder, as a 
consequence of germline mutations in either Fas or Fas ligand (FasL), abnormally 
express the B cell antigen B220 239. In terms of cytokine production, human DN T 
cells mainly produce IFNγ 169, however, they also produce IL-4, IL-5, and IL-10, but 
not IL-2 169. Although they do not express granzyme B, they do express the cytolytic 
protein, perforin 169. Altogether, human DN T cells are similar in phenotype to mouse 
DN T cells, suggesting that mouse models are a useful tool to study DN T cells. 
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1.5.3 Targets and mechanisms of action of DN T cells  
 
 The first evidence of an immunosuppressive function for DN T cells arose 
from a 25 year old study, when Strober and colleagues successfully cloned DN T 
cells from BALB/c mice and subsequently demonstrated that DN T cells mediate 
suppressor activity in a mixed-lymphocyte reaction (MLR)213. Although the DN T 
cells were not void of any contaminating NKT cells, these results still suggested an 
immunoregulatory potential for DN T cells and, consequently, prompted investigators 
to further explore the function of this rare T cell population. 
 
 In subsequent years, the immunoregulatory function of DN T cells has mainly 
been studied using the TCR transgenic system for several reasons. As explained 
above, using an αβTCR transgene not only increases the number of DN T cells 
thereby facilitating the study of this otherwise rare T cell subset, but the insertion of a 
given αβTCR transgene also facilitates the isolation of a pure DN T cell population 
void of other contaminating CD4-CD8- T cell subsets. Importantly, DN T cells in 
humans and in non-transgenic mice exhibit a similar phenotype to DN T cells from 
TCR transgenic mice, demonstrating that the characteristics of DN T cells do not 
represent a transgenic artefact. Therefore, studies using the TCR transgenic system 
will undoubtedly give insight into the immunoregulatory function of DN T cells. 
 
1.5.3.1 The immunoregulatory function of TCR transgenic DN T cells  
 
 The functional properties of DN T cells have been mainly studied using the 
2C TCR transgenic mouse model, which is a MHC class I-restricted model where the 
DN T cells express the transgenic αβTCR heterodimer as detected by the 1B2 anti-2C 
clonotypic monoclonal antibody 240. Using this model, 2C DN T cells were shown to 
suppress the proliferation and cytotoxic activity of 2C TCR transgenic CD8+ T cells 
in vitro, but not of CD8+ T cells carrying other antigen specificities 171, 218, 241, 242, 243. 
In addition to blocking CD8+ T cell proliferation and function, 2C DN T cells can 
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also directly lyse CD8+ T cells 171, 186, 218, 225, 243, 244, 245. The DN T cell-mediated 
suppression of CD8+ T cells using the 2C TCR transgenic model requires the specific 
recognition of alloantigens through the TCR and can take place by three different 
mechanisms, as demonstrated by Dr. Li Zhang's group. The first of these mechanisms 
describes the direct recognition of an allogeneic-MHC expressed on target CD8+ T 
cells by the TCR on the effector DN T cells241. The second mechanism describes the 
opposite, such that there is a direct recognition of an allogeneic-MHC expressed on 
the effector DN T cells by the TCR on the target CD8+ T cells 241. Accordingly, 
blocking the MHC on 2C DN T cells impedes their ability to suppress CD8+ T cells 
241. The third mechanism involves a process known as trogocytosis 246. Essentially, 
through trogocytosis, DN T cells acquire allogeneic-MHC from an antigen-presenting 
cell through their TCR and the acquired allogenic-MHC molecule is then presented 
on the surface of the DN T cell 171, 247. Syngeneic CD8+ T cells that carry the same 
TCR specificity as DN T cells can subsequently recognize the acquired allogeneic-
MHC now expressed by DN T cells 171. In all of the mechanisms described, in which 
an antigen-specific TCR-MHC interaction occurs between the target and effector 
cells, the target CD8+ T cell will receive a death signal from the effector DN T cell 
due to a Fas-FasL interaction 171, 218. Indeed, it has been demonstrated that Fas-
deficient DN T cells are cytotoxic towards Fas-sufficient, but not Fas-deficient, CD8+ 
and CD4+ T cells, whereas FasL-deficient DN T cells are unable to carry out this 
function 171, 248. Accordingly, 2C DN T cells obtained from FasL-deficient mice had a 
significantly reduced, but not completely abrogated, ability to kill allogeneic DCs 
(further discussed below) 249. Therefore, it is believed that the Fas-FasL interaction 
between DN T cells and their target requires FasL expression on the DN T cell and 
Fas expression by the target cell (Figure 4A). Altogether, the immunoregulatory 
activity of 2C TCR transgenic DN T cells is cell contact-dependent, perforin-
independent and is mediated through Fas-FasL interactions 171, 186, 218, 241 
 
 Interestingly, 2C DN T cells were recently shown to down-regulate the 
expression of co-stimulatory molecules, namely CD80 and CD86, on mature DCs 249. 
Furthermore, 2C DN T cells can lyse both immature and mature DCs in an antigen-
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specific and Fas/FasL-dependent fashion in vitro 249. Thus, in addition to their direct 
immunoregulation of CD8+ T cells, DN T cells can also prevent naive T cell 
activation/proliferation indirectly through the inhibition of APCs. Figure 4A 
summarizes the targets and mechanism of action of TCR transgenic DN T cells. 
 
 With regards to the mechanism of action of DN T cells, the immunoregulatory 
function of TCR transgenic DN T cells is thus dependent on various factors, 
including cell contact, perforin and Fas-FasL interactions. Notably, various 
mechanisms are known to affect the efficacy of DN T cell immunoregulation. For 
instance, IL-10 has been shown to significantly reduce the cytotoxic function of 2C 
DN T cell clones towards CD8+ T cells in vitro 224, 250. Moreover, IL-10 was shown to 
induce the cellular apoptosis of 2C DN T cells 250. Additionally, Ly-6A also 
contributes to 2C DN T cell function as the killing of activated CD8+ T cells is 
significantly reduced in the presence of blocking antibodies to Ly-6A or when using 
Ly-6A-deficient 2C DN T cell clones 224. Interestingly, Ly-6A expression on 2C DN 
T cells is reduced in the presence of IL-10 224, suggesting that IL-10 also indirectly 
affects 2C DN T cell function by reducing Ly-6A expression. Lastly, the Fcγ receptor 
(FcRγ), which is expressed on 2C DN T cells 251, is also important for 2C DN T cell 
function as 2C.FcRγ-/- DN T cells are less efficient at inhibiting CD8+ T cell function 
251. Altogether, IL-10, Ly-6A and FcRγ play a crucial role, directly or indirectly, on 
the immunoregulatory function of DN T cells (Figure 4A). 
 
1.5.3.2 The immunoregulatory function of non- transgenic DN T cells  
 
 Similarly to TCR transgenic DN T cells, non-transgenic DN T cells maintain 
an antigen-specific suppressive activity towards CD8+ T cells in vitro 171, 224, 241, 242, 
245. Interestingly, DN T cells from non-transgenic mice also suppress both CD4+ and 
CD8+ T cell responses 170, 229, 248, 252, 253. Importantly, in contrast to 2C DN T cells, 
non-transgenic DN T cells do not require Fas-FasL interactions in order to mediate 
their cytotoxic function towards CD8+ T cells (Figure 4B). Rather, this cytotoxic 
function of non-transgenic DN T cells, which are free of most γδ T cells and NKT 
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cells, is perforin-dependent as perforin-deficient DN T cells are unable to efficiently 
lyse activated CD8+ T cells as well as CD4+T cells 170, 229. However, two separate 
studies demonstrated that the cytotoxic effect towards CD8+ T cells is in fact Fas-
FasL dependent 171, 248. Therefore, additional studies are necessary to clarify these 
diverging results. 
 
 Non-transgenic DN T cells have also shown cytotoxic activity towards 
activated B cells and DCs 170, 249. Non-transgenic DN T cells directly lyse activated B 
cells in a contact- and perforin/granzyme-dependent manner170, while DC elimination 
is Fas/FasL dependent249. Moreover, non-transgenic DN T cells can down-regulate 
the expression of co-stimulatory molecules, CD80 and CD86, expressed on antigen-
presenting mature DCs249. Additional DN T cell targets were also identified using the 
non-transgenic setting that were not investigated using the TCR transgenic system, 
including plasma cells 170, macrophages 254, and NK cells 255, where the latter was 
shown to be lysed using a perforin-dependent mechanism 255. Figure 4B summarizes 
the targets and mechanism of action of non-transgenic DN T cells. 
 
 Although the immunoregulatory function of non-transgenic DN T cells is 
mainly dependent on cell contact and granzyme/perforin, other mechanisms are 
known to affect the efficacy of non-transgenic DN T cell function. As was observed 
for 2C DN T cells, non-transgenic DN T cell expression of Ly-6A was demonstrated 
to be crucial for optimal DN T cell function, as Ly-6A-deficient DN T cells have 
impaired cytotoxicity towards CD8+ T cells 224. Furthermore, CTLA-4-/- DN T cells 
are unable to mediate the downregulation of costimulatory molecule expression on 
DCs 249. Therefore, Ly-6A and CTLA-4 are critical for non-transgenic DN T cell 
function (Figure 1B).  
 
 Notably, the mode of action and immunoregulatory properties of TCR 
transgenic DN T cells appear to quite reliably reflect those of non-TCR transgenic 
DN T cells, attesting to the validity of using TCR transgenic settings to explore the 
phenotype and function of this cell type, which is found in low frequency thus 
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challenging to isolate in the non-transgenic setting (Figure 4A and 4B). Moreover, it 
is noteworthy that the non-TCR transgenic T cells used in the above experiments 
were either sorted by flow cytometry or purified using magnetic beads to exclude 
most, but not all, δγ T cells and NKT cells. Indeed, a pure population of DN T cells is 
difficult to achieve as a specific marker to discriminate DN T cells from type II NKT 
cells is lacking. Due to this challenge, we cannot disregard the possibility that any 
variation observed for the mechanism of action of DN T cells using a non-transgenic 
system is due to type II NK T cell contamination. However, both TCR transgenic and 
non-transgenic DN T cells exhibit comparable phenotypes and functions, suggesting 
that these isolation procedures reliably yield a sufficient number of 
immunoregulatory DN T cells. Nevertheless, additional studies using non-transgenic 
DN T cells isolated from CD1d-deficient mice are both necessary and crucial to 
eventually help resolve the exact function of immunoregulatory DN T cells in the 
absence of potentially contaminating NKT cells.  
 
1.5.3.3 The immunoregulatory function of human DN T cells 
 
 The observations made using both TCR transgenic and non-transgenic 
systems have demonstrated that DN T cells may be of particular interest for cellular 
therapy due to their ability to eliminate various cellular targets in an antigen-specific 
manner. Although few studies have been performed using human DN T cells, a 
parallel can be made between the function of DN T cells in humans and mice (Figure 
4C). First, DN T cells are cytotoxic towards CD8+ T cells, where the trogocytosis of 
MHC molecules by human DN T cells enables them to lyse CD8+ T cells in an 
antigen-specific manner 169. Moreover, human DN T cells efficiently suppress both 
CD4+ and CD8+ T cell responses in vitro 238. However, as opposed to murine DN T 
cells, Voelkl and colleagues have demonstrated that human DN T cell inhibit CD4+ T 
cell proliferation independently of perforin/granzyme as well as  transforming growth 
factor beta (TGFβ), IL-10 and Fas-FasL interactions 238. Although the exact 
mechanism of action was not determined, DN T cell inhibition of CD4+ T cell 
proliferation was shown to be dependent on cell contact, TCR signalling and 
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intracellular protein transport as the presence of a transwell, Lck inhibitor or 
monensin, respectively, blocked the CD4+ T cell suppression 238. Clearly, additional 
studies are needed to validate the cellular targets of human DN T cells as well as their 
mechanism of action. 
 
Figure 4. The targets and mechanism of action of DN T cells.  TCR transgenic (A), 
human (B) and non-transgenic (C) DN T cells target various cell populations using 
different mechanisms of actions. Modified from 156 (Hillhouse, E.E. & Lesage, S. A 
(2012)). 
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1.5.3.4 In vivo function of immunoregulatory DN T cells 
 
 Although the literature for the in vitro function of DN T cells is vast, 
publications on the in vivo function of DN T cells are quite sparse. Indeed, using non-
transgenic DN T cells, a single study has confirmed a targeted population in vivo, 
namely B lymphocytes. Ma, Y and colleagues 256 used a cardiac xenotransplantation 
model to verify whether DN T cell transfer, in addition to treatment with an 
immunosuppressive reagent, could ameliorate graft survival. Importantly, the transfer 
of perforin-sufficient, not perforin-deficient, DN T cells led to an increase in graft 
survival, which correlated with an increase in B cell apoptosis as well as a decrease in 
anti-donor total immunoglobulin (Ig) G and IgM antibody production and IgG graft 
deposition. Moreover, DN T cells from a third party also induced B cell apoptosis, 
indicating an antigen non-specific mechanism of action in vivo. Therefore, non-
transgenic DN T cells eliminate B cells in vivo using perforin-dependent and antigen-
independent mechanisms.  
 
 The in vivo function of DN T cells has also been studied using a TCR 
transgenic system, namely the 3A9 TCR transgenic model, which, as opposed to the 
2C TCR model, is a MHC class II-restricted model 257 where the DN T cells express 
the transgenic αβTCR heterodimer as detected by the 1G12 anti-3A9 clonotypic mAb 
258. Following the studies performed by Ma, Y and colleagues 256, our lab has 
demonstrated that a single transfer of autologous TCR 3A9 transgenic DN T cells 
resulted in a significant reduction in antigen-specific  IgG, but not IgM, autoantibody 
serum levels in diabetes-susceptible mice in comparison to mice that did not receive 
3A9 DN T cells 214, further suggesting that DN T cells can eliminate autoreactive B 
cells in vivo via an antigen-specific mechanism. However, it remains to be 
demonstrated whether 3A9 DN T cells can directly lyse autoreactive B cells and via 
which mechanism of action this cytotoxic activity occurs.  
 
 Altogether, the observations made using both TCR transgenic and non-
transgenic systems have demonstrated that DN T cells may be of particular interest 
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for cellular therapy due to their ability to eliminate various cellular targets in an 
antigen-specific manner and that a parallel can be made between the function of DN 
T cells in both humans and mice. 
 
1.5.4 DN T cells in transplantation and disease modelsv 
 
 A central objective in organ transplantation and the treatment or prevention of 
autoimmune disease is the achievement of antigen-specific immune tolerance. As DN 
T cells exhibit a unique antigen-specific immunoregulatory potential towards 
multiple cellular targets, it suggests that DN T cells may serve as a solution to this 
challenge. Consequently, investigators were prompted to examine the role of DN T 
cells in various disease models, including graft-vs-host disease, graft tolerance, 
cancer and autoimmunity.  
 
1.5.4.1 Graft tolerance 
 
 Although donor leukocyte infusion (DLI) is primarily used to prevent the 
relapse of cancer via its graft-vs-tumor effect, DLI treatments are also beneficial in 
solid organ transplants. In an attempt to understand why DLI has a positive outcome 
on allograft survival, Dr. Zhang’s group took advantage of the antigen-specific 2C 
TCR transgenic model260, 261, where the 2C TCR is alloreactive to the Ld MHC class I 
molecule240. Predictably, skin grafts bearing a single MHC mismatch at Ld are rapidly 
rejected by the 2C TCR recipient mice due to the expression of Ld MHC class I 
molecule on the donor skin cells260, 261. However, the injection of donor spleen cells 
to the 2C TCR recipient mice prior to the skin graft efficiently induced antigen-
specific allograft tolerance260, 261. Interestingly, the antigen-specific tolerance to skin 
allografts induced by the transfer of donor T cells was proposed to be mediated by 2C 
                                                 
v Text similar to that in section 1.5.4 and its subsections was recently accepted for publication as a review article: 
Reference 259. Hillhouse EE, Delisle JS, Lesage S. Immunoregulatory CD4(-)CD8(-) T cells as a potential 
therapeutic tool for transplantation, autoimmunity, and cancer. Frontiers in immunology 2013, 4: 6.. Hillhouse, 
E.E., Delisle, J.S. & Lesage, S. Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for 
transplantation, autoimmunity, and cancer. Frontiers in immunology 4, 6 (2013). 
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TCR transgenic DN T cells as DN T cell numbers are increased directly within the 
skin allograft following adoptive transfer of donor lymphocytes242 and this increase 
correlated with antigen-specific tolerance of both skin and cardiac allografts 171, 225, 
243, 244. Moreover, only the 2C TCR transgenic DN T cell subset, but not the 2C CD4+ 
or 2C CD8+ T cell subset, was able to suppress an MLR response in vitro171. 
Subsequently, Zhang's group went on to show that the injection of 2C TCR F1 DN T 
cell clones was sufficient to induce prolonged survival of both skin and cardiac 
allografts survival171, 244, demonstrating that DN T cells do indeed promote 
allotolerance. Importantly, the allograft tolerance was antigen-specific, as full MHC-
mismatched third party grafts were rapidly rejected171. Collectively, these data 
demonstrate that 2C DN T cells are sufficient to induce both skin and cardiac 
allograft survival, suggesting that immunoregulatory DN T cells contribute to the 
benefits of DLI on allograft survival. 
 
 To further understand the mechanism by which 2C DN T cells promote 
antigen-specific allograft tolerance, Young and colleagues undertook the examination 
of the leukocytes found within the tolerated skin grafts. Indeed, the 2C DN T cells 
isolated from mice which had received donor spleen cells prior to the skin graft 
demonstrate an enhanced suppressive function towards 2C CD8+ T cells in vitro242, 
demonstrating that 2C DN T cells promote graft tolerance, at least in part, through the 
elimination of pathogenic CD8+ T cells. Furthermore, the comparison of 
transcriptome profiles between 2C TCR F1 DN T cells clones that are able or unable 
to confer cardiac allograft tolerance revealed FcR as a potential molecule involved in 
defining the tolerogenic potential of 2C DN T cells225. The importance of FcR 
expression on 2C DN T cells for the induction of allograft tolerance was confirmed as 
the adoptive transfer of FcRγ-sufficient, but not FcRγ-deficient, 2C DN T cells prior 
to transplantation increased skin allograft survival251. Altogether, these results 
demonstrate that 2C DN T cells participate in allograft tolerance, likely by inhibiting 
pathogenic 2C CD8+ T cell responses, at least in the MHC class I-restricted graft 
tolerance model156. 
 
 45 
 These observations were not limited to the 2C TCR transgenic setting. 
Accordingly, DLI treatment prior to transplantation in the non-transgenic setting 
resulted in long-term cardiac xenograft survival as well as an increase in the 
proportion of DN T cells in recipient mice252, suggesting that non-transgenic DN T 
cells contribute to graft tolerance. Consistent with this, DN T cells isolated from DLI-
treated mice are able to promote the survival of cardiac 170, 253 and skin grafts 248 
while in vitro-generated DN T cells can also promote skin as well as pancreatic islet 
allograft tolerance229, 262. Importantly, the graft tolerance provided by non-transgenic 
DN T cells is antigen-specific as third-party skin allografts were rejected 248, further 
demonstrating a key characteristic of DN T cells, namely antigen-specificity.  
 
 The targets of non-transgenic DN T cells during the induction of tolerance are 
diverse, as is expected. Indeed, DLI-activated DN T cells efficiently suppressed the 
proliferation of both CD4+ and CD8+ T cell anti-donor reactive cells252, 253, which 
may explain how the injection of non-transgenic rat donor spleen cells prevented 
CD4+ T cell-mediated cardiac xenograft rejection in recipient mice252, 253. 
Additionally, it was also shown that non-transgenic DN T cells can eliminate B cells 
in vivo, leading to a reduction in anti-donor specific antibody levels and delayed 
cardiac xenograft rejection256, suggesting that DN T cells can prevent antibody-
mediated acute graft rejection, which is a major obstacle in xenograft survival. Taken 
together, these findings suggest that, as opposed to the MHC class I-restricted 2C 
TCR DN T cells, non-transgenic DN T cells promote antigen-specific graft tolerance 
via the suppression of CD4+ and CD8+ T cells as well as B cells.  
 
 The mechanism of action of DN T cells during graft tolerance has also been 
studied using the non-transgenic setting. As mentioned in Section 1.5.3.1, Fas-FasL 
interactions have been proposed as the molecular mechanism by which DN T cells 
eliminate anti-donor T cells, while the elimination of B cells is considered to be 
perforin-mediated170, 171, 218, 256. By taking advantage of Fas-deficient lpr/lpr mice, 
Ford et al. demonstrated that DN T cells can mediate their immunoregulatory 
function through the Fas pathway as long as the target T cells express a functional 
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Fas protein248. Indeed, DN T cells from lpr mice could effectively delay both single 
MHC class I- and single MHC class II-mismatched skin allograft rejection248. 
Moreover, mice that received perforin-sufficient, but not perforin-deficient, DN T 
cells ultimately accepted their cardiac xenograft transplant256. In summary, non-
transgenic DN T cells can clearly induce an antigen-specific tolerance to both 
allografts and xenografts by eliminating or inhibiting the function of various target 
immune cells via perforin-mediated and/or Fas/FasL pathways. Altogether, these 
results validate the potential to use DN T cells as a cellular treatment to promote graft 
survival. 
 
1.5.4.2 Graft-vs-host disease (GVHD)  
 
 In the treatment of hematological malignancies, allogeneic hematopoietic cell 
transplantation (AHCT) can eradicate several blood cancers that are reported to be 
incurable by chemotherapy alone. Despite indisputable successes, the efficacy of 
AHCT is still limited by cancer recurrence and the development of GVHD263. While 
the acute form of GVHD is triggered by direct T cell recognition of 
histocompatibility antigens, the pathophysiology of chronic GVHD remains more 
elusive and relies on several immune cell types264. Currently, 40 to 80% of patients 
develop chronic GVHD after AHCT, which brings substantial morbidity and 
mortality265. Several lines of evidence suggest that immunoregulatory immune cells, 
including immunoregulatory DN T cells, are paramount to GVHD prevention.  
 
 DN T cells exhibit an immunoregulatory function that would make them an 
ideal candidate for the prevention of GVHD. A potential role for DN T cells in the 
prevention of GVHD can be traced back to over two decades ago when Bruley-
Rosset and colleagues demonstrated that the transfer of spleen cells from pre-
immunized mice was able to inhibit GVHD only when DN T cells were included in 
the cellular preparations266. Although the DN T cells were not void of contaminating 
NKT cells, these results were the first to demonstrate a potential role for DN T cells 
in the prevention of GVHD. The combination of these findings along with functional 
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studies that demonstrated their prominent antigen-specific immunoregulatory 
potential, led investigators to further examine the contribution of DN T cells towards 
GVHD prevention using the 2C TCR single MHC mismatch model243. Specifically, 
mice bearing a single MHC-mismatch (Ld) injected with Ld-specific 2C TCR 
transgenic spleen cells survived for more than 150 days without any clinical or 
histological signs of acute or chronic GVHD243, 267. The tolerance of donor spleen 
cells may be explained, at least in part, by the accumulation of 2C TCR DN T cells243, 
267, which can effectively inhibit pathogenic CD8+ T cell responses, in recipient 
mice243. Indeed, GVHD development caused by the transfer of 2C CD8+ T cells was 
significantly decreased when recipient mice were co-infused with 2C DN T cell 
clones243. Based on these findings and what is known about the function of 2C DN T 
cells, Young and colleagues have proposed the following explanation for the role of 
DN T cells in the prevention of GVHD267; Following the transfer of allogeneic 
splenocytes to the recipient, DN T cells become activated and expand to become the 
major subset of T cells. DN T cells will then acquire allogeneic-MHC molecules from 
APCs, which can be recognized by anti-host T cells with the same TCR specificity. 
The anti-host T cells are subsequently killed by the DN T cells via the Fas/FasL 
pathway. Although it is not known whether the prevention of GVHD is caused 
directly through the elimination of alloreactive T cells, indirectly as a result of the 
elimination host DCs or B cells, or a combination of both, it is clear that DN T cells 
do indeed play a role in the prevention of GVHD. 
  
 Subsequently, the role of non-transgenic DN T cells in GVHD prevention was 
investigated using both parent to F1 and fully MHC-mismatched bone marrow 
transplantation following either a myeloablative255 or non-myeloablative regimen268. 
In stark contrast to CD4+ and CD8+ T cells, the co-injection of non-transgenic DN T 
cells with T cell-depleted bone marrow into a sublethally irradiated host ensured 
prolonged recipient survival in the absence of clinical signs of GVHD255, 268, 
indicating that DN T cells are not alloreactive nor pathogenic in this context. 
Moreover, this led to stable mixed chimerism and, as opposed to bone marrow 
transplantation alone, promoted donor allotolerance255, 268. Together, these findings 
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demonstrate that, as opposed to CD4+ or CD8+ T cells, the transfer of allogeneic DN 
T cells does not cause GVHD. Rather, DN T cells prevent GVHD, induce mixed 
chimerism and promote donor-specific allotolerance. 
 
 In support of Strober and colleagues' initial experiment in mouse in 1989, 
Kusnierz-Glaz and colleagues demonstrated that human DN T cells were also able to 
suppress a MLR in vitro, indicating that DN T cells may be able to prevent GVHD in 
humans269. Despite the lack of a pure DN T cell population due to the absence of the 
necessary NKT cell markers during DN T cell isolation, these results still paved the 
way for additional studies on human DN T cells and their role in the prevention of 
GVHD. More recently, two studies further suggested that human DN T cells are able 
to prevent GVHD as a clear correlation was observed between an elevated proportion 
of DN T cells and a low incidence of GVHD development in patients following 
AHCT270, 271. Indeed, the stem cells used for AHCT are currently most commonly 
obtained from the peripheral blood mononuclear cells of granulocyte colony-
stimulating factor (G-CSF)-treated donors, where G-CSF is used to mobilize CD34+ 
hematopoietic stem cells into the blood264. Interestingly, in addition to skewing 
towards a T helper 2 (Th2) phenotype, G-CSF treatment also results in an increase in 
the proportion of immunoregulatory DN T cells in the blood269. The combination of 
these two phenotypes may explain why the transfer of CD34+ stem cells isolated 
following G-CSF treatment does not increase the incidence of acute GVHD relative 
to classical bone marrow transplants. Together, these observations support the view 
that human DN T cells may prevent GVHD.  
 
1.5.4.3 Cancer 
  
 Although immunoregulatory T cells are known to promote tolerance, they 
typically have a negative impact on cancer prognosis 272, 273, 274, 275. Indeed, the ability 
of Tregs to maintain the anti-tumor T cell responses remains controversial as Tregs 
have been demonstrated to also inhibit anti-tumor T cell responses, which could 
ultimately contribute to the progression of cancer272, 273, 274, 275, 276. However, DN T 
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cells exhibit a counter-intuitive anti-tumoral role, regardless of their 
immunoregulatory activity. Specifically, both 2C TCR transgenic and non-transgenic 
DN T cells isolated from the spleens of mice that were co-infused with a lethal dose 
of A20 lymphoma cells together with allogeneic splenocytes demonstrated cytotoxic 
activity towards A20 lymphoma cells in vitro267. Subsequently, Young and colleagues 
demonstrated that the injection of either 2C DN T cell clones or non-transgenic DN T 
cells was sufficient to prevent A20 lymphoma tumor growth267. Interestingly, Young 
and colleagues did not observe killing towards the P815 tumor cells and attributed 
this observation to the low expression of Fas by the P815 cell line, whereas the A20 
tumor cell line expresses a high level of Fas267. Importantly, Young and colleagues 
were able to demonstrate that the lysing of the tumor cells was indeed Fas-dependent 
as 2C DN T cell clones that had been pre-incubated with a Fas-Fc fusion protein prior 
to the co-culture with A20 tumor cells had a decrease in their killing ability267. Thus, 
the elimination of tumor cells by DN T cells is Fas-dependent, at least in the 2C TCR 
transgenic system. 
 
 To further define the potential use of DN T cells in the treatment of 
hematological malignancies, Merims et al. performed a pre-clinical study in acute 
myeloid leukemia (AML) patients undergoing complete remission following standard 
chemotherapy277. In this study, they demonstrate that DN T cells can be readily 
isolated from the blood of AML patients. Moreover, the isolated DN T cells maintain 
their phenotype following a proficient cellular expansion reaching nearly 500-fold in 
two weeks277. Of interest, the DN T cells isolated and expanded in vitro demonstrated 
efficient cytolytic activity towards the autologous leukemic cells in 6 out of 7 
patients277. Importantly, the anti-tumoral activity of DN T cells may extend beyond 
hematological malignancies, as melanoma-reactive DN T cells have also been 
successfully isolated from a previously immunized melanoma patient278. Altogether, 
these results demonstrate that DN T cells exhibit anti-tumoral activity all the while 
promoting tolerance. 
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 The antigen-specific immunoregulatory potential of DN T cells in graft 
tolerance suggests that they may also participate in the induction of immune tolerance 
in various autoimmune settings. As a result, the role of DN T cells has been mostly 
explored in systemic lupus erythematosus (SLE), autoimmune lymphoproliferative 
syndrome (ALPS) and mouse models of autoimmune diabetes, as described below. 
 
1.5.4.4 Systemic lupus erythematosus (SLE) 
 
 Although SLE patients present with greater numbers of DN T cells in their 
peripheral blood 279, these DN T cells are major producers of IL-17 280, which is 
pathogenic in this disease 281, 282. Moreover, IL-17-producing DN T cells can be 
found in the kidney sections of patients with lupus nephritis 279. These results lead 
Crispin and colleagues to suggest that DN T cells themselves are pathogenic in SLE. 
However, it must be noted that, in these studies, DN T cells were defined as CD4-
CD8-TCRαβ+ cells, which may contain contaminating NKT cells. NKT cells do 
indeed include a subset of CD4-NK1.1- IL-17-producing cells 283. Moreover, using a 
mouse model, the activation of NKT cells through the administration of α-GalCer 
exacerbated disease whereas the inhibition of NKT cell activation using an anti-CD1d 
blocking antibody resulted in disease amelioration, suggesting that NKT cells are 
implicated in SLE pathogenesis 284. Thus, as for the response against infections, NKT 
cells cannot be ruled out as the true IL-17-producing cell subset involved in the 
pathogenesis of SLE. Altogether, an uncertain, yet possible, role for DN T cells in the 
pathogenesis of SLE remains to be defined. 
 
1.5.4.5 Autoimmune lymphoproliferative syndrome (ALPS) 
 
 ALPS is a rare disorder characterized by mutations in either Fas or Fas ligand 
(FasL) 285, 286, which results in defective Fas-mediated apoptosis and, consequently, 
the abnormal proliferation of lymphocytes. Similar to patients with SLE, ALPS 
patients on average present with a tenfold increase in DN T cell proportion 176, 239, 287 
and a sizeable proportion of CD4-CD8-TCR+ DN T cells can also be found in the 
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lymphoid organs of the murine models for ALPS, namely lpr/lpr (Fas-deficient) and 
gld/gld (FasL-deficient) mice 232, 233, 234. Moreover, a greater proportion of DN T cells 
from ALPS patients, in comparison to healthy controls, express the B cell antigen, 
B220 239, which is consistent with findings in lpr/lpr mice 236. Accordingly, B220 
expression is a general feature of proliferating T cells 288, which explains why healthy 
patients also express B220+ DN T cells. Although it cannot be denied that a drastic 
increase in the proportion of DN T cells can be observed in lpr/lpr and gld/gld mice, 
as well as ALPS patients, there is no evidence to suggest that the accumulation of DN 
T cells is pathogenic. Indeed, Fas-deficient DN T cells found in lpr/lpr mice, but not 
FasL-deficient mice found in gld/gld mice, remain functional 248. Hence, as DN T 
cell-mediated suppression depends on interactions between FasL on DN T cells and 
Fas on target T cells 248 it has been suggested that DN T cells accumulate in an 
attempt to compensate for their inability to suppress autoimmune T cells in lpr/lpr 
mice 248.  
 
1.5.4.6 Autoimmune diabetes 
 
 The tolerogenic role of DN T cells in the prevention of autoimmune diabetes 
was first revealed using the P14/RIP-gp transgenic mouse model, where the MHC 
class I-restricted P14 TCR transgene recognizes the lymphocytic choriomeningitis 
virus (LCMV) protein, gp33–41 (gp33), which is expressed under the rat insulin 
promoter (RIP) in this model, forcing its expression in the pancreatic tissue. The 
resulting double transgenic P14/RIP-gp mice do not spontaneously develop 
diabetes289. However, when treated with gp33 peptide in combination with an anti-
CD40 agonist antibody, P14/RIP-gp mice carry a very high percentage of gp33-
reactive T cells and rapidly develop diabetes290.  Indeed, P14/RIP-gp transgenic mice 
develop diabetes as a result of the infiltration of pancreatic islets by activated CD8+ T 
cells and the subsequent destruction of the insulin-producing β cells. Using this 
model, it was shown that the transfer of gp-33 activated P14 DN T cells one day prior 
to diabetes induction can inhibit diabetes development186. These results were the first 
indication that DN T cells may participate in the prevention of a CD8+ T cell-driven 
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autoimmune diabetes pathology, further lending support for a potential in vivo role of 
DN T cells towards the elimination of CD8+ T cells in vivo.   
 
 The protective role of DN T cells in diabetes development was further 
investigated by our group using the 3A9 TCR:insHEL transgenic system, in which 
the MHC class II-restricted 3A9 TCR transgene recognizes a peptide from hen egg 
lysozyme (HEL) presented by I-Ak, while the insHEL transgene forces the expression 
of HEL in the pancreatic tissue. Although TCR:insHEL BALB.K mice are relatively 
resistant to autoimmune diabetes, CD47-deficient TCR:insHEL BALB.K mice have a 
high and spontaneous incidence of diabetes. Using this model of spontaneous 
autoimmune diabetes, a single transfer of 3A9 DN T cells in the TCR:insHEL CD47-
deficient BALB.K transgenic model was able to significantly inhibit the development 
of autoimmune diabetes 214. As noted previously, 3A9 DN T cell transfer lead to a 
significant reduction in antigen-specific autoantibody serum levels 214, suggesting the 
in vivo elimination of autoreactive B cells. Although this model is imperfect in that it 
is a CD47-deficient model, where CD47 is implicated in apoptosis, phagocytosis, cell 
migration and T cell responses 291, 292, it is nevertheless a spontaneous model of 
autoimmune diabetes and the results complement the findings of Ford and colleagues 
186 suggesting that DN T cells may be of therapeutic interest for autoimmune 
diabetes.   
 
 Interestingly, the proportion of DN T cells is significantly reduced in diabetes-
prone mice in comparison to diabetes-resistant mice in both the transgenic and non-
transgenic systems 214. It is of relevance that both the non-transgenic and 
TCR:insHEL transgenic diabetes-prone NOD mouse models exhibit a low number of 
DN T cells relative to other diabetes-resistant strains as it suggests that low DN T cell 
numbers are associated with diabetes susceptibility. Importantly, these results suggest 
that the restoration of DN T cell number can prevent autoimmune diabetes 
development in otherwise diabetes-susceptible mice.  
 
 53 
 The role of DN T cells in the prevention of autoimmune diabetes was also 
recently evaluated using non-transgenic DN T cells. Indeed, Duncan and colleagues 
have demonstrated that non-transgenic DN T cells can protect from autoimmune 
diabetes230. Specifically, diabetes induction was inhibited if DN T cells were 
transferred into recipient NOD.SCID mice 1 month prior to co-infusion with 
diabetogenic splenocytes, whereas the simultaneous co-infusion of diabetogenic 
splenocytes and DN T cells does not protect from disease230. However, as NKT cells 
were not fully excluded from the cellular preparation, additional studies using NKT 
cell-depleted non-transgenic DN T cells are warranted to firmly establish the 
biological function of these cells in the prevention of autoimmune diabetes in 
diabetes-susceptible NOD mice. Notably, further investigation is still needed to verify 
the role of DN T cells in autoimmune diabetes development using non-lymphopenic 
NOD mice, thus under more physiological and spontaneous conditions. Nevertheless, 
these results do provide useful information regarding the critical time of treatment 
initiation as well as evidence that non-transgenic DN T cells may exhibit the potential 
to inhibit autoimmune diabetes development in non-transgenic mice.  
 
 A most recent study further evaluated the role of non-transgenic DN T cells in 
autoimmune diabetes. Here, it was shown that 50% of CD4+ T cells isolated from an 
MLR (with or without GAD65 peptide) had been converted to CD4-CD8- T cells. 
These CD4+ T cell-converted DN T cells sorted by flow cytometry were shown to 
delay autoimmune diabetes onset when adoptively transferred to NOD.SCID mice in 
combination with diabetogenic T cells262. This delay was further enhanced when 
using GAD65 antigen to stimulate the CD4+ T cells, thereby likely generating a 
higher proportion of GAD65-specific DN T cells. Moreover, a single transfer of DN 
T cells enriched for GAD65 specificity was able to prevent diabetes development in 
5-week-old NOD mice and decrease blood glucose levels in new-onset diabetic NOD 
mice. Lastly, GAD65-specific DN T cells in combination with rapamycin treatment, 
and not DN T cells or rapamycin alone, promoted islet allograft transplant survival in 
new-onset diabetic NOD mice. Therefore, GAD65-specific CD4+ T cell-converted 
DN T cells can prevent and reverse the development of autoimmune diabetes as well 
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as promote islet allograft survival262. It remains to be determined whether DN T cells 
originating from down-regulation of CD4 expression upon in vitro stimulation exhibit 
the same characteristics as DN T cells present in vivo. Nevertheless, this study 
presents an interesting and potentially translatable therapeutic approach for the 
generation of antigen-specific tolerogenic CD4-CD8- T cells in the prevention of 
autoimmune diabetes.  
 
1.5.4.6.1 Comparing DN T cells and NK T cells and their role in autoimmune 
diabetes pathology 
 
 Indeed, type II NK T cells express a similar immunoregulatory function as 
DN T cells Not only do NKT cells share various phenotypical features with DN T 
cells, they also share a common immunoregulatory mechanism of action, which has 
been mostly investigated in the autoimmune diabetes setting. As is observed for DN 
T cells, diabetes-susceptible NOD mice also exhibit a marked deficiency in NKT cell 
number 293, 294 as well as NKT cell function, as observed by the decrease in IL-4 
production 293, 294, 295, 296, 297. However, in contrast to DN T cells, the reduction in NK 
T cell number is more pronounced in the thymus and, to a lesser extent, in the 
periphery 294. Importantly, CD1d-deficient, thus NKT cell-deficient, NOD mice 
exhibit an accelerated onset of autoimmune diabetes 298, 299, suggesting that NKT 
cells, similar to DN T cells, play a role in the prevention of autoimmune diabetes 
progression. Accordingly, CD4-CD8- thymocytes, which are enriched for NKT cells, 
were shown to prevent the development of autoimmune diabetes when transferred 
into 4-week-old NOD recipient mice 294. Moreover, the in vivo treatment of NOD 
mice with the α-GalCer ligand, which activates type I NKT cells, was shown to 
prevent diabetes in NOD mice 297, 300, 301, while TCR transgenic NOD mice carrying a 
CD1d-restricted TCR transgene that is specific for type II NKT cells also prevented 
autoimmune diabetes development 302. Therefore, similar to DN T cells, both type I 
and type II NKT cells play a role in diabetes resistance.  
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 As the discrimination between DN T cells and type II NK T cells remains a 
challenge (refer to Section 1.5.1), these results further demonstrate that the use of 
CD1d-deficient mice, which, by definition, lack both type I and type II NK T cells, is 
essential for the study of non-transgenic DN T cells devoid of any contaminating 
cells. Indeed, the lack of a specific marker to discriminate DN T cells from type II 
NKT cells renders it difficult to assure the purity of the DN T cells being studied, 
which may lead to ambiguous interpretations of results and the role DN T cells play 
in disease pathology. Accordingly, the study of non-transgenic DN T cells using 
CD1d-deficient mice would secure the integrity of the DN T cells and the 
corresponding results.  
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1.6 Future directions 
 Altogether, DN T cells may be of particular interest for cellular therapy due to 
their ability to eliminate various cellular targets in an antigen-specific manner. 
However, there is a clear lack of in vivo data to validate the various targets of DN T 
cells that were established using in vitro assays which will need to be resolved 
moving forward. Indeed, to our knowledge, only B cells have been confirmed as 
targets of DN T cells in vivo 256. Moreover, the lack of a specific marker to identify 
DN T cells remains a central issue in this field of study. Indeed, as a specific marker 
to discriminate DN T cells from type II NKT cells is lacking, we cannot disregard the 
possibility that some of the variation that has been observed for the mechanism of 
action of DN T cells in both non-transgenic mice and human studies is due to type II 
NK T cell contamination. As a result, we propose that CD1d-deficient mice are both 
necessary and crucial for the study of non-transgenic DN T cells since, by definition, 
these mice lack both type I and type II NK T cells, thus allowing to specifically 
isolate DN T cells. Moreover, the isolation and validation of a specific marker able to 
differentiate DN T cells from type II NKT cells should remain a priority. This marker 
will not only facilitate studying DN T cells in the non-transgenic setting, but also in 
humans, including the translation to various clinical studies. Indeed, DN T cells 
demonstrate therapeutic potential in various disease settings, including autoimmune 
diabetes. We believe there is a need to further investigate the role of DN T cells in the 
prevention of autoimmune diabetes in the non-transgenic system, which is more 
physiologically relevant to humans. To do this, the implementation of CD1d-deficient 
mice becomes crucial for the isolation of DN T cells void of any contaminating NKT 
cells. As such, the study of their function in diabetes-susceptible mice as well as their 
ability to prevent autoimmune diabetes in the non-transgenic setting will help to 
reveal their therapeutic potential in the context of autoimmune diabetes in humans. 
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1.7 Rationale, hypothesis and objectives  
 DN T cells exhibit an antigen-specific immunoregulatory potential in various 
experimental settings, including the prevention of autoimmune diabetes. Indeed, by 
taking advantage of the 3A9 TCR:insHEL transgenic system, we have shown that 
low DN T cell proportion associates with autoimmune diabetes susceptibility and that 
a single transfer of TCR transgenic DN T cells is sufficient to prevent disease 
progression in otherwise autoimmune diabetes-prone mice 214. Interestingly, the DN 
T cell-injected mice presented with a significant reduction in antigen-specific 
autoantibodies 214. Altogether, these results suggest that DN T cell restoration leads to 
the elimination of autoreactive B cells in vivo and that DN T cells may be of 
therapeutic interest for diabetic patients. However, before moving towards a clinical 
setting, it is important to characterize DN T cells in the non-transgenic, TCR 
polyclonal setting, therefore under more physiologically relevant conditions, as well 
as determine whether DN T cells in the diabetes-susceptible NOD mouse are 
functional. This led us to hypothesize that: 
Restoring DN T cell number in non-Tg autoimmune-prone mice prevents 
diabetes onset and may be of therapeutic interest for autoimmune diabetes in 
humans.  
The main objectives of the thesis are to: 
 Determine DN T cell phenotype and proportion using non-transgenic mice. 
 Verify whether DN T cells from diabetes-susceptible mice are equally 
functional. 
 Demonstrate whether non-transgenic DN T cells can delay/prevent diabetes 
development in vivo. 
 Define the mechanism of action of non-transgenic DN T cells in vivo.  
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CHAPTER 2 : ARTICLE 1 
2.1 IL-10 limits the expansion of immunoregulatory CD4-CD8- 
T cells in autoimmune-prone NOD mice 
Erin E. Hillhouse, Claudine Beauchamp, Geneviève Chabot-Roy, Véronique Dugas, 
Sylvie Lesage 
This article was published in Immunology and Cell Biology 88, 771-780 (2010) and was 
merited the title of "Outstanding Observation" as well as a "News and Commentary" on 
the article. 
I evaluate my contribution to this article at 85%. I participated in the experimental design 
alongside G. Chabot-Roy and S. Lesage. C. Beauchamp demonstrated the 3A9 DN T cell 
IL-10 production (Figure 3).  G. Chabot-Roy determined the cellular target of 3A9 DN T 
cells by performing a cytotoxicity assay (Figure 1D). C. Beauchamp and V. Dugas 
contributed to the phenotyping of 3A9 DN T cells (Figure 1A,1C). Personally, I 
performed the experiments that produced the remaining figures. I set up the CD107a 
assay and determined both the cytotoxic potential and cytotoxic activity of 3A9 DN T 
cells, with the exception of Figure 1D. I performed all of the cellular expansions as well 
as the proliferation and apoptosis assays. I actively participated in the interpretation and 
analysis of the results, the generation of the figures, the writing of the manuscript as well 
as the response to the reviewers, which were accomplished with the help of S. Lesage.  
The results presented in this article are essential to the thesis as they describe the target of 
3A9 DN T cells and show the comparable cytotoxic activity of 3A9 DN T cells from the 
diabetes-resistant and -susceptible genetic backgrounds. Therefore, these results 
demonstrate that the association of DN T cells to T1D susceptibility is due to a deficiency 
in DN T cell number, not function. In addition, the findings presented in this article 
reveal that DN T cell expansion is regulated, at least in part, by IL-10, suggesting that the 
IL-10 pathway may contribute to the regulation of DN T cell number. 
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2.2 Abstract   
 
 Regulatory T cells appear to show great potential for use in cellular therapy. In 
particular, CD4-CD8- (DN) T cells, which compose 1 to 3% of total T lymphocytes, 
exhibit prominent antigen-specific immune tolerance properties and confer immune 
tolerance in models of allografts and xenografts. We have recently demonstrated that 
autoimmune-diabetes prone mice carry fewer DN T cells and that this phenotype 
contributes to autoimmune-diabetes susceptibility, suggesting that increasing DN T cell 
number in autoimmune-prone individuals may be of therapeutic interest. To achieve this 
goal, we must first determine whether the remaining DN T cells in autoimmune-prone 
mice are functional.  In addition, we must identify the parameters which regulate the 
numbers of DN T cells. Herein, we evaluate the immunoregulatory properties of DN T 
cells in the autoimmune-prone NOD genetic background. Using the 3A9 TCR transgenic 
mice, we demonstrate that DN T cells from both diabetes-resistant B10.Br and 
genetically autoimmune-prone NOD.H2k mice show an equivalent immuno-regulatory 
potential on a per cell basis. However, upon stimulation, there is a tenfold increase in the 
number of 3A9 TCR transgenic DN T cells that produce IL-10 from NOD.H2k mice in 
comparison to B10.Br mice. We further demonstrate that IL-10 facilitates DN T cell 
apoptosis and thus may regulate the number of DN T cells. Together, our results 
demonstrate that, although reduced in number, DN T cells from mice carrying an 
autoimmune-prone genetic background exhibit a potent cytotoxic potential and that DN T 
cell expansion is regulated at least in part by IL-10. 
 
Keywords: autoimmune diabetes, IL-10, immune regulation, T cells, transgenic mice 
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2.3 Introduction 
 
 Many different T cell subsets have been shown to regulate immune responses 
and/or autoimmunity including CD4+CD25+FoxP3+ naturally occurring T cells (nTregs), 
IL-10-producing CD4+ Tr1 cells, TGF-β-producing CD4+ Th3 cells, CD8+CD28- T cells, 
CD4-CD8- (DN, double negative) T cells, CD4+CD8+ (DP, double positive) T cells, and 
Natural Killer T (NKT) cells 1-3. The contribution of these respective subtypes to the 
proper control of immune tolerance and prevention of autoimmune disease remains to be 
defined. Their diverse antigenic specificity and/or distinct mode of action hint that the 
contribution of each of these T cell subsets to specific peripheral tolerance requirements 
may vary 2. Hence, there is a need to further examine the contribution of various T cell 
subsets to autoimmune predisposition.  
 
 Of these regulatory T cell subsets, CD4-CD8- (DN) T cells compose 1%–3% of 
peripheral T lymphocytes in both mice and humans 4, 5. Importantly, the insertion of a 
TCR transgene has facilitated the identification and isolation of DN T cells, as well as 
their implication in antigen-specific immunosuppression 6-12. Indeed, using various TCR 
transgenic mouse models, it has been shown that DN T cells carry a unique 
immunoregulatory potential, which resides in their ability to specifically suppress T cells 
in an antigen-specific manner 13-18. DN T cells acquire antigen-specific peptide/MHC 
complexes through their interaction with antigen presenting cells and can subsequently 
present peptide/MHC complexes to CD8 T cells and eliminate the latter 13, 17. 
Interestingly, these characteristics are equally shared by human DN T cells 4. Moreover, 
non-transgenic DN T cells can also efficiently eliminate activated B cells presenting the 
cognate antigen 5. Taken together, these data demonstrate that the immunosuppressive 
function of DN T cells is mediated, at least in part, through the antigen-specific 
elimination of activated T or B cells. 
 
 This antigen-specific immunoregulatory function of DN T cells was further 
revealed in the context of transplant tolerance mouse models 13, 14, 19. Pre-transplant 
 62 
treatment with donor–lymphocyte infusion (DLI) results in a significant increase in the 
proportion of antigen-specific DN T cells in accepted allografts and xenografts 13, 14, 19. In 
addition, in vivo transfer of antigen-specific DN T cell clones prevents skin and cardiac 
allograft rejection 13, 15. Activated DN T cells were also shown to protect from graft-vs-
host disease and antigen-induced autoimmune diabetes 16, 18. Therefore, the relatively rare 
DN T cell subset exhibits a remarkably potent immunosuppressive potential in multiple 
model systems, from transplantation to autoimmunity. 
 
 More recently, our group investigated the role of DN T cells in spontaneous 
models of autoimmune-diabetes. We took advantage of the 3A9 TCR:insHEL transgenic 
system, where the 3A9 TCR transgene recognizes a peptide from hen egg lysozyme 
(HEL) in the context of I-Ak 20, while the insHEL transgene enforces expression of HEL 
in the pancreatic tissue 21. TCR:insHEL BALB.K mice are relatively resistant to 
autoimmune-diabetes progression and the deletion of CD47 in this strain is sufficient to 
break immune tolerance leading to a high diabetes incidence in TCR:insHEL CD47-
deficient BALB.K mice 22. Interestingly, the proportion of DN T cells was much reduced 
in the autoimmune-diabetes prone CD47-deficient mice and a single transfer of DN T 
cells in the CD47-deficient BALB.K transgenic model was sufficient to prevent 
autoimmune diabetes onset 22. Of relevance, we also showed that both NOD non-
transgenic and TCR transgenic autoimmune diabetes-prone mouse models exhibited a 
low number of DN T cells relative to other autoimmune diabetes-resistant strains 22. 
Together, these results suggest that restoring DN T cell number in autoimmune-prone 
mice prevents diabetes onset and may be of therapeutic interest for type 1 diabetes.  
 
 The primary objective of this study was thus to determine whether the activity of 
DN T cells is naturally impaired in the spontaneous autoimmune diabetes-prone NOD 
genetic background. We opted to compare 3A9 TCR DN T cells from autoimmune 
resistant B10.Br and autoimmune-prone NOD.H2k mice 9. Surprisingly, DN T cells 
originating from both genetic backgrounds efficiently eliminate their target cells 
demonstrating that the cytotoxic function of DN T cells is not impeded in autoimmune-
prone mice. However, we find that DN T cells derived from the NOD genetic background 
 63 
produce more IL-10, which reduces the extent of DN T cell expansion. Altogether, the 
association of DN T cells to autoimmune diabetes susceptibility is most probably due to 
the homeostatic regulation of DN T cells. 
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2.4 Results 
 
2.4.1 3A9 TCR transgenic DN T cells are cytotoxic towards B cells 
 
 Using non-transgenic and TCR transgenic models, it has been previously shown 
that DN T cells are cytotoxic towards T cells or B cells 5, 7, 13, 23. We first aimed to 
determine whether DN T cells observed in 3A9 TCR transgenic mice carried a cytotoxic 
potential. To obtain purified DN T cells, we isolated 3A9 TCR transgenic T cells on the 
basis of CD4-CD8- 1G12+ expression. Importantly, we show that 1G12+ DN T cells do 
not express DX5 or stain with aGal-Cer CD1d-tetramer (Figure 1a), suggesting that they 
are not CD4-CD8- NKT cells. Moreover, following antigen-stimulation (anti-CD3, anti-
CD28, IL-2 and IL-4), at least 90% of DN T cells remain CD4-CD8-FoxP3-, with some 
experiments reaching purities above 99% (Figure 1b and data not shown). We 
subsequently demonstrate that these highly purified 3A9 DN T cells from both B10.Br 
and NOD.H2k mice express a high level of granzyme B upon antigenic stimulation in the 
presence of cytokines (Figure 1c). Moreover, 3A9 DN T cells from both strains 
efficiently stain with anti-CD107a, a degranulation marker.  
 
 As DN T cells in other systems are cytotoxic towards either T cells or B cells  5, 7, 
13, 23, we next wanted to determine the specificity of 3A9 DN T cells. Using activated B 
and T cells as targets for activated 3A9 DN T cells from the B10.Br strain, we show that 
B10.Br 3A9 DN T cells efficiently eliminated HEL-antigen loaded B cells (Figure 1d). 
This killing is completely inhibited by the presence of EGTA suggesting a dependence on 
perforin/granzyme granules to mediate the cytotoxicity 24. Moreover, the 3A9 DN T cells 
eliminated B cells in an antigen-specific manner, as they did not eliminate B cells in the 
absence of HEL (Figure 2a, left) Surprisingly, 3A9 DN T cells were unable to eliminate 
T cells (Figure 1d), as opposed to the DN T cells from 2C TCR and P14 TCR transgenic 
models 13, 18. We are tempted to suggest that this difference is attributed to MHC-
restriction, where MHC class II-restricted 3A9 DN T cells have a different specificity 
compared to MHC class I-restricted 2C TCR and P14 TCR DN T cells. Notwithstanding, 
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these data suggest that 3A9 DN T cells from the B10.Br background are directly 
cytotoxic towards B cells.  
 
2.4.2 3A9 DN T cells from B10.Br and NOD.H2k mice show comparable 
antigen-specific deletion of activated B cells  
 
 We have previously shown that a reduction in DN T cell number is associated 
with autoimmune disease predisposition 22. These results do not preclude the fact that DN 
T cell function may also be altered in autoimmune-prone mice, further contributing to 
disease susceptibility. Therefore, we investigated whether the immuno-regulatory 
potential of DN T cells from a NOD genetic background was impaired. Surprisingly, 
NOD.H2k 3A9 DN T cells were able to eliminate activated B cells loaded with HEL 
antigen (Figure 2a, right). As for the B10.Br 3A9 DN T cells, this response was both 
antigen-specific and inhibited by EGTA. These results suggest that DN T cells from 
either strain of mice exhibited cytotoxicity towards activated B cells. Interestingly, the 
suppressive activity of B10.Br 3A9 DN T cells appeared to exceed that of the NOD.H2k 
3A9 DN T cells based on the absolute value of their cytotoxicity (Figure 2a, left and right 
panels, respectively). However, it should be noted that the relative difference in the 
cytotoxic activity of B10.Br and NOD.H2k 3A9 DN T cells is indeed equivalent as the 
background levels of cytotoxicity are increased for the control target cells from the 
B10.Br background. Therefore, variations between the spontaneous release of 51Cr from 
target cells of the B10 and NOD backgrounds, rather than the DN T cells themselves, 
may account for the differences observed in the absolute values of the cytotoxicity. 
 
 To directly compare the cytotoxic efficiency of 3A9 DN T cells from both strains, 
we generated F1 (B10.Br x NOD.H2k) mice, where F1 B cells could be used as common 
targets for 3A9 DN T cells from both genetic backgrounds. Our results clearly 
demonstrate that 3A9 TCR DN T cells from both B10.Br and NOD.H2k background were 
equally cytotoxic towards B cells (Figure 2b). Based on these results, we conclude that, 
on a per cell basis, the DN T cell cytotoxic function is not impeded in the autoimmune-
prone NOD genetic background.  
 66 
 
2.4.3 3A9 DN T cells from NOD.H2k mice produce more IL-10 
 
 Although the cytotoxic efficiency of 3A9 TCR DN T cell from either B10.Br or 
NOD.H2k mice was comparable, we sought to investigate the existence of any other 
potential functional differences between DN T cells from these diabetes-resistant and -
susceptible strains. Upon further phenotypic characterization of 3A9 DN T cells from 
B10.Br and NOD.H2k mice, we found that DN T cells that had undergone antigenic 
activation in the presence of cytokines produced equivalent amounts of IFNγ (data not 
shown). Interestingly, however, the production of IL-10 was considerably elevated in 
NOD.H2k 3A9 DN T cells (Figure 3a). Indeed, the culture supernatant of 3A9 DN T 
cells from NOD.H2k mice contained tenfold more IL-10 when compared to those of 
B10.Br mice. This increased quantity of IL-10 in the supernatant reflects an increased 
proportion of NOD.H2k 3A9 DN T cells efficiently producing IL-10 (Figure 3b). 3A9 
DN T cells from the NOD genetic background are, thus, functionally different from those 
of the B10.Br strain in terms of IL-10 production. 
 
2.4.4 IL-10 does not affect the cytotoxic potential of 3A9 DN T cells 
 
 IL-10 is primarily defined as an immunosuppressive cytokine and has been shown 
to impede different aspects of T cell responses 25. More importantly, IL-10 had been 
previously shown to reduce the cytotoxic potential of 2C TCR DN T cells 26. As a result, 
we verified the ability of IL-10 to hinder the cytotoxic function of 3A9 DN T cells. The 
cytotoxic potential of 3A9 DN T cells from B10.Br and NOD.H2k mice was thus assessed 
in the presence or absence of IL-10. Interestingly, the expression of granzyme B and 
CD107a (Figure 4a) as well as the antigen-specific cytotoxic activity of 3A9 DN T cells 
from either mouse strain was not affected by the presence of IL-10 in the culture (Figure 
4b).  
 
2.4.5 IL-10 impedes 3A9 DN T cell in vitro expansion 
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 Still, the activation of the 3A9 DN T cells in the presence of IL-10 revealed a 
different alteration in DN T cells. Indeed, we noted that the yield of 3A9 DN T cells 
cultured in the presence of IL-10 was repeatedly lower. We, thus, quantified the 
expansion of 3A9 DN T cells from B10.Br and NOD.H2k mice, in the presence or 
absence of IL-10. In each experiment, 3A9 DN T cells from B10.Br mice showed a 
significant reduction in cell expansion when cultured in the presence of IL-10 (Figure 5a, 
left). Notably, the expansion of 3A9 DN T cells from NOD.H2k mice, cultured in the 
absence of additional IL-10, was significantly lower than that of DN T cells from B10.Br 
mice. Moreover, although NOD.H2k 3A9 DN T cells efficiently produce IL-10, this 
response is not completely saturated as the addition of IL-10 to the cultures of 3A9 DN T 
cells from NOD.H2k mice slightly reduced their expansion (Figure 5a, right). These 
results demonstrate that IL-10 restrains DN T cell expansion and suggest that the reduced 
expansion potential of 3A9 DN T cells from NOD.H2k mice compared to that of B10.Br 
mice is the result of their elevated IL-10 production.  
 
2.4.6 IL-10 facilitates DN T cell apoptosis. 
 
 Next, we wanted to determine the mechanism by which the presence of IL-10 
influenced DN T cell expansion. Cellular expansion is a balance between the rate of 
proliferation and the rate of cell death. Therefore, we first verified the impact of IL-10 on 
DN T cell proliferation in vitro. Using CFSE-labelled 3A9 DN T cells, we demonstrate 
that IL-10 did not affect the proliferative response of DN T cells of either mouse strain 
(Figure 5b). These data indicate that the difference in DN T cell expansion potential 
between the two strains was not a consequence of a defect in cellular proliferation. In 
addition, these results demonstrate that IL-10 does not affect DN T cell proliferation. 
 
 Therefore, to explain the decrease in cellular expansion, we suspected that IL-10 
facilitated DN T cell apoptosis. The percentage of apoptotic 3A9 DN T cells upon a 6 to 
8 day culture was monitored by Annexin V staining (Figure 6). First, a higher proportion 
of 3A9 DN T cells from NOD.H2k mice, which spontaneously produce high levels of IL-
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10, underwent apoptosis when compared to the B10.Br counterpart (compare Figures 6a 
and 6b without additional IL-10). Second, the percentage of apoptotic 3A9 DN T cells 
from B10.Br mice was elevated when IL-10 was added to the culture. Moreover, 
although this tendency was not significant overall, 3A9 DN T cells from NOD.H2k mice 
also showed a slight increase in apoptosis in some experiments when IL-10 was added to 
the culture, which is most probably attributed to the high level of endogenous IL-10 
production by these cells. To further confirm the finding that IL-10 facilitated DN T cell 
apoptosis, we cultured 3A9 DN T cells from NOD.H2k mice, which produce high levels 
of endogenous IL-10, with 10μg/ml of an antibody targeting the IL-10 receptor. Indeed, 
the presence of this blocking antibody resulted in an increase in the cellular expansion of 
3A9 DN T cells from NOD.H2k mice (Figure 7a), as well as a decrease in their level of 
apoptosis (Figure 7b). Together, these results suggest that IL-10 impedes DN T cell 
expansion and correlates with an increase in DN T cell apoptosis.  
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2.5 Discussion 
 
 DN T cells are rare and potent immunosuppressive cells, which eliminate their 
target T cells or B cells in an antigen-specific manner 5, 13. Importantly, the insertion of a 
TCR transgene facilitates the identification and isolation of DN T cells, as well as their 
implication in antigen-specific immunosuppression 6-12. Indeed, the DN T cell subset 
exhibits a potent immunosuppressive potential in multiple model systems, including graft 
rejection13-15, 19, graft-vs-host disease16 and autoimmune diabetes 18. We have recently 
demonstrated that autoimmune-diabetes prone mice exhibit fewer DN T cells than the 
autoimmune-resistant mouse strains 22. In addition, we have shown that, in a syngenic 
3A9 TCR BALB.K transgenic system, a single transfer of DN T cells is sufficient to 
confer resistance to diabetes progression 22. These results suggest that modulation of DN 
T cell number may be of therapeutic interest, if DN T cell function is not affected in 
autoimmune diabetes-prone individuals. Herein, we examined the cytotoxic activity of 
DN T cells from both autoimmune diabetes-resistant and -prone mice. We further 
explored the role of IL-10 production by DN T cells from the NOD genetic background 
in the regulation of DN T cell expansion.  
 
 To compare the function of DN T cells in the autoimmune-resistant and -prone 
mice, we took advantage of the 3A9 TCR transgene, as it has been interbred to both the 
autoimmune-resistant B10.Br and autoimmune-prone NOD.H2k strains. Indeed, apart 
from the MHC locus, NOD.H2k mice are genetically identical to the NOD strain. 
Therefore, comparison of 3A9 DN T cells from B10.Br and NOD.H2k mice allows us to 
define whether the autoimmune-prone NOD genetic background influences DN T cell 
function. Using this model, we have provided compelling evidence that the cytotoxic 
ability was similar between the two strains. This result supports the view that autologous 
transfer of DN T cells in autoimmune-prone mice or individuals may be of therapeutic 
interest. We aim to further explore this novel antigen-specific therapeutic avenue. 
 
 DN T cells isolated from the non-transgenic system demonstrate antigen-specific 
cytotoxicity towards both T cells and B cells 5. Interestingly, DN T cells from various 
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TCR transgenic models have been reported to specifically eliminate CD8 T cells 13-18, 
while we report that the 3A9 DN T cells target B cells. We believe that the difference in 
target cell specificity may be attributed to MHC-restriction where the 2C and P14 TCR 
transgenes, most commonly used to study DN T cell cytotoxicity, are both MHC class I-
restricted, as opposed to the 3A9 TCR transgene, which is MHC class II-restricted. 
Notably, since the 3A9 TCR transgene is class II restricted, these transgenic mice hold a 
very limited number of HEL-specific CD8 T cells. Nevertheless, we extensively tested 
the cytotoxic potential of 3A9 DN T cells towards T cells by using total spleen, purified 
CD4 or purified CD8 T cells from 3A9 TCR transgenic mice (Figure 1d and data not 
shown). We have also attempted to pre-immunize the 3A9 TCR transgenic mice using 
HEL antigen with or without adjuvant. Yet, in all of these conditions, 3A9 DN T cells 
were unable to eliminate the 3A9 TCR transgenic CD4 or CD8 targets (data not shown). 
Consequently, we propose that MHC specificity dictates the cellular target of DN T cells, 
where the class II-restricted 3A9 DN T cells specifically recognize the HEL-peptide 
presented by I-Ak molecules at the surface of B cells. The study of DN T cell function in 
additional MHC class I and class II-restricted TCR transgenic models should help resolve 
this issue. Alternatively, isolation of DN T cells from non-transgenic mice may also help 
further unravel their function in immune tolerance.  
  
 We have previously shown that the proportion of DN T cells was reduced in 
autoimmune-prone mice. Our present results show that the cytotoxic function of DN T 
cells from autoimmune-prone mice is comparable to that of autoimmune-resistant mice. 
Upon further comparison of DN T cell functions between these strains, we went on to 
demonstrate that DN T cells from the NOD.H2k background produce more IL-10, which 
limits their expansion potential. Although others have previously shown that IL-10 
inhibits the cytotoxic function of DN T cell 27, we herein demonstrate that IL-10 has no 
direct effect on DN T cell cytotoxicity towards activated B cells in the 3A9 TCR 
transgenic setting. One possibility for this discrepancy is the nature of the DN T cells 
utilized in these assays. Indeed, IL-10 inhibited the cytotoxic potential of DN T cell 
clones 26, whereas we demonstrate that IL-10 does not influence the cytotoxic potential of 
primary cell cultures. Nonetheless, despite our observation that IL-10 had no direct effect 
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on DN T cell cytotoxicity on a per cell basis, it must be noted that IL-10 would ultimately 
have a secondary effect on DN T cell cytotoxicity since the presence of IL-10 results in a 
reduction in their cellular expansion, which will subsequently decrease the magnitude of 
the global cytotoxic response.  
  
 The pro-apoptotic role of IL-10 has also been reported for other cell types, 
including monocytes, Th1 cells, and dendritic cells 25. It should be noted that the role of 
IL-10 in diabetes progression is controversial, and has been demonstrated to both protect 
from and accelerate disease development. For instance, daily IL-10 subcutaneous 
treatment of 9–10-week-old NOD mice delayed the onset of diabetes, reduced the 
severity of insulitis and significantly reduced disease incidence 28. Furthermore, systemic 
administration with an IL-10/Fc fusion protein in female NOD mice from 5 to 25 weeks 
of age blocked diabetes development and provided lasting protection after treatment was 
terminated 29. In contrast to these immunosuppressive effects of IL-10, the transgenic 
expression of IL-10 by insulin-producing pancreatic β cells or glucagon-producing 
pancreatic α cells led to an accelerated onset of diabetes in NOD mice 30-33. These 
findings suggest that the IL-10 location plays a deciding role on the outcome of diabetes 
development where systemic IL-10 confers protection whereas islet-specific IL-10 
exacerbates diabetes progression. It is tempting to speculate that the presence of IL-10 
within the pancreatic islets impedes DN T cell expansion and thereby inhibits their 
immunoregulatory function, while systemic administration of IL-10 dominantly 
contributes to other immunosuppressive mechanisms.  
  
 Interestingly, IL-10 genetic polymorphisms have been associated with 
autoimmune diabetes susceptibility, as well as in the progression of various autoimmune 
diseases, such as lupus, rheumatoid arthritis, and colitis 25, 34, 35. Clearly, IL-10 has an 
impact on a multitude of autoimmune disorders and extensive studies are required to 
define the mechanistic contribution of these genetic polymorphisms to the various 
pathologies. Although the Il10 gene is not located within an insulin-dependent diabetes 
(Idd) susceptibility locus, IL-10 production by T cells is regulated at least in part by 
genetic polymorphisms encoded within the Idd5.1 susceptibility locus 36. As a result, we 
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are currently investigating whether the Idd5 susceptibility locus plays a role on the 
regulation DN T cell number. 
 
 We have previously reported that a single transfer of DN T cells in the CD47-
deficient BALB.K transgenic model was sufficient to prevent autoimmune diabetes onset 
22. Other regulatory T cell subsets have been shown to confer protection from diabetes 
progression, such as Foxp3+ Tregs37-39 and NKT cells 40, 41. Interestingly, both of these 
cell types also produce IL-1039, 41, 42. Moreover, it has recently been shown that in the 
absence of IL-10 signalling there is a subsequent decrease in both expression of Foxp3 by 
Tregs as well as their suppressive activity 43. This contrasts with our study where 
increased IL-10 signalling has no effect on DN T cell function yet facilitated DN T cell 
apoptosis resulting in decreased cell numbers. These observations highlight the 
interdependent cellular complexity of in vivo immune regulation. 
 
 Other than IL-10 production, DN T cells have an intriguing resemblance to NKT 
cells. They both carry a similar phenotype, where both DN T cells and a subset of NKT 
cells express TCRβ yet lack CD4 and CD8 co-receptor expression22, 44, 45; they both 
demonstrate cytotoxic activity as shown throughout this manuscript and 46, 47; they are 
both present in lower numbers in NOD mice and they both confer protection from 
diabetes development 22, 48. Moreover, we have recently shown that the CD47 pathway is 
implicated in the regulation of DN T cell numbers 22, while NKT cell numbers are 
regulated by Idd13 49, 50, a diabetes-susceptibility locus which encodes the highly 
polymorphic cellular ligand of CD47, namely CD172a 51, 52. Together, these data strongly 
suggest that DN T cells carry an NKT cell-like phenotype. Notwithstanding, we have 
identified DN T cells in non-transgenic mice that are phenotypically similar to 3A9 TCR 
transgenic DN T cells. Indeed, as demonstrated herein for 3A9 TCR transgenic DN T 
cells (Figure 1a), the DN T cells isolated from non-transgenic mice lack DX5 expression 
and do not stain with CD1d-tetramer 22 .Taken together, these results suggest that 
although DN T cells exhibit similarities to NKT cells, they compose a unique subset. 
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 In summary, evaluating the role of DN T cells in the 3A9 TCR transgenic setting 
has highlighted their antigen-specific mode of action towards activated B cells. 
Moreover, we have demonstrated that the cytotoxic potential of DN T cells on a per cell 
basis is not altered in autoimmune-prone mice or in the presence of IL-10. However, IL-
10 facilitates DN T cell apoptosis resulting in an inefficient cellular expansion in vitro. 
We have previously shown that the CD47 pathway influences the proportion of DN T 
cells in vivo 22. Future studies should decipher the contribution of both the IL-10 and the 
CD47 pathway in the homeostatic regulation of DN T cells. Altogether, as the cytotoxic 
function of DN T cells is normal in genetically autoimmune-prone mice, we propose that 
the association of DN T cells to diabetes resistance is most probably due to the regulation 
of DN T cell number. Therefore, with regards to new approaches in cellular therapy, our 
main focus should lie on the restoration and expansion of DN T cell numbers in an 
antigen-specific manner, which may contribute to immune-regulation and prevent 
autoimmune disease progression.  
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2.6 Methods 
 
Mice 
3A9 TCR 53 and insHEL (ILK-3) 21 transgenic mice on B10.Br, NOD.H2k and F1 
(B10.Br x NOD.H2k) background have been previously described 9. Studies were 
approved by the Maisonneuve-Rosemont Hospital ethics committee overseen by the 
Canadian Council for Animal Protection. 
 
Flow cytometry  
6–12-wk old non-diabetic mice (Diastix negative) were analyzed. Single cell suspensions 
of lymphoid organs were prepared by mechanical disruption through a 70 μm sterile cell 
strainer (BD Biosciences). NH4Cl was used for erythrocyte lysis of single cell 
suspensions from spleens. αGal-Cer-loaded CD1d-tetramer is a generous gift from Dr. 
David Serreze. Intracellular staining for granzyme B (16G6, eBiosciences) and IL-10 
(JES5-16E3, Biolegend) were performed using BD Biosciences Cytofix/Cytoperm Kit. 
The FITC Anti-Mouse/Rat Foxp3 Staining Set was used for Foxp3 staining according to 
the manufacturer's instructions (eBiosciences). Anti-clonotypic 1G12 antibody, specific 
to the 3A9 TCR 54, was detected using APC-labelled anti-mouse IgG1 (clone X56, BD 
Biosciences). PerCP-labelled CD8α (53-6.7) and PerCP-labelled 7-AAD were purchased 
from BD Pharmingen. All other antibodies and staining reagents were purchased from 
Biolegend. Data was collected on a FACSCalibur or FACS LSR II (BD Biosciences) and 
analyzed using FlowJo software (Treestar). 
 
Cell purification 
Prior to DN T cell sorting, cell suspensions were stained with biotin-labelled anti-mouse 
B220 antibody (RA3 6B2, Biolegend) and B220+ cells were removed using the 
EasySep™ biotin selection kit (Stem Cell). The B220 negative fraction was then stained 
with antibodies to CD4, CD8 and 3A9 TCR (using the 1G12 clone) and sorted using a 
FACS Vantage (BD Biosciences) for CD4-CD8-1G12+ DN T cells (purity > 90%). For 
some experiments, DN T cells were obtained by removing CD4, CD8 and B220 positive 
cells using the EasySep™ biotin selection kit. This procedure efficiently removed CD4+, 
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CD8+ and B220+ cells (< 10% contaminating cells). B and T cells were also selected 
using the EasySep™ PE selection kit, respectively staining for B220 or CD3 (purity > 
85%). Similar results were obtained when B and T cells were sorted (purity > 95%). 
 
Cellular expansion  
Sorted DN T cells (250 000 cells/ml) were cultured in the presence of plate-bound anti-
CD3 (1μg/ml, 145-2C11) and anti-CD28 (10μg/ml, 37.51) with IL-2 (30U/ml), IL-4 (30 
U/ml) ± IL-10 (10ng/ml) or anti-IL-10R (10μg/ml, 1B1.3a) for 5 to 7 days, in RPMI 
supplemented with 10% fetal bovine serum (Invitrogen), 1% Penicillin Streptomycin 
(Invitrogen), 1% HEPES 1M (GIBCO) and 0.1% 2-mercaptoethanol 1000X (GIBCO). 
Cytokines were purchased at Feldan Bio. Cell cultures were monitored daily for 
confluence and cytokine supplemented media was added when cell density was > 1x106 
cells/ml. Cell number was quantified by trypan blue exclusion.  
 
Cytotoxic potential  
DN T cells were sorted or enriched using using the EasySep™ biotin selection kit as 
described above and cultured in the presence of either soluble anti-CD3 and irradiated 
APCs (T-depleted spleen cells, 2.5 Gy, 250 000 cells/ml) or plate-bound anti-CD3 and 
anti-CD28, with IL-2, IL-4 ± IL-10, at the same concentrations as indicated for cellular 
expansion. For granzyme B detection, cells were re-stimulated at day three for 4h with 
PMA (50ng/ml) (Sigma), ionomycin (0.5μg/ml) (Sigma), and Brefeldin A (10 μg/ml) 
(Sigma), prior to intracellular staining. For CD107a (LAMP1) staining, we replaced 
Brefeldin A with mononesin (2nM) (BD biosciences) and the anti-CD107a antibody was 
added during the 4h re-stimulation 55.  
 
Cytotoxicity 
Sorted or enriched DN T cells were stimulated 7 days in vitro with either soluble anti-
CD3 and irradiated APCs or plate-bound anti-CD3 and anti-CD28, IL-2, IL-4 ± IL-10. 
LPS (1μg/ml) and anti-CD3 + irradiated APCs + IL-2 were used to stimulate B and T 
cells, respectively, in vitro for 2 days, and HEL antigen (1mg/ml) (Sigma) was added in 
the last 24h of culture. Target cells were washed and loaded with 50μCi 51Cr (Perkin 
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Elmer) for 90 min. DN T cells and target cells were quantified by trypan blue exclusion 
prior to co-culture in order to obtain the desired DN T cell to target cell ratio. DN T cells 
and target cells were incubated for 3h in the presence or absence of EGTA (0.16mM) (J. 
T. Baker). %Cytotoxicity = 100*(E –S)/(M – S), where E = experiment, S = spontaneous 
and M = maximal release. 
 
Measurement of cytokines in the supernatant of cultured DN T cells 
DN T cells were sorted from TCR transgenic B10.Br and NOD.H2k mice and cultured for 
3 days with soluble anti-CD3, irradiated APCs, IL-2 and IL-4. The amount of IL-10 from 
the supernatant of cultured DN T cells was measured by an ELISA kit (Biolegend) 
according to the manufacturer’s protocol.  
 
Proliferation assay 
For proliferation assays, sorted DN T cells were labelled with CFSE (2μM) (Invitrogen) 
and washed twice in cold supplemented RPMI prior to culture. CFSE-labelled DN T cells 
were cultured in the presence of plate-bound anti-CD3, anti-CD28, with IL-2, IL-4 ± IL-
10, as above. CFSE dilution was monitored by flow cytometry. 
 
Apoptosis assay 
Sorted DN T cells were cultured in the presence of plate-bound anti-CD3 and anti-CD28, 
with IL-2, IL-4 ± IL-10 for 6 to 8 days. Apoptosis was quantified by flow cytometry 
using Annexin-V.  
 
Statistics 
The paired student’s t test or the Mann-Whitney U statistical test was applied where 
appropriate. 
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2.9 Figures  
 
 
 
 
 
 
 
Figure 1: 3A9 DN T cells efficiently eliminate activated B cells. A) 3A9 TCR B10.Br 
splenocytes were stained for CD4, CD8, 1G12, DX5 and CD1d-tetramer. DX5 (left 
panel) and CD1d-tetramer (right panel) expression is shown for CD4-CD8- gated cells 
relative to 1G12 expression. B) B10.Br 3A9 DN T cells were cultured with anti-CD3, 
anti-CD28, IL-2 and IL-4. After 7 days, DN T cells were stained CD4, CD8β, and Foxp3 
expression. C) B10.Br and NOD.H2k 3A9 DN T cells cultured for 3 days with anti-CD3, 
APCs, IL-2 and IL-4. Left panels, Intracellular expression of granzyme B with (thick) or 
without cytokine stimulation (shaded). Right panels, CD107a expression with (thick) or 
without (shaded) PMA and ionomycin restimulation. D) The percent specific lysis is 
shown for 3A9 B10.Br DN T cells towards HEL-pulsed LPS-activated B cells or anti-
CD3, APC and IL-2 activated T cells in the presence, or not, of EGTA. All data is 
representative of at least 3 independent experiments. 
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Figure 2: The cytotoxic function of 3A9 DN T cells from autoimmune-prone mice is 
not impaired. 3A9 DN T cells and B cells were isolated from the spleens of TCR 
transgenic B10.Br or NOD.H2k mice. A) The percent specific lysis is shown for B10.Br 
(left) and NOD.H2k (right) 3A9 DN T cells towards HEL-pulsed LPS-activated B cells 
from B10.Br and NOD.H2k mice, respectively. EGTA was added in some conditions, as 
indicated. B) The percent specific lysis is shown for B10.Br (filled shapes) and NOD.H2k 
(open shapes) 3A9 DN T cells towards a common target, HEL-pulsed LPS-activated F1 
(B10.Br X NOD.H2k) B cells. Representative of 4 independent experiments. 
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Figure 3. DN T cells from the diabetes-susceptible mice produce greater quantities 
of IL-10. 3A9 DN T cells were isolated from the spleen of TCR transgenic B10.Br or 
NOD.H2k mice and cultured in the presence of anti-CD3, APCs, IL-2 and IL-4 for 3 days. 
A) IL-10 levels were quantified by ELISA from the 3-day culture supernatant. Mean ± 
SD of at least 3 independent experiments. B) IL-10 was measured by intracellular 
staining. Representative of at least 3 independent experiments. *p <0.05 (Mann-Whitney 
U). 
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Figure 4. IL-10 does not impede DN T cell cytotoxic function. DN T cells and B cells 
were isolated from spleens of 3A9 TCR transgenic B10.Br or NOD.H2k mice. A) 
Intracellular expression of granzyme B (left panels) and CD107a expression (right 
panels) are shown for DN T cells cultured in the presence of anti-CD3, anti-CD28, IL-2, 
IL-4 (solid) and IL-10 (dotted). B) The percent specific lysis is shown for 3A9 B10.Br 
and NOD.H2k DN T cells that were cultured with (dotted) or without IL-10 (solid) 
towards HEL-pulsed LPS-activated F1 (B10.Br X NOD.H2k) B cells. Representative of 
at least 3 independent experiments. 
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Figure 5. IL-10 impedes DN T cell expansion but not DN T cell proliferation. 3A9 
DN T cells were sorted from B10.Br or NOD.H2k mice and activated using anti-CD3, 
anti-CD28, IL-2, and IL-4. A) Cellular expansion is shown for 3A9 DN T cells that were 
stimulated as described above ± IL-10 for 6 to 8 days. *p <0.05 (Paired student’s t test). 
B) Cellular proliferation was measured using CFSE-labelled 3A9 DN T cells that were 
stimulated as described above with (dotted) or without (solid) IL-10. Representative of at 
least 3 independent experiments. 
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Figure 6. IL-10 increases cellular apoptosis. 3A9 DN T cells were isolated from the 
spleens of B10.Br and NOD.H2k mice and stimulated with anti-CD3, anti-CD28, IL-2 
and IL-4 ± IL-10 for 5 to 7 days. Amount of apoptotic cells was quantified by Annexin V 
staining. A) Representative results are shown. B) A compilation of all experiments are 
shown. *p <0.05 (Paired student’s t test). 
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Figure 7. Blocking IL-10 signalling increases DN T cell expansion while decreasing 
DN T cell apoptosis.  Sorted NOD.H2k 3A9 DN T cells were stimulated with anti-CD3, 
anti-CD28, IL-2 and IL-4 ± anti-IL-10R for 7 days. A) Cellular expansion was quantified 
by cell count using trypan blue exclusion. B) The amount of apoptotic DN T cells was 
quantified by Annexin V staining.  
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3.1 Immunoregulatory CD4-CD8- T cells, a novel cellular 
therapeutic preventing autoimmune diabetes 
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This article is in the final stages of preparation for submission to Nature Medicine. 
 I evaluate my contribution to this article at 85%. I participated in the experimental 
design alongside S. Lesage. C. Beauchamp and V. Dugas participated in the phenotyping 
of TCR transgenic DN T cells (Supplementary Figure 2).  G. Chabot-Roy set up the 
insulin autoantibody ELISA assay (Figure 5D) and assisted me in the experiments 
involving pancreatic islet isolations. M. Giroux determined the cytotoxic activity of 
human DN T cells (Figure 6C) and participated in the investigation of the cytotoxic 
potential of human DN T cells (Figure 6B). Personally, I performed all experiments 
pertaining to the study of non-transgenic DN T cells, including the phenotyping, 
cytotoxicity assays, insulin autoantibody ELISA assay, in vivo transfer experiments and 
the diabetes incidence study. Moreover, I participated in the investigation of the cytotoxic 
potential of human DN T cells. I actively participated in the interpretation and analysis of 
the results, with the help of S. Lesage. I personally generated the figures and wrote the 
manuscript taking S. Lesage's comments and suggestions into consideration.  
 The results presented in this article are central to the thesis as they demonstrate 
that DN T cells from diabetes-susceptible mice exhibit fewer DN T cells. We further 
show that non-transgenic DN T cells mediate their immunoregulatory function by 
eliminating B cells presenting islet antigens in vitro and that the transfer of non-
transgenic DN T cells leads to a decrease in germinal center B cells directly within the 
pancreatic islets in vivo as well as a reduction in insulin autoantibody levels. Importantly, 
this article is the first to demonstrate that DN T cells can decrease diabetes incidence in 
non-transgenic, non-lymphopenic NOD mice. 
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3.2 Abstract 
 
 The design of treatments for autoimmune disease, such as type 1 diabetes, is 
geared towards the induction of antigen-specific of immune tolerance. CD4-CD8- 
immunoregulatory DN T cells exhibit antigen-specific immune tolerance and are thus 
gaining interest as a potential cellular therapeutic. We demonstrate that low DN T cell 
proportion is associated with diabetes susceptibility in NOD mice, where a single transfer 
of DN T cells is sufficient to decrease diabetes incidence. DN T cells mediate their 
immunoregulatory function by specifically eliminating B cells presenting islet antigens, 
leading to a decrease in germinal center B cells directly within the pancreatic islets and a 
concomitant decrease in insulin autoantibody levels. In addition, human DN T cells 
exhibit similar properties to mouse DN T cells. Altogether, these results demonstrate that 
DN T cells may be of therapeutic interest for autoimmune diabetes in humans.  
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3.3 Introduction 
 
 Autoimmunity can give rise to the destruction of healthy organs, glands, joints or 
the central nervous system due to a break in immune tolerance, which is dependent on the 
immune system discriminating between self and non-self. A prominent role in the 
prevention of autoimmunity has been attributed to the number and function of regulatory 
cell subsets, including CD4+CD25+FoxP3+ naturally occurring T cells (Tregs), IL-10-
producing CD4+ Tr1 cells, natural killer-like T (NKT) cells1-8, and B10 regulatory B 
cells9-11. One of these regulatory T cell populations, namely DN T cells that lack the 
expression of CD4 and CD8 T cell co-receptors, has been studied in both mice and 
humans for their contribution to peripheral tolerance, disease prevention and their 
potential for use in cellular therapy. Indeed, observations made using both TCR 
transgenic and non-transgenic systems have demonstrated that DN T cells may be of 
particular interest for cellular therapy due to their ability to eliminate various cellular 
targets, including T cells, B cells, NK cells, dendritic cells and macrophages, in an 
antigen-specific manner (reviewed in 12). Consequently, DN T cells are gaining interest 
as a potential cellular therapeutic in various disease settings including graft-vs-host 
disease13-15, cancer16,17 and autoimmune diabetes 18-21.  
  
 Autoimmune diabetes results from the immune-mediated destruction of the 
insulin-secreting β cells present within the pancreatic islets. The NOD (non-obese 
diabetic) mouse spontaneously develops autoimmune diabetes and has been a key tool for 
investigating the aetiology of human type 1 diabetes22,23. Indeed, the broadly 
immunosuppressive anti-CD3 therapy, which has been successful in the treatment of 
new-onset type 1 diabetic patients during clinical trials, is a protocol initially developed 
in the NOD mouse 24,25, demonstrating a parallel in disease development between humans 
and mice. Therefore, mouse models, such as the NOD mouse strain, are a useful tool as 
they allow for the characterization of the cellular mechanisms involved in the progression 
of autoimmune diabetes.  
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 Indeed, using mouse models, we have shown that, in comparison to autoimmune 
diabetes-resistant mice, the proportion of TCR transgenic DN T cells is significantly 
reduced in autoimmune diabetes-susceptible mice18, which suggests an association 
between low DN T cell number and autoimmune diabetes susceptibility. Despite a 
reduction in cell number, we have also demonstrated that TCR transgenic DN T cells 
from autoimmune diabetes-resistant and -susceptible mice exhibit an equally potent 
cytotoxic function in vitro26. Together, these results propose that a deficiency in DN T 
cell number rather than function contributes to autoimmune diabetes susceptibility. 
Consequently, we demonstrated that a single transfer of DN T cells is sufficient to 
prevent diabetes progression in autoimmune diabetes-prone mice using a TCR transgenic 
setting18. Therefore, these results suggest that the restoration of DN T cell number can 
inhibit autoimmune diabetes development.  
  
 Although T cells are known to destroy pancreatic islets, B cells are also 
implicated in disease development. First, B cells contribute to disease progression, as the 
elimination of most B cells using anti-CD20 treatment reverses or delays diabetes 
progression in both mice and humans 27,28. Moreover, both B cell-deficient NOD mice 
and NOD mice with an I-Ag7 deficiency confined to the B cell compartment were 
protected from the development of autoimmune diabetes29,30, suggesting that the antigen 
presentation function of B cells contributes to disease pathogenesis. Indeed, central to the 
development of autoimmune diabetes lies an antigen-specific response to islet antigens31-
33. Another major function of B cells is the production of antibodies. Accordingly, 
autoantibodies to islet antigens, such as insulin autoantibodies (IAA), serve to predict the 
onset of diabetes34,35 while maternally transmitted autoantibodies have been shown to 
contribute to the onset of disease in NOD offspring36,37. Altogether, B cells clearly 
contribute to autoimmune diabetes pathogenesis. 
  
 Here, we demonstrate that non-transgenic autoimmune diabetes-prone mice 
present with fewer DN T cells in comparison with autoimmune diabetes–resistant mice 
and that the restoration of DN T cell number in non-transgenic NOD mice significantly 
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decreases disease development. Moreover, we describe the phenotype and antigen-
specific function of DN T cells as well as their role in vivo. Finally, we reveal the 
functional characteristics of human DN T cells and their potential for the development of 
therapeutic approaches. 
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3.4 Results 
3.4.1 Non-transgenic DN T cells are reduced in autoimmune diabetes-prone 
mice 
 The specific isolation of immunoregulatory DN T cells from non-transgenic mice 
is complicated by the fact that DN T cells share the CD4-CD8-TCRαβ
+ phenotype with a 
subset of NKT cells 12. Indeed, a proportion of CD4-CD8-TCRβ+ cells that stain negative 
for the α-galactosyl ceramide-loaded CD1d tetramer, which is specific for type I NK T 
cells 38,39, still express NK1.1, which is expressed by natural killer (NK) and NKT cells3 
(Supplementary Figure 1A), but is also expressed by a fraction of DN T cells 
(Supplementary Figure 1C). Therefore, NKT cell surface markers cannot be used to 
effectively distinguish NKT cell subsets from DN T cells. However, immunoregulatory 
DN T cells differ from NKT cells, in that all NKT cells express a TCR restricted to CD1d 
molecules and are thus absent in CD1d-deficient mice40. As a result, we have chosen to 
use CD1d-deficient mice for the purification of DN T cells throughout these studies, 
where non-transgenic DN T cells can be easily isolated based on a CD4-CD8-CD19-
TCRβ+ phenotype (Supplementary Figure 1B). Using this gating strategy, both the 
proportion (Figure 1A) and absolute cell number (Figure 1B) of DN T cells was 
determined for the spleen and lymph nodes of CD1d-deficient mice on the autoimmune 
diabetes-resistant C57BL/6 (B6) and BALB/c genetic backgrounds as well as the 
autoimmune diabetes-prone NOD genetic background. Indeed, the proportion and 
absolute number of DN T cells is significantly reduced in the secondary lymphoid organs 
of the autoimmune diabetes-prone mice. These results suggest an association between a 
reduced DN T cell number and autoimmune diabetes susceptibility in the non-transgenic 
setting. 
 
3.4.2 Non-transgenic DN T cells express an activated phenotype  
  
 DN T cells have been mostly characterized in TCR transgenic settings where DN 
T cells exhibit an activated phenotype in the presence of their cognate antigen whereas 
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they express a naive phenotype in the absence of cognate antigen (reviewed in 12). As a 
result, we chose to compare the phenotype of non-transgenic DN T cells to DN T cells 
from a TCR transgenic model.  More specifically, to further characterize the non-
transgenic DN T cells in the absence of any contaminating NKT cells, we compared the 
DN T cell surface phenotype of the non-transgenic CD1d-deficient mice alongside DN T 
cells from TCR transgenic mice, namely the 3A9 TCR:insHEL transgenic mouse model. 
In this model, the 3A9 TCR transgene, which can be detected using the 1G12 anti-3A9 
clonotypic mAb 41, recognizes a HEL peptide in the context of I-Ak and the insHEL 
transgene is expressed under the rat insulin promoter 41,42. As expected, DN T cells from 
either CD1d-deficient mice or 3A9 TCR:insHEL double transgenic mice all expressed 
the T cell marker, CD3, and expressed an intermediate level of another T cell marker, 
CD5 (Supplementary Figure 2A), analogous to 3A9 TCR single transgenic DN T cells 
18. Moreover, in comparison to 3A9 TCR DN T cells, which express a naive phenotype 
18, DN T cells from 3A9 TCR:insHEL double transgenic mice, bearing the HEL cognate 
antigen for the TCR transgene, express the activation markers CD122, CD69 and CD44 
(Supplementary Figure 2B). Interestingly, DN T cells from CD1d-deficient mice 
expressed similar levels of the various activation markers (Supplementary Figure 2B). 
Altogether, non-transgenic DN T cells express a similar activated phenotype as DN T 
cells from the 3A9 TCR:insHEL double transgenic system where DN T cells are 
activated by the presence of HEL, which represents a self-antigen. 
 
3.4.3 Non-transgenic DN T cells exhibit antigen-specific cytotoxic activity 
 
 As the diabetes-susceptible NOD mice clearly demonstrate a deficiency in DN T 
cell number, we wanted to verify whether NOD mice also exhibit a deficiency in DN T 
cell function. However, due to the low number of DN T cells, in vitro cellular expansion 
is necessary in order to obtain a sufficient number of DN T cells to study. Indeed, we can 
readily expand DN T cells from non-transgenic mice by approximately 90-fold after 1 
week in culture (Supplementary Figure 3). Subsequently, we examined whether non-
transgenic DN T cells expressed cytotoxic potential. Accordingly, we demonstrate that 
expanded NOD CD1d-/- DN T cells do indeed express the cytolytic enzymes, granzyme 
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B and perforin, and, following re-stimulation, efficiently stain with the degranulation 
marker, anti-CD107a (Figure 2A). Therefore, DN T cells from diabetes-prone mice 
demonstrate cytotoxic potential.  
 
 As we have previously shown that 3A9 TCR transgenic DN T cells are cytotoxic 
towards B cells in an antigen-specific manner in vitro, we next wanted to validate these 
results in the non-transgenic setting. Due to the polyclonal nature of the TCR and the 
target antigens involved in diabetes progression, we decided to use a pool of islet 
antigens to study the function of non-transgenic DN T cells. Using activated B cells as 
targets, we show that B6.CD1d-/- DN T cells efficiently eliminate islet antigen-loaded B 
cells, but not HEL-loaded B cells, where HEL (hen egg lysozyme) is a non-relevant 
antigen (Figure 2C). Following the findings of Figure 2B, these results confirm that 
non-transgenic DN T cells do recognize self-antigens. Interestingly, this killing is 
completely inhibited by the presence of ethylene glycol tetraacetic acid (EGTA) (Figure 
2B), suggesting a dependence on perforin/granzyme granules to mediate the 
cytotoxicity43.  Therefore, non-transgenic DN T cells mediate an antigen-specific 
cytotoxic activity towards B cells using the perforin/granzyme pathway. 
 
3.4.4 A single transfer of DN T cells is sufficient to reduce the diabetes 
incidence in NOD mice. 
 
 As NOD. CD1d-/- DN T cells exhibit a deficiency in number rather than function, 
we next wanted to determine whether the restoration of DN T cell number in autoimmune 
diabetes-prone mice prevented disease development in the non-transgenic setting. Due to 
the low number of DN T cells, in vitro cellular expansion is necessary. DN T cells were 
first sorted from non-transgenic NOD.CD1d-/- mice and expanded in vitro. 2x106 
activated DN T cells were transferred to 12 week-old non-diabetic female NOD mice. In 
comparison to non-injected or to activated CD4+ T cell-injected controls, mice that were 
injected with activated DN T cells exhibited a significant reduction in the incidence of 
diabetes up to 32 weeks of age (Figure 3 and Supplementary Figure 4). Therefore, a 
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single autologous transfer of expanded DN T cells is sufficient to significantly decrease 
diabetes progression. 
 
3.4.5 Transferred DN T cells migrate to, and proliferate within, pancreatic 
lymph nodes 
 
 As DN T cells impeded diabetes progression in NOD mice, we argued that they 
reached lymphoid organs, where they eliminated antigen-specific B cells. Indeed, the 
transferred DN T cells could be tracked to the spleen and peripheral lymph nodes as early 
as 24 hours, and for at least 4 weeks, post-transfer (Supplementary Figure 5). 
Moreover, the transferred DN T cells maintain their CD4-CD8- phenotype and do not 
upregulate B220 (Figure 4A), where B220 is expressed by DN T cells in Fas- or FasL-
deficient mice 44,45. Interestingly, a higher proportion of transferred DN T cells 
preferentially accumulate in the spleen and pancreatic lymph nodes in comparison to both 
skin-draining and mesenteric lymph nodes (Supplementary Figure 5). In addition, in 
both the spleen and the pancreatic lymph nodes, DN T cells express the activation marker 
CD69 (Figure 5B) and have entered cellular division (Figure 5C), suggesting that they 
recognize a self-antigen inducing their activation at these sites. Altogether, these results 
suggest that a preferential activation and proliferation of the transferred DN T cells 
occurs within the spleen and pancreatic lymph nodes.  
 
3.4.6 DN T cell transfer leads to a reduction in germinal center B cells 
within pancreatic islets 
 
 Following these results, we postulated to that transferred DN T cells also migrated 
to the pancreatic islets, which is the site of beta cell destruction during diabetes 
development. Using CD45 allelic markers, we were able to track the transferred DN T 
cells to the pancreatic islets (Figure 5B). Accordingly, we find that a higher proportion of 
NOD.CD1d-/- DN T cells express the chemokine receptor CXCR5 in the pancreatic 
lymph nodes (Figure 5A), where CXCR5 is required for homing into germinal 
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centers46,47. Interestingly, the transfer of activated DN T cells leads to a decrease in the 
proportion of both GL7+CD95+ germinal center B cells as well as total GL7+ activated 
B cells within the pancreatic islets (Figure 5C) as well as a decrease in insulin 
autoantibody (IAA) serum levels (Figure 5D). In contrast, the transfer of CD4+ T cells 
leads to an increase in IAA serum levels (Figure 5D). Altogether, these results 
demonstrate that the reduction in germinal center B cells within the pancreatic islets and 
IAA serum levels in diabetes-susceptible NOD mice both correlate with the specific 
transfer of DN T cells.  
 
3.4.7 Human DN T cells exhibit a therapeutic potential 
 
 As the transfer of expanded DN T cells results in a decrease in diabetes incidence 
in non-transgenic NOD mice, we wanted to verify whether human DN T cells exhibit 
similar properties.  First, human DN T cells can be isolated from total PBMCs based on a 
CD4-CD8-CD56-Vα24-Jα18-TCRβ+ phenotype (Figure 6A). Following a 3 week 
expansion, DN T cells do indeed express the cytolytic enzymes, granzyme B and perforin 
(Figure 6B), demonstrating that human DN T cells exhibit cytotoxic potential. As murine 
DN T cells are cytotoxic towards B cells in vitro26 (Figure 2) and DN T cell transfer 
leads to a reduction in activated B cells in vivo (Figure 5C), we wanted to verify whether 
human DN T cells exhibit cytotoxic activity towards B cells, as well. Here, irradiated 
allogeneic B cells were used as the target cells and cultured overnight in the presence of 
expanded human DN T cells. Indeed, in the presence of human DN T cells, a greater 
proportion of B cells undergo cell death in comparison to B cells cultured alone (Figure 
6C). Therefore, similar to murine DN T cells, human DN T cells do exhibit cytotoxic 
activity towards B cells in vitro. 
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3.5 Discussion  
 
 This article is the first to demonstrate that DN T cells can inhibit diabetes 
development in non-transgenic, non-lymphopenic NOD mice. We further show that DN 
T cells mediate their immunoregulatory function by specifically eliminating B cells 
presenting islet antigens. This immunoregulatory function of non-transgenic DN T cells 
correlates with both a decrease in germinal center B cells directly within the pancreatic 
islets as well as a reduction in insulin autoantibody levels, where DN T cells 
preferentially migrate to the pancreas. Moreover, this article is the first to demonstrate 
that human DN T cells are cytotoxic towards B cells as they have previously only been 
shown to target T cells48,49, demonstrating the similarity between murine and human DN 
T cells.  
 
 Importantly, we are not the only group to have demonstrated that DN T cells can 
inhibit autoimmune diabetes in the non-transgenic setting. Accordingly, Zhang and 
colleagues have shown that autoimmune diabetes induction was inhibited when islet-
specific DN T cells were transferred to 5-week-old NOD mice21.  However, this study 
used CD4-CD8- T cells that were converted from activated CD4+ T cells, which were not 
void of contaminating NK T cells, in vitro. Indeed, as a high proportion of NK T cells 
express CD4 and as NK1.1 is not expressed by the NOD mouse strain, where an NK1.1 
antibody was used in the preparation of the CD4+ T cells, we cannot rule out the 
possibility that the observations made throughout this study were due to contaminating 
NK T cells. Conversely, our study uses CD1d-deficient mice, which are void of all NK T 
cells, as well as ex vivo isolated DN T cells followed by in vitro activation. Thus, our 
findings are the first to show that non-transgenic, uncontaminated DN T cells inhibit 
diabetes development in non-lymphopenic NOD mice. Furthermore, we have also 
revealed both the mechanism of action of non-transgenic DN T cells as well as the 
similarities between non-transgenic and human DN T cells. Therefore, our study is the 
first to clearly demonstrate the therapeutic potential of DN T cells for the treatment of 
autoimmune diabetes in humans. 
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 DN T cells are of particular therapeutic interest for autoimmune diabetes because 
they inhibit immune responses in an antigen-specific manner48,50. Accordingly, the use of 
DN T cells in immunotherapy should lead to fewer side-effects along with a decreased 
risk of infections, which remains a major concern in the application of broad 
immunosuppressive regimens. With the ever growing evidence of the unique antigen-
specific immunosuppressive properties of DN T cells, it is timely to address the in vivo 
impact of DN T cells on the immune response. The use of antigen-specific 
immunoregulatory DN T cells may eventually present itself as an alternative strategy to 
broad immunosuppressive regimens that lead to undesired side-effects, such as the 
rituximab treatment, which depletes all B cells as opposed to activated antigen-specific B 
cells27,51.  
 
 Interestingly, Serreze and colleagues recently published an article demonstrating 
that B cell downregulate their expression of CD20 following their entry into pancreatic 
islets52.  Consequently, anti-CD20 treatment, which has shown promising results in early 
clinical trials for autoimmune diabetes reversal27, is unable to eliminate B cells found 
directly within the islets, where β cell destruction occurs52. Therefore, there are no current 
treatments that can efficiently target B cells within pancreatic islets. Our data in non-
transgenic mice shows that DN T cell injection directly decreases the number of activated 
B cells within pancreatic lesions, suggesting that DN T cells could be more effective than 
anti-CD20 treatment at abrogating the local inflammatory autoimmune response. 
Moreover, as DN T cell transfer results in a decrease in antigen-specific autoantibody 
levels18 (Figure 5D), this anticipates that autoantibodies can serve as a biomarker for the 
efficiency of DN T cell therapy.   
 
 In conclusion, we have demonstrated the impact of DN T cell proportion on 
autoimmune diabetes progression in non-transgenic NOD mice, elucidated the cellular 
mechanism by which DN T cells impede autoimmune responses in vivo and defined the 
characteristics of human DN T cells, all key aspects for the development of future 
therapeutic approaches. Altogether, these results demonstrate that DN T cells may be of 
therapeutic interest for autoimmune diabetes in humans.  
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3.7 Methods 
 
Mice 
 6 to 12 week-old mice were used for all the experiments. 3A9 TCR 53 and insHEL 
(ILK-3) 42 transgenic mice on the B10.Br background have been previously described 41 
and were maintained at the Maisonneuve-Rosemont Hospital housing facility (Montreal, 
Canada). C57BL/6 and NODg7 mice were purchased from the Jackson Laboratory. 
NODg7, NOD.CD45.2, B6.SJL, NOD.Rag1-/- mice, and CD1d-deficient mice on the 
NOD, C57BL/6, and BALB/c backgrounds were maintained at the Maisonneuve-
Rosemont Hospital housing facility (Montreal, Canada). Studies were approved by the 
Maisonneuve-Rosemont Hospital ethics committee and overseen by the Canadian 
Council for Animal Protection. 
 
Isolation of human cell populations 
 Heparinized blood samples were obtained from healthy donors. Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation. Cells 
were then stained with antibodies against CD4, CD8, CD56, Vα14-Jα24, and TCRαβ. 
The human DN T cells (CD4- CD8- CD56- Vα14-Jα24- TCRαβ+) or CD8+ T cells (CD4- 
CD8+ CD56- Vα14-Jα24- TCRαβ+) were sorted by using a FACS Aria III (BD 
Biosciences).  Cells were also stained using antibodies against CD19 and TCRαβ+ and B 
cells (CD19+TCRαβ-) were sorted using a FACS Aria III (BD Biosciences). Sorted cells 
were reanalyzed after cell sorting and routinely showed more than 95% purity. Studies 
were approved by the Maisonneuve-Rosemont Hospital ethics committee. Informed 
consent was provided according to the Declaration of Helsinki.  
 
Isolation of murine cell populations 
 Murine cell suspensions were stained with antibodies against CD4, CD8β, CD19 
and TCRβ.  CD4-CD8-CD19-TCRβ+ DN T cells and CD4+CD8-CD19-TCRβ CD4+ T 
cells were sorted using a FACS Aria III (BD Biosciences) (purity > 95%). B cells were 
purified using the EasySep PE selection kit, where B cells were first stained with CD19-
biotin followed by streptavidin-PE. B cells were routinely enriched to >90% . 
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Cellular expansion  
 Sorted T cell populations from mice were cultured at 37˚C at a concentration of 
250 000 cells/ml for 7 days in the presence of plate-bound anti-CD3 (1μg/ml, 145-2C11, 
Biolegend) and anti-CD28 (10μg/ml, 37.51, Biolegend) as well as  IL-2 (30U/ml, Feldan 
Bio) and IL-7 (10ng/ml, generously provided by Dr. Martin Guimond) in RPMI 
supplemented with 10% fetal bovine serum (Invitrogen), Penicillin (100U/ml)- 
Streptomycin (100ug/ml) (Gibco), 0.01M HEPES (Gibco) and 2-mercaptoethanol 
0.055mM (Gibco).  
 
 Sorted T cell populations from human PBMCs were cultured at 37˚C at a 
concentration of 250 000 cells/ml for 21-28 days in the presence of plate-bound anti-CD3 
(10μg/ml, HIT3a, Biolegend) and anti-CD28 (5μg/ml, CD28.2, Biolegend) in RPMI 
supplemented with 10% human serum (Sigma) and Penicillin (100U/ml)-Streptomycin 
(100ug/ml)-L-Glutamine (29.2 mg/ml) (Gibco). 24 hours following initial culture, 
cytokines were added to the culture, including IL-2 (30U/ml, Feldan Bio), IL-7 (10ng/ml, 
generously provided by Dr. Martin Guimond) +/- IL-4 (30U/ml,Feldan Bio). 
 
 Cell cultures were monitored daily for confluence and cytokine supplemented 
media was added when cell density was > 1x106 cells/ml. Cell number was quantified by 
trypan blue exclusion.  
 
Flow cytometry  
 6 to 12 week-old non-diabetic mice (Diastix negative) were analyzed. Single cell 
suspensions of lymphoid organs were prepared by mechanical disruption through a 70 
µm sterile cell strainer (BD Biosciences). NH4Cl was used for erythrocyte lysis of single 
cell suspensions from spleens. Islets were isolated by ductal Collagenase (Sigma) 
injection to inflate the pancreas. The pancreas was then incubated 20 min at 37°C and 
washed with a solution containing FBS. Islets were handpicked and dissociated using a 
pipette tip. Human cells were prepared as described above. Cell counts were performed 
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by trypan blue exclusion using a hemacytometer. Intracellular stainings for granzyme B 
(anti-mouse: 16G6, eBioscience, anti-human: GB11, eBioscience) and perforin (anti-
mouse: eBioOMAK-D, eBioscience, anti-human: dG9, eBioscience) were performed 
using BD Biosciences Cytofix/Cytoperm Kit. Anti-clonotypic 1G12 antibody, specific 
for the 3A9 TCR 54, was detected using APC-labelled anti-mouse IgG1 (clone X56, BD 
Biosciences). For anti-mouse antibodies, alpha GalCer:CD1d complex (clone L363) and 
GL7 (clone GL-7) were purchased from eBioscience, while CD95 (Fas) (clone Jo2) and 
CXCR5 (clone 2G8) was purchased from BD Biosciences. For anti-human antibodies, 
CD56 (clone CMSSB) and Valpha24-Jalpha18 TCR (clone 6B11) were purchased from 
eBioscience. All other antibodies and staining reagents were purchased from Biolegend. 
Data was collected on a FACSCalibur or FACS LSR II (BD Biosciences) and analyzed 
using FlowJo software (Treestar). 
 
Diabetes monitoring  
 DN T cells and CD4 T cells were sorted from the spleen of NOD.CD1d-/- mice 
and expanded in vitro. 2 million expanded DN T cells or CD4 T cells were then injected 
intravenously in non-diabetic (diastix negative) 12 week-old female NODg7 mice, where 
non-injected female NODg7 mice served as a control. The diabetes incidence was 
monitored every two weeks using Diastix glucose test strips, which analyzes glucose 
levels in the urine. Diabetic mice showed 2 consecutive Diastix positive tests and blood 
glucose levels above 17mM.  
 
Cytotoxic potential  
 Cells were sorted and cultured as indicated above. For granzyme B and perforin 
detection, cells were re-stimulated for 4h with phorbol 12-myristate 13-acetate (PMA) 
(50ng/ml) (Sigma), ionomycin (0.5g/ml) (Sigma), and brefeldin A (10 g/ml) (Sigma), 
prior to intracellular staining. For CD107a (LAMP1) staining, we replaced Brefeldin A 
with mononesin (2nM) (BD biosciences) and the anti-CD107a antibody was added 
during the 4h re-stimulation55.  
 
Cytotoxicity 
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 Sorted murine DN T cells were stimulated 7 days in vitro with plate-bound anti-
CD3 and anti-CD28, IL-2, and IL-7. Lipopolysaccharide (LPS) (1g/ml, Sigma) was 
used to stimulate B cells in vitro for 2 days. HEL antigen (1mg/ml) (Sigma) or islet 
antigen was added in the last 24h of culture. Islet antigen was prepared by incubating 
isolated islet cells with DNase (Sigma) for 10 minutes at 37˚C. Islets were isolated from 
B6.CD1d-/- mice or NOD.Rag-/- mice, rather than NOD.CD1d-/- or NOD mice, because 
no lymphocytic infiltration can be found in NOD.Rag-/- mice. Target B cells were 
washed and loaded with 50Ci 51Cr (Perkin Elmer) for 90 min. DN T cells and B cells 
were quantified by trypan blue exclusion prior to co-culture in order to obtain the desired 
effector to target cell ratio. DN T cells and B cells were incubated for 3h at 37˚C in the 
presence or absence of EGTA (0.16mM) (J. T. Baker). %Cytotoxicity = 100*(E –S)/(M – 
S), where E = experiment, S = spontaneous and M = maximal release. 
 
 For human cells, sorted B cells are incubated for 10 minutes at 37˚C with Cell 
Trace Violet (5 μM, Invitrogen). B cells are then incubated on ice for 5 minutes with cold 
FBS before washing with RPMI. B cells are distributed to the wells of a 96-well plate 
(round bottom). Subsequently, sorted and expanded human DN T cells (or CD8 T cells as 
a control) are washed and distributed to the wells yielding the appropriate effector to 
target cell ratio. Effector T cells and B cells were quantified by trypan blue exclusion 
prior to co-culture in order to obtain the desired effector to target cell ratio. Following an 
overnight co-culture, cells were washed and stained with propidium iodide (PI) and 
analyzed using flow cytometry. % Cytotoxicity = 100*(E–S), where E = experiment, S = 
spontaneous, where spontaneous cell death was calculated as the amount of B cells 
staining positive for PI in the absence of effector T cells. 
 
Proliferation assay 
 For proliferation assays, 2x106 expanded DN T cells were labelled with CFSE 
(2M) (Invitrogen) and washed twice in cold supplemented RPMI prior to adoptive 
transfer. CFSE dilution was monitored by flow cytometry. 
 
Insulin autoantibody ELISA 
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 Insulin (Anaspec) was immobilized onto microwells. The diluted serum samples, 
added to the microwells. IgG specific antibodies to insulin in the serum sample bind to 
the insulin molecules on the microwells. Serum, which was previously incubated with 
insulin, will have already formed antibody-antigen complexes and be unable to bind to 
the insulin on the microwells, thus serving as a background control. After washing off 
unreacted serum materials, horseradish peroxidase-labeled polyclonal goat anti-mouse 
IgG (Poly4053, Biolegend) was added. After thorough washing to remove the unbound 
enzyme, TMB substrate solution was added and the color development was measured 
using spectrophotometry. The intensity of the color, namely the optical density (OD), is 
directly proportional to the concentration of insulin autoantibody in the sample. All 
samples were run in duplicate. The level of insulin autoantibody in the sample = (average 
of sample OD) - (average of background control OD). 
 
Statistics 
 The paired student's T test and Logrank (Mantel-Cox) statistical tests were 
applied where appropriate. 
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3.8 Figures 
 
 
Figure 1. The proportion and absolute number of DN T cells is reduced in non-
transgenic NOD.CD1d-/- mice. The spleen and lymph nodes were harvested from 8-12 
week old non-transgenic CD1d-deficient mice of B6, BALB/c and NOD genetic 
backgrounds and stained with antibodies against CD19, CD4, CD8, CD5 and TCRβ to 
determine the proportion (A) and absolute number (B) of non-transgenic DN T cells 
(CD19- CD4- CD8- TCRβ+ CD5low). Mann Whitney test was performed. * p < 0.05, 
** p < 0.01, *** p < 0.001. 
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Figure 2. Non-transgenic DNT cells demonstrate an antigen-specific cytotoxic 
activity towards activated B cells. Non-transgenic B cells and DN T cells were sorted 
from the spleen of NOD.CD1d-/- mice.  Sorted DN T cells were stimulated for 7 days in 
vitro with anti-CD3, anti-CD28, IL-2 and IL-7.  A) In vitro expanded non-transgenic DN 
T cells were re-stimulated for 4 h with PMA, ionomycin and monensin along with the 
anti-CD107a antibody before intracellular staining. The level of perforin, granzyme B 
and CD107a is shown. Expanded DN T cells that were not re-stimulated were used as a 
control for CD107a expression (grey filled histogram in right panel). n≥3. (B) The 
percent-specific lysis is shown for NOD.CD1d-/- DN T cells toward target 
lipopolysaccharide-activated NOD.CD1d-/- B cells that were loaded, or not, with islet 
antigens. Representative of 2 experiments. (C) The percent-specific lysis is shown for 
B6.CD1d-/- DN T cells toward target LPS-activated B6.CD1d-/- B cells at a 10:1 effector 
to target ratio that were loaded with either islet antigens or the non-relevant HEL antigen, 
as indicated. EGTA was added in some conditions, as indicated. n=1.  
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Figure 3. In vitro expanded non-transgenic DN T cells reduce the incidence of 
diabetes in NOD mice. DN T cells were sorted from the spleens of 8-12 week old 
NOD.CD1d-/- mice and activated in vitro for 7 days with anti-CD3, anti-CD28, IL-2 and 
IL-7. 2x106 cells were injected intravenously into 12 week-old non-diabetic female NOD 
mice. Diabetes incidence is depicted for DN T cell-injected and non-injected mice up to 
32 weeks of age. The Logrank (Mantel-Cox) test was performed for statistical analysis. 
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Figure 4. Preferential activation and proliferation of transferred DNT cells in the 
pancreatic lymph nodes. Non-transgenic DN T cells were sorted from the spleen of 
NOD.CD1d-/- (CD45.1) mice. Following a 7 day expansion in vitro with anti-CD3, anti-
CD28, IL-2 and IL-7, 1-2 x 106 non-transgenic DN T cells were injected intravenously 
into non-diabetic 10-12 week-old recipient NOD.CD45.2 mice. 4 weeks post-transfer, the 
spleen, skin-draining lymph nodes (LN), pancreatic lymph nodes (pLN) and mesenteric 
lymph nodes (mLN) were harvested. (A) The expression of CD4, CD8, B220 (B) and 
CD69 is shown for the transferred DN T cells (CD45.1+). (C) Expanded DN T cells were 
stained with CFSE prior to their transfer. The histograms depict the level of expression of 
CFSE for the transferred DN T cells (CD45.1+CD45.2-). The percentage of cells that have 
not entered proliferation is shown. n≥3. 
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Figure 5. Transferred DN T cells migrate to the pancreatic islets and induce a 
reduction in germinal center B cells. (A) The spleen, skin-draining lymph nodes (LN) 
and pancreatic lymph nodes (pLN) were harvested from 8-12 week old NOD.CD1d-/- 
mice and stained with antibodies against CD19, CD4, CD8, and TCRβ for the isolation of 
non-transgenic DN T cells (CD19- CD4- CD8- TCRβ+). The histograms depict the level 
of expression of CXCR5 on DN T cells. n=3. (B-D) DN T cells were sorted from the 
spleens of 8-12 week old NOD.CD1d-/- (CD45.1) mice. Following a 7 day expansion in 
vitro with anti-CD3, anti-CD28, IL-2 and IL-7, 2 x 106 non-transgenic DN T cells, or 
PBS, were injected intravenously into non-diabetic 10-12 week-old recipient 
NOD.CD45.2 mice. 2 weeks post-transfer, (B) the proportion of transferred DN T cells 
(CD45.1+ TCRβ+) and (C) the proportion of activated B cells (B220+ CD3- GL-7+, top 
panel) and germinal center B cells (B220+CD3-GL-7+CD95+, bottom panel) in 
pancreatic islets was quantified by flow cytometry, representative of at least 3 
experiments. (D) Serum insulin autoantibody (IAA) levels were measured by ELISA 
before (pre‐) and two weeks after (post‐) DN T or CD4 T cell injection in NOD mice. 
These preliminary results are paired from individual mice. 
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Figure 6. Human DN T cells exhibit phenotypic and functional properties 
reminiscent of mouse DN T cells. Human DNT cells (CD4-CD8-CD56-Vα24-Jα18-
TCRαβ+) were isolated from total PBMCs. A) Gating strategy for sorting and quantifying 
the proportion of DN T cells is shown. B) Human DN T cells were stained intracellularly 
for perforin and granzyme B expression following a 3 week expansion, Representative of 
at least 3 experiments. C) Expanded human DN T cells (or CD8 T cells as a control) were 
co-cultured overnight with Cell Trace Violet (CTV)+ autologous or allogeneic B cells. 
Following the overnight co-culture, cells were washed and stained with propidium iodide 
(PI) and analyzed using flow cytometry. The right panels illustrate a typical FACS dot 
plot for the negative control with CTV+ B cells alone (top) and in the presence of CTV- 
DN T cells (bottom). Percent specific lysis of target B cells is shown in the bar graph (left 
panel). n≥3.  
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Supplementary Figure 1. Strategy for isolating DN T cells free of contaminating 
NKT cells. DN T cells and a subset of NKT cells share a common CD4- CD8- TCRβ+ 
phenotype. (A) The spleen was harvested from 8-12 week old B6 mice and stained with 
antibodies against CD4, CD8, TCRβ, NK1.1 and the α-GalCer:CD1d complex. (B) A 
proportion of DN T cells express NK1.1. The spleen was harvested from 8-12 week old 
B6.CD1d-/- mice and stained with antibodies against CD4, CD8, CD19, TCRβ and 
NK1.1. (C) Gating strategy used to sort DN T cells from the spleen is shown for 
NOD.CD1d-/- mice. Sorted cells are CD4- CD8- CD19- TCRβ+ (left panels). Cell purity 
was routinely above 95% (right panels). Results are representative of at least 3 
independent experiments. 
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Supplementary Figure 2. Non-transgenic DN T cells express an activated phenotype. 
The spleen was harvested from 8-12 week old mice and stained with antibodies against 
CD4, CD8, and TCRβ or 1G12 and CD19 or B220 for the isolation of non-transgenic DN 
T cells (CD19- CD4- CD8- TCRβ+) or TCR transgenic DN T cells (B220- CD4- CD8- 
1G12+). The histograms depict the level of expression of (A) pan-T cell markers, CD3 
and CD5, as well as (B) activation markers, CD122, CD69 and CD44, on B220+ cells 
(shaded), CD4+ cells (dashed) and DN T cells (solid) from CD1d-deficient B6, BALB/c 
and NOD mice as well as TCR 3A9 and TCR 3A9:insHEL transgenic mice. The 
percentage of DN T cells that stained positive for the marker is shown in the upper right 
corner. Results are representative of at least 3 independent experiments.  
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Supplementary Figure 3. Expansion of non-transgenic DNT cells in vitro. Non-
transgenic DN T cells were sorted from the spleen of CD1d-deficient B6 and NOD mice.  
Sorted cells were stimulated for 7 days in vitro with anti-CD3, anti-CD28, IL-2 and IL-7.  
Similar expansion efficiency was observed irrespective of the genetic background of the 
mice. Compilation of cellular expansion results is depicted.  
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Supplementary Figure 4. In vitro expanded non-transgenic CD4 T cells do not affect 
the incidence of diabetes in NOD mice. CD4 T cells were sorted from the spleens of 8-
12 week old NOD.CD1d-/- mice and activated in vitro for 7 days with anti-CD3, anti-
CD28, IL-2 and IL-7. 2x106 cells were injected intravenously into 12 week-old non-
diabetic female NOD mice. Diabetes incidence is depicted for CD4 T cell-injected and 
non-injected mice up to 32 weeks of age. The Logrank (Mantel-Cox) test was performed 
for statistical analysis. 
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Supplementary Figure 5. Transferred DNT cells migrate to various organs post-
transfer.  Non-transgenic DN T cells were sorted from the spleen of NOD.CD1d-/- 
(CD45.1) mice. Following a 7 day expansion in vitro with anti-CD3, anti-CD28, IL-2 and 
IL-7, 1-2 x 106 non-transgenic DN T cells were injected intravenously into non-diabetic 
10-12 week-old recipient NOD.CD45.2 mice. At 24 hours, 2 and 4 weeks post-transfer, 
the spleen, skin-draining lymph nodes (LN), pancreatic lymph nodes (pLN), mesenteric 
lymph nodes (mLN) and thymus were harvested and cells were stained for CD45.1, 
CD45.2 and TCRβ. The transferred DN T cells (CD45.1+CD45.2-) have been gated and 
their proportion is shown. Representative of at least 3 experiments. 
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CHAPTER 4: DISCUSSION 
 
 The results presented in this thesis provide insight into the function of DN T 
cells as well as the ability to prevent autoimmune diabetes through the restoration of 
DN T cell number in non-transgenic diabetes-susceptible mice. Accordingly, the 
findings in this thesis have revealed the therapeutic potential for DN T cells in the 
treatment of autoimmune diabetes in human patients. 
 
 
4.1.  Non-transgenic DN T cells: Phenotype and proportion 
 
 The specific isolation, and consequently investigation, of non-transgenic DN 
T cells is complicated by the fact that DN T cells share the CD4-CD8-TCRαβ
+ 
phenotype with a subset of NKT cells (reviewed in 156, Hillhouse, E.E., Lesage, S., 
2012). However, as NKT cells are known to express a TCR restricted to CD1d 
molecules and are thus, by definition, absent in CD1d-deficient mice210, we chose to 
use CD1d-deficient mice for the purification of DN T cells throughout these studies 
to ensure a population of DN T cells void of any contaminating NKT cells. 
 
 Due to their scarcity in the non-transgenic setting, DN T cells have been 
mostly characterized using TCR transgenic settings. Indeed, DN T cells have been 
shown to exhibit a naive phenotype in the absence of cognate antigen, whereas they 
exhibit a more activated phenotype in the presence of cognate antigen (reviewed in 
156, Hillhouse, E.E., Lesage, S., 2012). To characterize the phenotype of non-
transgenic DN T cells in the absence of any contaminating NKT cells, we compared 
DN T cells from CD1d-deficient mice on the NOD, C57BL/6 (B6) and BALB/c 
genetic backgrounds alongside TCR transgenic DN T cells from both the 3A9 TCR 
and 3A9 TCR:insHEL transgenic mouse models. In this model, the 3A9 TCR 
transgene, which can be detected using the 1G12 anti-3A9 clonotypic mAb 258, 
recognizes a HEL peptide in the context of I-Ak and the insHEL transgene is 
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expressed under the rat insulin promoter 258, 303. As expected, DN T cells from the 
3A9 TCR transgenic mice, thus in the absence of the cognate antigen, exhibit a naive 
phenotype whereas the DN T cells from the 3A9 TCR:insHEL transgenic mice, for 
which the HEL antigen is present, exhibit an activated phenotype (Article 2, 
Supplementary Figure 2). Interestingly, the phenotype of DN T cells from CD1d-
deficient mice was analogous to that of DN T cells from the 3A9 TCR:insHEL 
transgenic mice, such that they expressed similar levels of the various activation 
markers (Article 2, Supplementary Figure 2). Furthermore, whereas DN T cells 
expressing the 3A9 TCR are monoclonal such that they express Vα3 and Vβ8.2 TCR 
chains304, DN T cells from non-transgenic mice express a polyclonal TCR repertoire 
(Appendix 2).  Because 3A9 TCR transgenic DN T cells are activated by the 
presence of HEL, which represents a self-antigen as it is expressed under the rat 
insulin promoter258, 303, these results suggest that non-transgenic DN T cells also 
recognize self-antigens resulting in their activated phenotype ex vivo.  
 
 Other regulatory T cell populations, such as NKT cells and Tregs, express an 
activated phenotype305, 306, 307 and are also known to recognize self-antigen. Indeed, 
NK T cells recognize lipid self-antigen, where β-galactosylceramide (β -GalCer),  
isoglobotrihexosylceramide (iGb3) 308 and β-D-glucopyranosylceramide (β-
GlcCer)309 have been identified for type I NK T cells and  the sulfated 
galactosylceramide, sulfatide, has been identified for type II NKT cells184. Deficiency 
in NKT cells have also been implicated in autoimmune diseases in both mice and 
humans, such as gastritis, multiple sclerosis, and autoimmune diabetes 159. Tregs also 
recognize self-antigens310, 311, which is an important element to permit their thymic 
development 237. Moreover, Treg deficiency is also associated with autoimmune 
disease development. For instance, the dysfunction of the transcriptional activator 
FOXP3, which is a master regulator for the development of Tregs, leads to the 
progression of IPEX (immunodysregulation polyendocrinopathy enteropathy X-
linked syndrome), which is a rare disease linked to the development of autoimmune 
diseases, including autoimmune diabetes 312. Moreover, mice that are thymectomized 
on day 3 of life develop organ-specific autoimmune disease, such as gastritis, unless 
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the mice received a transfer of CD4+ T cells within 2 weeks of birth, where the 
inhibitory activity was attributed to CD4+CD25+ Tregs 313. Together, these results 
demonstrate that regulatory T cell populations such as NKT cells and Tregs recognize 
self-antigens and are consequently linked to the suppression of autoimmunity.  
 
 Our lab has previously demonstrated that diabetes-susceptible mice present 
with fewer DN T cells than diabetes-resistant mice in the TCR transgenic setting 
(Appendix 1, Figure 4), which initiated our investigation into the difference in DN T 
cell proportion between diabetes-susceptible and -resistant mice in the non-transgenic 
setting. The use of CD1d-deficient mice facilitated the realization of this study as it 
ensured a DN T cell population void of any contaminating NKT cells and, thus, a true 
difference in proportion. Indeed, both the proportion and absolute number of non-
transgenic DN T cells is significantly reduced in the secondary lymphoid organs of 
diabetes-susceptible NOD CD1d-deficient mice in comparison to diabetes-resistant 
B6 and BALB/c CD1d-deficient mice (Article 2, Figure 1). These results suggest an 
association between a low DN T cell number and autoimmune diabetes susceptibility 
in the non-transgenic setting. In addition, these results confirmed that the difference 
in DN T cell numbers observed in the TCR transgenic setting (Appendix 1, Figure 
4) was not an artefact of the insertion of the transgene. More importantly, the 
validation of a reduction in DN T cell number in diabetes-susceptible mice supported 
our hypothesis that an increase in DN T cell number could prevent autoimmune 
diabetes development in the non-transgenic setting. Therefore, to validate that a 
reduced number in DN T cells is causal to autoimmune diabetes development in the 
non-transgenic setting, we must attempt to restore DN T cell number. However, 
without functional DN T cells, a restoration of DN T cell number would be 
ineffective regardless of the increase in number. Therefore, we subsequently verified 
whether DN T cells from the diabetes-susceptible genetic background were in fact 
functional. 
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4.2. The function of DN T cells 
 
 Before determining whether DN T cells from diabetes-susceptible mice were 
functional, we first needed to determine the target of our DN T cells. The function of 
DN T cells was determined using 3A9 TCR diabetes-resistant B10.Br mice for three 
main reasons. First, the insertion of the TCR transgene would increase DN T cell 
proportion, thus allowing for a sufficient number of cells to carry out functional 
assays. Second, we opted to use TCR transgenic mice from the B10.Br diabetes-
resistant background, as these mice present with a greater number of DN T cells in 
comparison to diabetes-susceptible mice (Appendix 1, Figure 4). Lastly, the 
utilization of the 3A9 TCR transgenic model would facilitate the study of the 
specificity of the DN T cells as the 3A9 TCR transgene is specific for the HEL 
antigen. As DN T cells from various TCR transgenic models have been reported to 
specifically eliminate CD8+ T cells171, 186, 218, 225, 243, 244, 245, we first verified whether 
3A9 DN T cells also eliminate T cells. Using, 3A9 TCR transgenic B10.Br mice, we 
show that DN T cells are not cytotoxic towards T cells, but rather are cytotoxic 
towards activated B cells (Article 1, Figure 1D). Moreover, the cytotoxicity is both 
antigen-specific, as DN T cells specifically kill B cells that are loaded with HEL 
(Article 1, Figure 1D), and dependent on the release of the cytolytic granules, 
granzyme and perforin, as the cytotoxicity was blocked by the presence of ethylene 
glycol tetraacetic acid (EGTA)314. Therefore, 3A9 DN T cells are cytotoxic towards 
activated B cells in an antigen-specific and granzyme/perforin-dependent manner. 
 Since the publication of Article 1 in 2010, 2C TCR transgenic DN T cells, 
which had previously only been shown to target CD8+ T cells171, 218, 225, 243, 244, 245, 
were shown to be also cytotoxic towards LPS-activated B cells in vitro315. This 
variation in broad vs B cell-limited target cell specificity between the 2C and 3A9 
TCR transgenic models, respectively, may be explained by the fact that the 3A9 TCR 
model is MHC class II-restricted, whereas the 2C TCR model is MHC class I-
restricted. Indeed, 3A9 DN T cells may be limited to exhibit cytotoxic activity only 
towards MHC class II expressing cells, including B cells, dendritic cells and 
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macrophages, while MHC class I-restricted 2C DN T cells do not exhibit such a 
limitation as MHC class I is expressed on all nucleated cells. The study of DN T cell 
function in additional MHC class I and class II-restricted TCR transgenic models 
should help resolve this issue.  
 Subsequently, we examined the cytotoxic activity of DN T cells from both 
autoimmune diabetes-resistant and -susceptible mice towards B cells to verify 
whether the cytotoxic activity from both strains was comparable. To do so, we 
compared the function of 3A9 DN T cells from B10.Br and NOD.H2k mice, where 
NOD.H2k mice are genetically identical to the NOD strain apart from the MHC locus. 
Therefore, as both B10.Br and NOD.H2k mice express the same MHC locus, this 
study would allow us to define whether the autoimmune-prone NOD genetic 
background influences DN T cell function. Using a common target cell, namely B 
cells from B10.Br x NOD. H2k F1 mice, we demonstrated that the cytotoxic activity 
of 3A9 DN T cells is comparable between diabetes-resistant and -susceptible strains 
(Article 1, Figure 2B). Moreover, the expression of the cytolytic granules, granzyme 
B and perforin, as well as the degranulation marker, CD107a, were equal between 
B10.Br and NOD. H2k 3A9 DN T cells (Article 1, Figure 1C). As the diabetes-
susceptible genetic background does not influence DN T cell function, these results 
demonstrate that the 3A9 DN T cells are associated with autoimmune diabetes due to 
a deficiency in DN T cell number rather than function. Interestingly, non-transgenic 
DN T cells from both the diabetes-susceptible genetic background express granzyme 
B, perforin, and CD107a (Article 2, Figure 2A), thus exhibit a comparable cytotoxic 
potential. Therefore, to validate that a reduced number in DN T cells, rather than a 
deficiency in their function, is causal to autoimmune diabetes development in the 
non-transgenic setting, we must attempt to restore DN T cell number in diabetes-
susceptible NOD mice.  
 
 Interestingly, upon further comparison of DN T cell functions between the 
diabetes-resistant and -susceptible strains, we revealed that 3A9 DN T cells from the 
NOD.H2k background produce more IL-10, which is characterized as an 
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immunosuppressive cytokine, on a per cell basis (Article 1, Figure 3). Two previous 
studies have shown that IL-10 inhibits the cytotoxic function of 2C DN T cell clones 
towards CD8+ T cells in vitro224, 250.  More, specifically, it was demonstrated that 
incubation with IL-10 significantly reduced Ly-6A expression on 2C DN T cells, 
where deficiency in Ly-6A did not affect the activation and proliferation of DN T 
cells but rather it impeded the ability of DN T cells to kill activated CD8+ T cells224. 
Moreover, Marra and colleagues demonstrated that IL-10 abrogates the suppressive 
function of 2C DN T cells by enhancing their susceptibility to cell death250. 
Therefore, we decided to verify whether IL-10 similarly impeded the function of 3A9 
DN T cells. Accordingly, we showed that IL-10 did not inhibit DN T cell cytotoxicity 
towards activated B cells in the 3A9 TCR transgenic setting on a per cell basis 
(Article 1, figure 4). Interestingly, although IL-10 did not affect the proliferation of 
3A9 DN T cells (Article 1, Figure 5B), the presence of IL-10 led to an increase in 
the cellular apoptosis of 3A9 DN T cells (Article 1, Figure 6). Therefore, in 
comparison to 2C DN T cells, we did not observe a reduction in 3A9 DN T cell 
function in the presence of IL-10. This difference might be attributed to various 
differences between the models. For instance, 3A9 DN T cells are cytotoxic towards 
activated B cells via a granzyme/perforin-dependent pathway (Article 1, Figure 2A), 
whereas 2C DN T cells are cytotoxic towards CD8+ T cells via the Fas/FasL 
pathway171. As a result, perhaps IL-10 impairs the Fas/FasL pathway, but not the 
granzyme/perforin pathway. As 2C DN T cells were recently shown to eliminate 
activated B cells in a perforin-dependent fashion315, it would be interesting to 
determine whether IL-10 inhibits 2C DN T cell cytotoxicity towards activated B 
cells. Indeed, this experiment would exclude differences in both the target cell and 
mechanism of action implicated. Another possibility pertains to the effect on Ly6A 
expression. Although 3A9 B10.Br DN T cells do express high levels of Ly6A214, it is 
possible that IL-10 does not induce a reduction in its expression in the 3A9 model. As 
a result, demonstrating whether IL-10 leads to a decrease in Ly6A expression on 3A9 
DN T cells would help to resolve this issue. Clearly, additional studies are needed in 
order to better explain the differences observed between the modulation of 2C and 
3A9 DN T cell function in the presence of IL-10. Nevertheless, we can conclude that 
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while we did not observe an impaired cytotoxic function of 3A9 DN T cells towards 
their target cell population on a per cell basis, IL-10 would ultimately decrease the 
degree of the global cytotoxic response as it induced DN T cell apoptosis. 
 
 Interestingly, as 3A9 DN T cells from the diabetes-susceptible genetic 
background, which have fewer DN T cells,  produce more IL-10 (Article 1, Figure 
3), which induces cellular apoptosis of DN T cells (Article 1, Figure 6), these results 
also suggest that IL-10 may play a role, at least in part, on the regulation of DN T cell 
number. Furthermore, activated 3A9 DN T cells from NOD.H2k mice express greater 
amounts of IL-10 receptor (IL-10R) than 3A9 DN T cells from B10.Br mice 
(Appendix 3), suggesting that 3A9 DN T cells from NOD.H2k mice may be more 
sensitive to IL-10-induced apoptosis. Indeed, the addition of an antagonistic IL-10R 
antibody led to an increase in the cellular expansion of 3A9 DN T cells from 
NOD.H2k mice (Article 1, Figure 7). This should be kept in mind for future studies 
on DN T cells in both mice and humans, such that a lower expansion of DN T cells 
from diabetes-susceptible individuals may be due to an increase in IL-10 production 
and thus cellular apoptosis in vitro, where the addition of an IL-10R blocking 
antibody can promote a better expansion of DN T cells. Moreover, results generated 
by my colleagues, Véronique Dugas and Roxanne Collin, demonstrate that the 
regulation of DN T cell number is multigenic, where chromosome 9 is linked to this 
regulation (unpublished data).  Interestingly, the alpha chain of IL-10R 316, is indeed 
located within chromosome 9.  Moreover, my colleagues have generated mice 
congenic for the Idd2 locus, which encompasses Il10ra, and have subsequently 
determined that the Idd2 locus partially restores DN T cell number (unpublished 
data). These results suggest the IL-10/IL-10R pathway may play a role in the 
regulation of DN T cell number in vivo for which Il10ra is a likely candidate gene. 
Altogether, it is tempting to speculate that the presence of IL-10 within the pancreatic 
islets of diabetes-susceptible mice impedes DN T cell expansion and thereby inhibits 
their immunoregulatory function, leading to the development of autoimmune 
diabetes.  
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 Determining whether Il10ra does indeed influence DN T cell number in vivo 
is yet to be determined. IL-10-deficient mice may seem like an appropriate tool to 
validate that the IL-10 pathway influences DN T cell numbers in vivo. However, the 
absence of the immunoregulatory cytokine IL-10 in these mice will likely influence 
many other cell populations and is known to lead to the development of an 
inflammatory disease, namely colitis317.  Thus, the inflammatory setting present in 
IL-10-deficient mice will preclude the analysis of the direct impact of IL-10 on the 
proportion of DN T cells.  Alternatively, we could take advantage of IL-10RA-
knockdown bone marrow chimeras. Indeed, supposing that the in vivo number of DN 
T cells is regulated, at least in part, by the ability of DN T cells to respond to IL-10, 
we would target Il10ra by shRNA in bone marrow cells from a 3A9 TCR transgenic 
NOD.H2k mouse, which would subsequently be transferred to a lethally irradiated 
recipient F1 (B10.Br x NOD.H2k) mouse at a 1:1 ratio with bone marrow from a 3A9 
TCR transgenic B10.Br mouse. 8 weeks following bone marrow transfer, we would 
isolate the various secondary lymphoid organs and determine the proportion of 3A9 
DN T cells from the donor mice. This experiment would allow us to verify whether 
the inhibition of the IL-10/IL-10R pathway promotes the restoration of 3A9 DN T 
cells from the diabetes-susceptible NOD background. The results from this 
experiment would help to clarify whether the IL-10/IL-10R pathway contributes, at 
least in part, to the regulation of DN T cell number in vivo. 
 
   
 Given that 3A9 DN T cells are cytotoxic towards activated B cells, we 
decided to determine whether non-transgenic DN T cells were also cytotoxic towards 
B cells. Similar to 3A9 TCR transgenic DN T cells, non-transgenic DN T cells 
mediate their immunoregulatory function by eliminating activated B cells in vitro 
(Article 2, Figure 2), where this cytotoxic function is dependent on granzyme and 
perforin, as shown by the inhibition of the cytotoxic activity in the presence of EGTA 
(Article 2, Figure 2C).  Therefore, non-transgenic DN T cells are cytotoxic towards 
activated B cells in a granzyme/perforin-dependent manner. 
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 Interestingly, non-transgenic DN T cells eliminate activated B cells presenting 
islet antigens, but not B cells presenting a non-relevant antigen such as ovalbumin 
(Article 2, Figure 2B), demonstrating that the function of DN T cells is self-antigen-
specific. These results further corroborate our findings that non-transgenic DN T cells 
exhibit an activated phenotype suggesting that they recognize self-antigens. These 
results are important as they suggest that activated DN T cells do not eliminate 
activated B cells presenting foreign antigen, as is the case during infection. Therefore, 
DN T cells do not induce global immunosuppression, which is associated with an 
increased risk of infection and is an undesired consequence of various types of 
immunotherapy. It would be of interest to verify whether this holds true for B cells 
presenting other self-antigens. As a result, DN T cell immunotherapy may present 
itself as an alternative strategy to broad immunosuppressive regimens that lead to 
undesired side-effects. 
 
 Altogether, as the cytotoxic function of DN T cells is normal in mice with a 
diabetes-susceptible genetic background, we propose that DN T cells are associated 
with autoimmune diabetes due to a deficiency in DN T cell number rather than 
function. Consequently, with regards to a cellular therapeutic approach for the 
treatment of autoimmune diabetes, our main focus should lie on the restoration and 
expansion of DN T cell numbers.  
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4.3. The in vivo role of non-transgenic DN T cells in 
autoimmune diabetes 
  
 We and others have demonstrated the therapeutic potential of DN T cells for 
the prevention of autoimmune diabetes development using the TCR transgenic 
setting186, 214. First, we showed that the proportion of 3A9 DN T cells was 
significantly decreased in the diabetes-susceptible CD47-deficient BALB.K mice, in 
comparison to the CD47-sufficient BALB.K mice (Appendix 1, Figure 3B). In order 
to verify whether the restoration of DN T cell number could impede autoimmune 
diabetes development, we performed a single transfer of 3A9 DN T cells from CD47-
sufficient BALB.K mice into diabetes-susceptible CD47-deficient 3A9 TCR:insHEL 
BALB.K transgenic mice. Indeed, a single transfer of DN T cells was sufficient to 
inhibit autoimmune diabetes development (Appendix 1, Figure 8). These results 
paved the way for the investigation into the therapeutic potential of DN T cells in 
non-transgenic mice. 
 
 As diabetes-susceptible CD1d-deficient NOD mice exhibit a deficiency in DN 
T cell number in comparison to diabetes-resistant mice (Article 2, Figure 1), we next 
wanted to determine whether the restoration of DN T cell number in diabetes-
susceptible mice prevented disease development in the non-transgenic setting. Due to 
the low number of DN T cells, in vitro cellular expansion is necessary in order to 
obtain a sufficient number of DN T cells. Furthermore, the expansion of DN T cells 
in vitro prior to their transfer is in line with the therapeutic protocol envisioned for 
the treatment of autoimmune diabetes in patients using DN T cells. Indeed, in human 
diabetic patients, the use of autologous DN T cells, thus cells originating from the 
recipient, would circumvent the need for immunosuppressive agents as the DN T 
cells would not undergo rejection. However, the transfer of isolated DN T cells back 
to the patient would not result in an increase in the proportion of DN T cells within 
this particular individual without an intermediate step of cellular expansion to 
increase their number. Essentially, the therapeutic protocol envisioned for DN T cells 
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in the treatment of autoimmune diabetes involves the isolation of DN T cells from the 
blood of the affected individual, the expansion of the DN T cells in vitro, followed by 
the transfer of the expanded DN T cells back to the patient (Figure 5).  
 
 
Figure 5. Illustration of the potential adoptive DN T cell therapy protocol for the 
treatment of autoimmune diabetes in humans. Modified from 318. 
 
Therefore, the in vitro expansion of DN T cells from diabetes-susceptible mice is a 
crucial factor in the investigation into the therapeutic potential of DN T cells. 
Accordingly, DN T cells sorted from non-transgenic CD1d-deficient mice can be 
readily expanded in vitro with an average cellular expansion of approximately 90-
fold in 7 days (Article 2, Supplementary Figure 3). Furthermore, transferred DN T 
cells survive in vivo post-transfer for at least 4 weeks, as we can track the transferred 
DN T cells to the spleen, skin-draining lymph nodes, pancreatic lymph nodes, and 
mesenteric lymph nodes at 24 hours, 2 weeks and 4 weeks post-transfer (Article 2, 
Supplementary Figure 5). Based on their survival post-transfer, these results further 
demonstrate the potential for activated DN T cells in adoptive cell therapy. 
Importantly,  in comparison to non-injected or activated CD4+ T cell-injected control 
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mice (Article 2, Supplementary Figure 4) the transfer of expanded DN T cells from 
CD1d-deficient NOD mice to 12 week-old non-diabetic female NOD mice results in 
a significant reduction in the incidence of diabetes up to 32 weeks of age, (Article 2, 
Figure 3). Therefore, a single autologous transfer of expanded DN T cells is 
sufficient to significantly decrease diabetes progression.  
 
 Modifications to the protocol for DN T cell transfer may reveal an alternative 
method that results in an improved, or possible complete, inhibition in autoimmune 
diabetes development. Indeed, adjustments in the quantity of DN T cells injected as 
well as the timing of injection may prove to be beneficial. Moreover, female NOD 
mice do not all progress to autoimmune diabetes at the same age such that overt 
diabetes is observed beginning at 12-14 weeks of age with approximately 80% of 
mice developing the disease by 30 weeks of age128, therefore it is possible that a 
single injection at 12 weeks of age is either too early or too late with regards to DN T 
cell impact on autoimmune diabetes initiation. Therefore, modifying the frequency of 
DN T cell transfers from a single transfer to multiple transfers may improve the 
inhibition of disease development as multiple transfers would cover a greater span of 
time/age resulting in an enhanced window of opportunity for the immunotherapeutic 
action of DN T cells. Furthermore, as non-transgenic DN T cells express a polyclonal 
TCR repertoire169 (and Appendix 2) and thus only a fraction are potentially specific 
for islet antigens, the use of islet-antigen specific, rather than polyclonal activation, 
DN T cells could also prove to be favourable. Indeed, we could expand DN T cells in 
vitro in the presence of irradiated antigen-presenting cells and pancreatic islet lysates, 
which would serve as the source of islet antigen. As such, only DN T cells that 
recognize and are specific for islet antigens would be activated and proliferate. As a 
result, we would obtain a population of DN T cells that have the potential to be more 
effective as they are specific to antigens expressed in the pancreas. Altogether, the 
sum of these factors merit further investigation.  
 
 Interestingly, two other groups230, 262 have investigated the ability of DN T 
cells to prevent autoimmune diabetes in non-transgenic mice, as mentioned in 
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Section 1.6.4.6. However, for both studies, either the DN T cells were not void of 
contaminating NK T cells230, 262 or the therapeutic potential of DN T cells was tested 
using a lymphopenic system 230. Conversely, our study uses CD1d-deficient mice, 
which are void of all NK T cells, as well as non-lymphopenic NOD mice. Therefore, 
our findings are the first to show that non-transgenic, uncontaminated DN T cells 
inhibit autoimmune diabetes development in non-lymphopenic NOD mice.  
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4.4. The in vivo mechanism of action of non-transgenic DN 
T cells 
 
 To our knowledge, there exists only one published study to date which has 
investigated the cellular target of non-transgenic DN T cells in vivo. Accordingly, 
using a cardiac xenotransplantation model, Ma, Y and colleagues demonstrated that 
the transfer of perforin-sufficient, not perforin-deficient, DN T cells led to an increase 
in graft survival, which correlated with an increase in B cell apoptosis as well as a 
decrease in anti-donor total IgG and IgM antibody production and IgG graft 
deposition 256. Together, this study demonstrated that the transfer of non-transgenic 
DN T cells leads to an increase in B cell apoptosis in vivo, which is dependent on the 
perforin pathway, as well as an associated decrease in anti-donor IgM and IgG 
antibody levels.  
 
 Our findings using the 3A9 TCR:insHEL transgenic model have further 
corroborated these results as we have shown that diabetes-susceptible CD47-deficient 
BALB.K TCR: insHEL mice that received a single transfer of 3A9 DN T cells from 
CD47-sufficient BALB.K 3A9 TCR mice exhibited a significant reduction in 
antigen-specific anti-HEL IgG, but not IgM, autoantibody serum levels in comparison 
to mice that did not receive DN T cell transfer (Appendix 1, Figure 8B,C).  These 
results further suggest that DN T cells eliminate B cells in vivo via an antigen-
specific mechanism, which is analogous with our in vitro observations (Article 1, 
Figure 2 and Article 2, Figure 2). In order to validate the cytotoxic function of 3A9 
DN T cells towards B cells in vivo, immunodeficient Rag-/- mice, that lack both B 
cells and T cells, were first injected with a 1:1 ratio of activated B cells loaded with 
HEL or ovalbumin (OVA) protein, then, 24 hours later were injected with 3A9 DN T 
cells. Mice that did not receive a transfer of DN T cells still demonstrated a 1:1 ratio 
of cells loaded with HEL or OVA in the spleen, however, mice that did receive a 
transfer of 3A9 DN T cells exhibited a drastic decrease in B cells presenting HEL but 
not of those presenting OVA, a protein which is not recognized by the TCR 3A9 
(results generated by Véronique Dugas, unpublished data). These results further 
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validate that 3A9 DN T cells eliminate B cells in an antigen-specific manner in vivo. 
Altogether, B cells remain the only target of DN T cells to be validated in vivo. 
 
 As DN T cells impeded autoimmune diabetes in otherwise diabetes-
susceptible NOD mice and have been shown to target B cells in vivo (256 and 
Appendix 1, Figure 8), we hypothesized that DN T cells migrated to the pancreas 
where they could eliminate autoreactive B cells. Indeed, autoreactive B cells are 
defined by their ability to produce autoantibodies and present self-antigens to 
autoreactive T cells thereby activating them (Figure 6), both of which are implicated 
in autoimmune diabetes development. Therefore, the elimination of such autoreactive 
B cells could explain the inhibition of autoimmune diabetes following DN T cell 
transfer. Indeed, the transferred DN T cells could be tracked to the pancreatic lymph 
nodes as early as 24 hours, and for at least 4 weeks, post-transfer where we observed 
a preferential accumulation of the transferred DN T cells in comparison to both the 
skin-draining and mesenteric lymph nodes (Article 2, Supplementary Figure 5). 
This accumulation correlated with a higher proportion of transferred DN T cells 
expressing the activation marker CD69 (Article 2, Figure 4B) and having entered 
cellular division, demonstrated by carboxyfluorescein succinimidyl ester (CFSE) 
staining (Article 2, Figure 4C). Together with our findings that non-transgenic DN T 
cells exhibit an activated phenotype ex vivo (Article 2, Supplementary Figure 2), 
which is representative of an ability to recognize self-antigens, and their ability to kill 
B cells presenting islet antigen (Article 2, Figure 2B), these results suggest that DN 
T cells recognize islet antigens presented in the pancreatic lymph node thus inducing 
their preferential activation, proliferation and accumulation at this site.  
 
Figure 6. Representation of the roles of autoreactive B cells in autoimmune disease, 
such as autoimmune diabetes. Modified from 319. 
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 As autoimmune diabetes is caused by the destruction of pancreatic insulin-
producing β cells, we next wanted to determine whether transferred DN T cells could 
impede the autoreactive response directly within the pancreatic islets. Indeed, we can 
track DN T cells to the pancreatic islets post-transfer (Article 2, Figure 5B). 
Moreover, a higher proportion of CD1d-deficient NOD DN T cells express the 
chemokine receptor CXCR5 in the pancreatic lymph nodes in comparison to the 
spleen and skin-draining lymph nodes (Article 2, Figure 5A), where CXCR5 is 
required for homing into germinal centers320, 321. Accordingly, the transfer of 
activated DN T cells leads to a decrease in the proportion of germinal center B cells 
directly within the pancreatic islets, which are represented by the expression of GL7, 
which is a marker of T and B cell activation but is mostly used as a marker of 
germinal center B cells, and Fas antigen (CD95) (Article 2, Figure 5C). As germinal 
centers are the site of the generation of antibody-producing plasma cells (further 
discussed below), we decided to investigate the serum levels of IAA. Indeed, we 
observed that mice that had received a transfer of DN T cells exhibited a decrease in 
serum IAA levels whereas mice that received a transfer of CD4+ T cells exhibited an 
increase in serum IAA levels (Article 2, Figure 5D), demonstrating that the decrease 
in IAA levels is specific to DN T cells. Therefore, the decrease in germinal center B 
cells correlates with a decrease in serum IAA levels, suggesting a decrease in 
autoreactive germinal center B cells recognizing islet antigen such as insulin. 
Although it is tempting to conclude that DN T cells eliminate germinal center B cells 
in vivo, a true appreciation of the complexity of germinal center formation makes this 
assumption less definite.  
  
 Germinal centers develop within the B cell follicles and are the site of B cell 
maturation (Reviewed in 81, Figure 7). Indeed, B cells are activated following their 
encounter with cognate antigen, which usually occurs within the T cell zone of 
lymphoid organs by interaction with T helper cells and dendritic cells.  Activated B 
cells then migrate into B cell follicles, start to proliferate and differentiate into 
centroblasts, thereby establishing germinal centres. The proliferating centroblasts 
activate the process of somatic hypermutation thus generating antibody variants. 
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Once the centroblasts have stopped proliferating, they are known as centrocytes, 
which are selected for based on the high affinity of their B cell receptor for the 
cognate antigen. Germinal center B cells will then compete for survival signals from 
follicular DCs and T cells in order to escape the default apoptosis pathway of 
germinal centre B cells. Selected germinal center B cells will undergo repeated 
rounds of proliferation, mutation and selection. The immunoglobulin genes of many 
germinal center B cells also undergo remodelled by isotype switching in order to 
increase their affinity for the cognate antigen. Finally, the B cells will differentiate 
into either plasma cells able to secrete large quantities of antibody or memory B cells 
that can be reactivated in subsequent contacts with the same antigen, both of which 
can now exit the germinal center. 
 
 
 
 
 
 
Figure 7. Representation of the B cell developmental pathways in the germinal 
center. Adapted from 322. 
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 Therefore, these results demonstrate that the transfer of DN T cells to 
diabetes-susceptible NOD mice correlates with a reduction in germinal center B cells 
as well as autoantibody-producing plasma cells directly within the pancreatic islets, 
which could be explained by a direct elimination of plasma cells and/or germinal 
center B cells. Indeed, the elimination of autoreactive germinal center B cells would 
lead to a consequential decrease in autoantibody-producing plasma cells, which 
draws a parallel to our findings. However, as illustrated in Figure 8, the elimination 
of either follicular DCs or T cells that provide survival signals to germinal center B 
cells would also ultimately result in the decrease in both germinal center B cells and 
differentiated plasma cells. Therefore, we cannot conclude on whether the reduction 
in germinal center B cells is a direct or indirect consequence of DN T cell transfer. 
The investigation into the exact target of DN T cells in vivo as well as their 
mechanism of action merits further investigation. The possible cellular targets of DN 
T cells whose elimination would result in a decrease in autoantibody levels is 
illustrated in Figure 8. 
 
 Altogether, the transfer of DN T cells leads a preferential activation and 
accumulation of transferred DN T cells within the pancreatic lymph nodes suggesting 
that DN T cells recognize self-antigen presented within the pancreatic lymph node, a 
proposition that corresponds with our findings that DN T cells eliminate B cells 
presenting islet antigens and express an activated phenotype ex vivo. Transferred DN 
T cells can also migrate to the pancreatic islets, which results in a decrease in both the 
proportion of germinal center B cells as well as serum IAA levels. These results 
correlate with our finding that DN T cells within the pancreatic lymph nodes express 
the germinal center homing receptor, CXCR5, demonstrating that DN T cells can 
indeed migrate to the germinal center, the site of both germinal center B cells and the 
generation of antibody-producing plasma cells.  
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Figure 8. Working hypothesis of possible cellular targets of DN T cells leading to a 
decrease of antigen-specific antibody levels in vivo. The above diagram represents 
the possible targets of DN T cells in vivo, any of which would ultimately lead to a 
decrease in antigen-specific antibody levels. As is seen above, possible targets of DN 
T cells include dendritic cells (DC), plasmablasts, memory B cells, plasma cells and 
T cells as well as follicular DC (FDC), germinal center (GC) B cells and follicular 
helper T  (TFH) cells within the germinal center. The DN T cells may lyse target cells 
through the release of perforin and granzymes, illustrated by the red arrows, or induce 
apoptosis through the Fas pathway, indicated by the yellow arrows. Modified from 
323. 
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4.5 Conclusion and future perspectives 
 The main objective of this thesis project was to determine whether the 
restoration of DN T cell number in non-transgenic mice prevents diabetes onset in 
otherwise diabetes-susceptible mice and, thus, may be of therapeutic interest for 
autoimmune diabetes in humans. Here, we showed that diabetes-resistant mice 
present with a higher proportion and cell number of DN T cells than diabetes-
susceptible mice in the non-transgenic setting, which associates a deficiency in DN T 
cell number with autoimmune diabetes susceptibility. We also determined that DN T 
cells eliminate activated B cells in vitro via a perforin/granzyme-dependent pathway. 
Importantly, the function of DN T cells is equal between the diabetes-resistant and -
susceptible mice, demonstrating that the association to autoimmune diabetes is due to 
a deficiency in DN T cell number rather than function. We established that the 
transfer of activated DN T cells could prevent autoimmune diabetes development in 
the non-transgenic setting, where the transfer of DN T cells correlates with a decrease 
in germinal center B cells and serum IAA levels. These results draw a parallel with 
our finding that DN T cells can migrate to both pancreatic lymph nodes and islets and 
that DN T cells can eliminate B cells presenting islet antigen in vitro. We thus 
propose that DN T cells either directly eliminate germinal center B cells presenting 
islet antigen in vivo or other cell populations involved in the maturation of 
autoreactive B cells in the germinal center, such as follicular dendritic cells or T cells. 
 
 DN T cells are of particular therapeutic interest for autoimmune diabetes 
because they inhibit immune responses in an antigen-specific manner (Article 1, 
Figure 2 and reviewed in 156, Hillhouse, E.E., Lesage, S., 2012). Interestingly, Tregs 
can also inhibit Ag-specific proliferation of target cells that are specific for the same 
antigen227, 324, 325.Moreover, this immunoregulatory function of Tregs is hindered in 
the absence of their cognate antigen. However, Tregs are also capable of mediating 
suppression in an antigen non-specific manner227, 324, 325. Indeed, antigen-specific 
Tregs are able to suppress target T cells of a different antigen specificity, but only in 
the presence of the cognate antigen of the Tregs325. Accordingly, once the Tregs are 
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activated by their cognate antigen, their suppressive function becomes antigen non-
specific325. Therefore, Treg suppression is dependent upon the presence of its cognate 
antigen, however, once activated, Tregs can mediate their suppressive function in 
both an antigen-specific and -non-specific fashion. In addition, Tregs can also inhibit 
tumor-specific effector cells, where tumor immunity can be enhanced in the absence 
of Tregs272, 274, while DN T cells have been demonstrated to promote tumor 
immunity267, 277. Altogether, DN T cells are a better option as a cellular therapeutic 
agent as they inhibit immune responses in an antigen-specific manner while 
maintaining tumor immunity. 
 
 Due to their antigen-specific immunoregulatory function, the use of DN T 
cells in immunotherapy should lead to fewer side-effects along with a decreased risk 
of infections, which remains a major concern in the application of broad 
immunosuppressive regimens. The use of antigen-specific immunoregulatory DN T 
cells may eventually present itself as an alternative strategy to broad 
immunosuppressive regimens that lead to undesired side-effects, such as the 
rituximab treatment, which depletes all B cells as opposed to activated antigen-
specific B cells76, 326. Moreover, the ability to readily expand DN T cells in vitro prior 
to their autologous transfer back to the patient evades the need for 
immunosuppressive drugs, which can dampen the immune response against infection 
and cancer. Therefore, DN T cells demonstrate key aspects for a successful cellular 
therapy. 
 
 Interestingly, Serreze and colleagues recently published an article 
demonstrating that B cells downregulate their expression of CD20 following their 
entry into pancreatic islets327.  Consequently, anti-CD20 treatment, also known as 
rituximab, which has shown promising results in early clinical trials for autoimmune 
diabetes reversal 76, is unable to eliminate B cells found directly within the islets327. 
Therefore, there are currently no treatments that can efficiently eliminate B cells 
directly within pancreatic islets where pancreatic β cell destruction occurs. The 
findings from this thesis demonstrate that the transfer of DN T cells decreases the 
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proportion of germinal center B cells directly within pancreatic islets, suggesting that 
DN T cells could be more effective than anti-CD20 treatment at abrogating the local 
inflammatory autoimmune response. Therefore, DN T cells exhibit the potential to 
become a novel cellular therapeutic agent for the treatment of autoimmune diabetes 
or, alternatively, can be combined with current therapies, such as anti-CD20 
treatment, to generate optimal outcomes. 
 
 Overall, DN T cells exhibit the potential to be used for various facets of 
autoimmune diabetes in humans. Based on our results, DN T cells demonstrate the 
therapeutic potential to be used for prevention and/or delay of autoimmune diabetes 
development in at-risk patients. Future studies investigating whether the transfer of 
DN T cells can reverse autoimmune diabetes in new-onset diabetes-susceptible mice 
will allow us to determine whether DN T cells also demonstrate a potential for the 
treatment of recently diagnosed autoimmune diabetes patients. Due to their 
immunoregulatory and antigen-specific function, it is also possible that DN T cells 
may also serve to replace the immunosuppressive agents that are used to promote 
islet cell and pancreas transplant survival. Importantly, DN T cell transfer results in a 
decrease in antigen-specific autoantibody levels214 (Article 2, Figure 5D), suggesting 
that autoantibodies can serve as a biomarker for the efficiency of DN T cell therapy. 
Indeed, the evaluation of autoantibody levels following treatment would allow for the 
modification in the course of the treatment, such as additional transfers or an increase 
in the amount of DN T cells injected. If the DN T cell treatment showed no signs of 
being effective for a particular patient, which is possible as all patients are different, 
the ability to evaluate the efficiency of DN T cell treatment via autoantibody levels 
would allow for a rapid change in the patient's form of treatment.  Lastly, as a low 
proportion of DN T cells is associated with autoimmune diabetes susceptibility in 
non-transgenic mice (Article 2, Figure 1) which are more physiologically relevant to 
humans, we propose that DN T cell proportion can serve as a biomarker to facilitate 
the identification of individuals at risk of developing autoimmune diabetes. 
Altogether, DN T cells exhibit the potential to be used for the treatment and diagnosis 
of diabetic patients. 
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 Following from the results presented in this thesis, we believe that it is timely 
to begin the translation to human DN T cell studies. Although human DN T cells 
have been investigated by other groups169, 238, they have not been investigated in the 
context of autoimmune diabetes. Indeed, it will be important to validate our results 
and to verify whether human DN T cells exhibit similar properties as murine DN T 
cells. Accordingly, it will be interesting to verify whether diabetic patients present 
with fewer DN T cells than otherwise healthy individuals and whether these DN T 
cells are indeed functional. Importantly, we have already commenced the study of 
human DN T cells. Indeed, we have demonstrated that we are able to efficiently 
isolate human DN T cells (Article 2, Figure 6A). Following their expansion in vitro, 
we have shown that human DN T cell both exhibit cytotoxic potential (Article 2, 
Figure 6B) as well as demonstrate cytotoxic activity towards B cells in vitro (Article 
2, Figure 6C). Importantly, we are the first to demonstrate that human DN T cells 
can target B cells in vitro, demonstrating a functional similarity between murine and 
human DN T cells. Nevertheless, due to a lack of a specific marker for the 
discrimination of DN T cells from type II NKT cells, we believe that it is crucial to 
invest into the identification of a cell marker for human DN T cells. This will not 
only ensure the purity of the human DN T cell population but will also facilitate their 
isolation and subsequent study. 
 
 In conclusion, we have demonstrated the impact of DN T cell proportion on 
autoimmune diabetes progression in non-transgenic NOD mice, elucidated the 
cellular mechanism by which DN T cells impede autoimmune responses in vivo and 
commenced the characterization of human DN T cells, all key aspects for the 
development of future therapeutic approaches. Therefore, the results presented in this 
thesis have paved the way for additional studies on the therapeutic potential of DN T 
cells for the treatment of autoimmune diabetes as well as other diseases of the 
immune system, such as GVHD and cancer (reviewed in 259, Hillhouse, E.E., Delisle, 
J.S. & Lesage, S., 2013). 
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Abstract 
 
CD47 and signal regulatory protein (SIRP) interactions have been proposed to take 
part in autoimmune disease susceptibility. Importantly, a recent genome wide 
association study for type 1 diabetes susceptibility highlighted the association of the 
20p13 region comprising the SIRP cluster, where some of the SIRP proteins encode 
functional ligands to CD47. Using a TCR transgenic mouse model at the brink of 
autoimmune disease, we demonstrate that CD47-deficiency is sufficient to break the 
immune tolerance and provoke the onset of autoimmune diabetes. Interestingly, 
CD47-deficient mice show a severe reduction in the number of mature CD4-CD8- T 
cells, and passive transfer of these CD4-CD8- T cells is sufficient to restore immune 
tolerance and prevent diabetes progression. Together, these findings constitute an in 
vivo demonstration that CD47 is involved in diabetes susceptibility and controls the 
homeostatic regulation of CD4-CD8- T cells.  
 
 
Keywords: T cells, tolerance, autoimmune diabetes, transgenic mice, CD47, signal 
regulatory protein 
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Introduction  
 
CD47 is a ubiquitously expressed atypical protein which encodes for five 
transmembrane domains that interact in cis with integrins to form a complete seven 
transmembrane complex, which signals through G-proteins [1]. CD47 is involved in 
various immunological processes, including apoptosis, phagocytosis, cell migration 
as well as T cell responses [1-12]. Particularly, CD47 ligation with either antibodies 
or its physiological ligand potentiates T cell activation [5-7]. The cellular ligands for 
CD47 include members of the signal-regulatory protein (SIRP) family, SIRP and 
SIRP [13, 14]. CD47 also interacts with thrombospondin, although this latter 
interaction is currently the subject of debate [14, 15].  
 
SIRP compose a family of genes, including SIRP, SIRP and SIRP proteins, which 
have most probably arisen as a consequence of gene duplication [16]. Their 
extracellular domains are highly homologous and are characteristic of the 
immunoglobulin superfamily, while their intracellular domains, and consequently 
their signaling, are very divergent [17]. Indeed, the SIRP family is defined as “paired 
receptors”, having both activating and inhibitory receptors [13, 18]. Of interest, the 
cellular expression and function of these CD47 ligands also differs. The biological 
function of the highly polymorphic SIRP protein has been most extensively studied 
in myeloid cells, where it is expressed [2, 7, 17]. Alternatively, SIRP expressed on T 
cells and NK cells, has been revealed as an important modulator of T cell responses 
[3, 19-21]. Thus, both CD47 and SIRP are known to influence T cell responses. 
 
More recently, CD47-SIRP interactions have been proposed to take part in T cell-
mediated autoimmune disease susceptibility. For instance, animals lacking the 
intracellular domain of SIRP become resistant to the development of a myelin 
oligodendrocyte glycoprotein peptide-induced EAE and collagen-induced arthritis 
[22, 23], whereas CD47-deficiency facilitates the progression of autoimmune 
hemolytic anemia in mice [24, 25]. In addition, autoimmune diabetes linkage studies 
in rat and mice have revealed respective associations with Iddm27 and Idd13, two 
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genetic loci encompassing the highly polymorphic Sirp gene [17, 26-28]. Moreover, 
a recent genome-wide association study for type 1 diabetes susceptibility in humans 
highlighted the association of the 20p13 region comprising the SIRP cluster [29]. 
Importantly, based on linkage disequilibrium (LD), the SIRP cluster contains three 
genes, namely SIRPD, SIRPB1, SIRPG some of which are known to encode 
functional ligands to CD47 [16, 29]. Therefore, we aimed to define the contribution 
of the CD47 pathway in autoimmune diabetes. 
 
For our studies, we use a TCR transgenic mouse model at the brink of autoimmune 
disease, allowing us to reveal the impact of subtle genetic differences in the 
regulation of T cell tolerance. In this transgenic model, deletion of CD47 is sufficient 
to break the immune tolerance, provoking the onset of autoimmune diabetes. We 
previously demonstrated that T cell central tolerance mechanisms were not altered in 
TCR transgenic CD47-deficient mice [30], therefore suggesting that defects in 
peripheral tolerance were at play. Accordingly, we observe a reduction in the number 
of mature CD4-CD8- T cells in association with disease susceptibility in different 
genetic backgrounds. Interestingly, these CD4-CD8- T cells are phenotypically 
similar to immunoregulatory T cells identified by others [31-34]. Moreover, we show 
that increasing the number of CD4-CD8- T cells is sufficient to confer immune 
tolerance and impede autoimmune diabetes development. Together, these findings 
lend support to the view that the CD47-SIRP pathway is implicated in susceptibility 
to autoimmune diabetes. 
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Materials and Methods:  
 
Mice 
3A9 TCR [35] and insHEL (Hen egg lysozyme (HEL)) under the rat-insulin promoter 
a.k.a ILK-3) [36] transgenic mice on B10.Br, NOD.H2k and BALB.K backgrounds 
have been previously described [30, 37]. CD47-deficient BALB/c mice [38] were 
bred to TCR:insHEL B10.Br mice as previously described [30]. Non-transgenic 
B10.Br (#000465) and NOD (#001976) mice were purchased from The Jackson 
Laboratory. The Maisonneuve-Rosemont Hospital ethics committee overseen by the 
Canadian Council for Animal Protection approved all experimental procedures. 
 
Flow cytometry  
6–12-wk old nondiabetic mice (Diascreen negative) were analyzed. All lymphoid 
organs were passed through a sterile cell strainer. Cell counts were performed by 
trypan blue exclusion using a hemacytometer. The FITC Anti-Mouse/Rat Foxp3 
Staining Set was used for Foxp3 staining according to the manufacturer’s instructions 
(eBiosciences). Anti-clonotypic 1G12 antibody recognizing the expression of the 3A9 
TCR [39] was used as a culture supernatant and detected using APC-labelled X56 
from BD. Anti-CD25 antibody was purchased from Caltag. All other antibodies were 
purchased from Biolegend. CD1d tetramer is a generous gift from Dr. David Serreze. 
Data was collected on a FACSCalibur (BD Biosciences), cells were sorted on a 
FACSVantage (BD Biosciences) and all data was analyzed with FlowJo software 
(Treestar). 
 
Proliferation and suppression assays 
To measure the extent of T cell proliferation, sorted CD4 and DN T cells were 
labeled with 2M CFSE (Invitrogen, [40]) and washed twice in cold RPMI 
containing 10% FCS prior to culture. They were stimulated in vitro (250 000 
cells/ml) for three days in the presence of irradiated T-depleted splenocytes (2.5 Gy, 
250 000 cells/ml) and anti-CD3 (1g/ml), with or without IL-2 (30 U/ml). To 
quantify the potential of Tregs at suppressing CD4 T cell proliferation, CD4+CD25- 
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effectors cells were sorted and labeled with CFSE as above, and cultured for 3 days in 
presence of the indicated ratio of CD4+CD25hi Tregs or CD4+CD25- control 
effector cells.  
Diabetes monitoring 
The diabetes incidence was monitored every two weeks using Diascreen, where 
diabetic mice were positive for two consecutive tests and showed blood glucose 
levels above 17mM. To evaluate the role of CD4-CD8- (double negative, DN) T 
cells, spleen and peripheral lymph nodes cells were obtained from BALB.K TCR 
mice. Where mentioned, DN T cells were enriched using EasySepTM biotin selection 
kit, efficiently removing >95% of CD4+ (RM4-5), CD8+ (53-6.7) and B cells 
(CD45R, RA3-6B2). More than 50% of the remaining cells were positive for 1G12 
expression. 10 million enriched DN T cells or 10 million selected CD4+ T cells 
(purity 95%) were then injected i.v. in non-diabetic (diastix negative) 9 week-old 
CD47-/- BALB.K TCR:insHEL mice. Alternatively, 6 week-old non-diabetic CD47-/- 
BALB.K TCR:insHEL mice were injected with 2 million sorted DN T cells. Sorted 
1G12+ DN T cells purity was above 90%. Serum was collected from diabetic mice 
(showing two consecutive Diascreen positive tests and blood glucose levels above 
17mM) or when mice reached 24 weeks of age. Anti-HEL IgM and IgG serum levels 
were measured by ELISA using HEL-coated plates and polyclonal goat anti-mouse 
IgM and IgG peroxidase conjugate antibodies (Calbiochem). 
 
Phenotyping and quantifying DN T cells in non-transgenic mice 
Phenotyping of non-transgenic DN T cells from the spleen and lymph nodes of 
B10.Br and NOD mice was performed by depleting CD4, CD8, B220, CD49b and 
TCR positive cells using EasySep™ biotin selection kit. For determining the 
number of DN T cells, cell separation was not performed to avoid cell loss. The 
proportion of DN T cells was obtained by electronic gating on TCR+CD5lowCD4-
CD8-B220-CD1d tetramer- cells and multiplied by the absolute cell number in each 
organ. 
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Statistics 
Mann-Whitney U test was performed where appropriate unless otherwise specified. 
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Results: 
 
CD47-deficient mice are prone to autoimmune diabetes.  
CD47-SIRP interactions regulate T cell responses [1-3, 5-7, 17] and the SIRP cluster 
has been recently associated with autoimmune diabetes progression [29]. We 
therefore elected to evaluate the impact of the CD47-SIRP pathway on diabetes onset 
in a T cell dependent model. As such, we took advantage of the TCR:insHEL 
transgenic mouse model, where the 3A9 TCR transgene recognizes a HEL peptide in 
the context of I-Ak and the insHEL transgene is expressed under the rat-insulin 
promoter [36, 37]. Accordingly, TCR:insHEL transgenic mice carry a significant 
number of autoreactive T cells [36, 37]. This model should thus help reveal the 
impact of subtle genetic differences in the regulation of T cell tolerance.  
 
In humans, both SIRP and SIRP bind to CD47, while the ligand for SIRP has not 
been defined [13, 17]. Murine SIRP also binds to CD47; however mice do not 
express SIRP [3]. To effectively disrupt the CD47-SIRP pathway and determine its 
impact on autoimmune disease progression, we monitored the diabetes incidence in 
TCR:insHEL CD47-deficient, which had been previously generated on the BALB.K 
background [30]. In this antigen-specific context, less than 20% of the TCR:insHEL 
CD47-sufficient mice developed autoimmune diabetes within 24 weeks (Figure 1). In 
contrast, within this same time frame, the incidence of diabetes reached 90% in 
TCR:insHEL CD47-deficient mice. Moreover, the onset of disease occurred much 
earlier in CD47-deficient mice, where the first diabetic mice appeared at 6 weeks as 
opposed to 15 weeks of age in CD47-sufficient mice (Figure 1). Together, these data 
highlight an important role for the CD47 pathway in the regulation of immune 
tolerance in a T-cell model of autoimmune diabetes. 
 
Tregs, CD4 and CD8 T cells are not influenced by the absence of CD47 
Both central and peripheral T cell tolerance defects may contribute to the 
pathogenesis of autoimmune diabetes. Although we have previously shown a defect 
in central tolerance using this TCR transgenic model on a different genetic 
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background [37], we have recently reported that CD47-deficiency does not affect 
thymic selection events in the TCR:insHEL BALB.K model [30]. Therefore, it is 
unlikely that defects in central tolerance describe the increased susceptibility to 
autoimmune diabetes in CD47-deficient mice.  
 
Subsequently, to evaluate the peripheral regulation of T cells independently of the 
previously ascribed effects of thymic negative selection processes [37], we examined 
the T cell populations in the spleen and lymph nodes of single TCR transgenic mice, 
i.e. in the absence of the insHEL transgene which causes negative selection of 
potentially autoreactive TCR transgenic T cells. As for the B10.Br and NOD.H2k 
genetic backgrounds [37], single TCR transgenic mice do not develop diabetes on the 
BALB.K genetic background (data not shown); consequently, any cellular differences 
observed by comparing CD47-deficient and –sufficient mice will reveal phenotypes 
associated with disease predisposition in the complete absence of islet inflammation. 
Moreover, the insertion of both TCR and insHEL transgenes is needed to allow 
diabetes progression, demonstrating that a sufficient number of HEL-specific T cells, 
in the presence of HEL expression in the pancreas, must be present to initiate the 
pathology. 
 
Peripheral T cell regulation is mediated at least in part by Foxp3-expressing CD4 
regulatory T cells (Tregs) known to limit auto-reactive T cell activation [41]. As a 
result, we first evaluated whether the absence of CD47 modulated the number or 
function of Tregs. By comparing 3A9 TCR clonotype (1G12)+ cells in the spleen and 
lymph nodes of TCR single transgenic CD47-deficient and –sufficient mice, we 
observed no significant difference in the proportion of Tregs or in their potential to 
inhibit in vitro CD4 T cell proliferation (Figure 2a and 2b). Indeed, CD47-deficient 
Tregs from 3A9 TCR transgenic mice were at least as efficient as those from CD47-
sufficient mice at inhibiting CD4 T cell proliferation, monitored by the extent of 
CFSE dilution. These results support previous findings demonstrating that neither the 
quantity nor the function of Tregs is reduced in CD47-deficient non-transgenic mice 
[42]. Rather, Tregs appear to slowly accumulate with age in CD47-deficient mice 
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[42]. Together, these data suggest that the increased susceptibility to autoimmune 
diabetes in CD47-deficient mice cannot be attributed to a defect in Treg homeostasis 
or function.   
 
Secondly, we showed that the proportion, the absolute number and activation markers 
of either CD4 or CD8 T cells were not altered in peripheral lymphoid organs of TCR 
transgenic CD47-deficient mice when compared with CD47-sufficient mice (Figure 
2c, Table I and data not shown). Together, these data suggest that the T cell pool is 
not affected by the absence of the CD47 molecule. 
 
Decreased proportion of CD4-CD8- T cells in CD47 deficient mice. 
Yet, while analyzing the CD4 and CD8 T cell subsets, we observed a high number of 
TCR clonotype 1G12+ cells lacking both CD4 and CD8 expression (Figure 3a). 
Indeed, approximately 50% of TCR clonotype 1G12+ cells were CD4-CD8-, revealing 
the presence of non-conventional T cells (Figure 3a). Almost 5% of total spleen cells 
and an astounding 15% of total lymph nodes cells were CD4-CD8-1G12+ (Figure 3b). 
We hereafter refer to these cells as double negative T (DN T) cells. More importantly, 
DN T cells were severely reduced in TCR CD47-deficient mice when compared with 
CD47-sufficient mice (Figure 3b). Finally, similar results were obtained in 
TCR:insHEL mice, where the number of DN T cells was also significantly lower in 
the absence of CD47 (data not shown). These results suggest that CD47 is associated 
with the homeostatic regulation of DN T cells. 
 
Elevated DN T cell numbers are associated with diabetes resistance.  
Hitherto, our results show that CD47-deficiency accelerates autoimmune diabetes 
progression and is associated with a reduced number of DN T cells in pre-diabetic 
mice. To determine whether elevated DN T cell number is associated with diabetes 
resistance, we investigated the proportion of DN T cells in two other genetic 
backgrounds. The proportion and number of DN T cells was comparable for both 
diabetes-resistant TCR B10.Br and BALB.K mice in the spleen and lymph nodes 
(Figure 4a, Table II). Moreover, both the diabetes-prone TCR NOD.H2k and CD47-
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deficient BALB.K mice show a severe reduction in DN T cell proportion and number 
(Figure 4a, Table II). Interestingly, similar to CD47-deficient and -sufficient mice, 
the TCR transgene on B10.Br and NOD.H2k backgrounds did not impact the 
proportion of CD4 and CD8 T cell subsets (Figure 4b). Finally, the discrepancy in 
DN T cell number between the B10.Br and NOD.H2k strains was also apparent in 
TCR:insHEL transgenic mice (Figure 4c). Thus, we find elevated DN T cell numbers 
in both diabetes-resistant TCR B10.Br and BALB.K CD47-sufficient mouse models 
and low DN T cell numbers in both diabetes susceptible TCR NOD.H2k and BALB.K 
CD47-deficient mouse models. Taken together, these results suggest that elevated DN 
T cell number is associated with autoimmune diabetes resistance. 
 
Phenotypic characterization of DN T cells. 
Immunoregulatory DN T cells have been previously described by others [31, 32]. 
These cells are rare in non-transgenic mice [43, 44] and humans [34]. Interestingly, 
the insertion of TCR transgenes has been shown to increase the proportion of DN T 
cells in many different models, including the HY-TCR, the 4E3-TCR, the 1H3.1 and 
the 2C-TCR transgenic mice [31, 32, 45-48]. Similarly, we have found that the 
proportion of DN T cells is considerably increased in the context of the 3A9 TCR 
transgene (Figure 3). As a sizeable proportion of DN T cells can be found in TCR 
transgenic mice, it is not surprising to find that the most extensive characterization of 
this cell type has been performed using the TCR transgenic settings [31, 32, 46]. We 
compared the phenotype of the 3A9 TCR transgenic T cells to these 
immunoregulatory DN T cells. 
  
Similar to the immunoregulatory 2C TCR transgenic DN T cells as well as the IH3.1 
DN T cells, those obtained in the 3A9 TCR transgenic mice are anergic and the 
anergy can be reversed upon addition of IL-2 [32, 46, 49] (Figure 5). Moreover, DN 
T cells from 2C, IH3.1 and 3A9 TCR transgenic mice exhibit a comparable 
phenotype, in that they express low levels of CD44, are negative for CD25, CD69, 
CD122 and Foxp3  expression and show high levels of Ly6A  [31, 32, 46, 50, 51] 
(Figure 6a). We performed additional phenotypic characterization and demonstrate 
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that 3A9 TCR transgenic DN T cells express many naïve T cell markers such as CD3, 
CD62L and CD45RB at levels comparable to CD4 T cells from TCR transgenic mice 
and low levels of CD5 [46, 52] (Figure 6b). Therefore, the CD4-CD8-1G12+ subset 
found in the 3A9 TCR transgenic mice defines a naïve T cell type and carries a 
similar phenotype to the previously defined immunoregulatory DN T cell subset.  
 
DN T cells are reduced in number in non-transgenic autoimmune prone NOD 
mice. Insertion of TCR transgenes are known to alter the homeostatic regulation of 
various T cell subsets [53]. We thus aimed to verify whether the increased number of 
DN T cells is associated with autoimmune diabetes resistance in a non-transgenic 
setting. We took advantage of the phenotypic characterization performed on TCR 
transgenic DN T cells to identify the rare DN T cells in non-transgenic mice. Spleen 
and lymph node cells from B10.Br and NOD mice were selected for lack of CD4, 
CD8, DX5, B220, and TCR expression (purity >95%). Up to 25% of this enriched 
cellular population are shown to express high levels of TCR, the majority of which 
do not stain for the CD1d-tetramer, thereby excluding potential contaminating CD4-
CD8- NKT cells from the analysisFigure 7a and data not shown) Finally, similar to 
the observations made for TCR transgenic DN T cells, these non-transgenic DNT 
cells showed a low level of CD5 expression (Figure 7a). Therefore, DN T cells can 
clearly be identified in a non-transgenic setting.  
 
As autoimmune-prone TCR transgenic mice show a severe reduction in the 
proportion of DN T cells, we quantified the proportion of DN T cells in H-2g7 non-
transgenic NOD mice. Our data demonstrate at least a three-fold reduction in DN T 
cell number in non-transgenic NOD mice when compared to diabetes-resistant 
B10.Br (Figure 7b). This result further supports the view that low DN T cell 
proportion is associated with diabetes susceptibility. 
 
DN T cells are sufficient to restore diabetes resistance.  
We next aimed to determine whether DN T cells were directly implicated in 
resistance to diabetes progression. We selected a group of 23 TCR:insHEL transgenic 
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CD47-deficient BALB.K mice, which tested negative for urine glucose (Diascreen) at 
9 weeks of age. Nine of these mice received 10 million DN T cells and the cohort of 
23 mice was monitored for diabetes incidence. At 24 weeks of age, only 1/9 mice 
which had received DN T cells was hyperglycemic, as compared to 11/14 in non-
injected animals (Figure 8a). As a control, 2 mice were injected with 10 million 
CD4+ T cells from TCR transgenic BALB.K mice and 1 of these became diabetic 
before 24 weeks (Table III). Moreover, to exclude the possibility that contaminating 
cells found in the DN T cell preparation were responsible for conferring protection 
from diabetes progression, we generated an additional cohort of mice, which were 
instead injected with 2 million DN T cells sorted to high purity. All of the four mice, 
injected at 6 weeks of age, have maintained low urine and blood glucose levels 
(Table III).   
 
Furthermore, we have previously shown that, in the TCR:insHEL model, anti-HEL 
IgG antibody levels correlate with diabetes susceptibility in other genetic 
backgrounds [37]. We thus quantified the HEL specific auto-antibodies in 
TCR:insHEL CD47-deficient mice, which had, or had not, received DN T cells. 
Levels of serum anti-HEL IgM auto-antibodies were similar between both groups 
(Figure 8b). Interestingly, DN T cell transfer in TCR:insHEL CD47-deficient mice 
not only protected the mice from diabetes progression but these recipients also 
showed a lower level of serum anti-HEL IgG auto-antibodies (Figure 8c). Taken 
together, these results suggest that restoring DN T cell number in diabetes-prone mice 
prevents diabetes progression. 
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Discussion: 
 
T cell-mediated autoimmune diabetes progresses similarly in humans and in NOD 
mice [54]. In support of this view, genetic susceptibility to autoimmune diabetes is 
quite concordant between the two species, where the MHC, PTPN22 and CTLA-4 
genetic polymorphisms associate with disease [55]. Moreover, insulin has been 
suggested as the initiating autoantigen in both humans and mice [56-59]. Finally, the 
mouse Il2 and human CD25 genes are also both associated with increased risk, 
suggesting that the IL-2 pathway is involved in disease susceptibility [55]. Herein, we 
lend support for the implication of yet another pathway which is involved in 
autoimmune diabetes progression in both species: the CD47-SIRP pathway.  
 
CD47-SIRP interactions modulate T cell responses and have been suggested to 
contribute to T cell-mediated autoimmune pathogenesis [17, 22, 23, 29]. Using a 
TCR transgenic mouse model, we demonstrated that CD47-deficiency is sufficient to 
break the immune tolerance and promote autoimmune diabetes progression. 
Transgenic mouse models have been commonly used to validate the implication of 
other biological pathways in the progression of autoimmune diabetes. A TCR 
transgenic approach was used to verify the association of the IL-2 candidate gene, 
located within the Idd3 locus, with autoimmune diabetes susceptibility [60]. In 
addition, the role of CTLA-4 in autoimmune diabetes was evaluated using a 
transgenic mouse model for a specific CTLA-4 isoform [61]. These studies highlight 
the importance of murine transgenic systems to reveal the in vivo role of candidate 
genes and/or pathways implicated in immune tolerance and associated with human 
autoimmune diseases. 
 
The introduction of the CD47-deficiency on non-transgenic C57BL/6 or BALB/c 
background, genetically resistant to autoimmune diseases, is not sufficient to cause 
autoimmune diabetes. This is not surprising, considering the multigenic character of 
autoimmune diseases, and certainly does not preclude a role for the CD47 pathway in 
autoimmunity. Autoimmune disease predisposition is a complex genetic trait, where 
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multiple genes are associated with disease progression [62]. By definition, one gene 
is thus not sufficient to confer disease progression. For example, the MHC I-Ag7, the 
most important factor contributing to autoimmune diabetes susceptibility in NOD 
mice, is not sufficient to confer diabetes susceptibility in autoimmune resistant 
C57BL/6 mice when these mice are made congenic for the H2g7allele (a.k.a. B6.g7) 
[63]. Furthermore, in support of a role for the CD47 pathway in autoimmunity, 
CD47-deficient autoimmune-prone NOD mice were shown to develop hemolytic 
anemia [25]. CD47 expression on erythrocytes is of critical importance [24, 64], and 
CD47-deletion may embrittle the red blood cells, increasing the predisposition to 
autoimmune hemolytic anemia in a strain already highly susceptible to autoimmune 
diseases. Thus, we propose that, as for other factors associated with autoimmune 
diabetes predisposition, the CD47 pathway is one of many parameters contributing to 
autoimmune disease susceptibility. 
 
Within the CD47 pathway, it is tempting to propose SIRP as the candidate gene. 
First, CD47 is only known to bind SIRP and SIRP [14]. Second, SIRP is not 
expressed in mice [16]. Third, SIRP is located within the Idd13 and Iddm27 diabetes 
susceptibility locus in mice and rats, respectively [26, 27]. Finally, SIRP is highly 
polymorphic [28]. However, it must be noted that the polymorphisms in the human 
SIRP gene are unlikely to affect binding with CD47 [13, 14]. Moreover, the human 
genetic association to type 1 diabetes was more strongly linked to SIRP and 
appeared to exclude SIRP as a candidate gene [29]. Thus, although we have 
demonstrated that ablating CD47 is sufficient to contribute to autoimmune disease 
progression, more studies are required to resolve the exact polymorphism and protein 
interactions increasing autoimmune diabetes susceptibility.  
 
In this study, we demonstrate that the CD47 pathway influences the homeostatic 
regulation of an unconventional T cell subset (the DN T cells), where DN T cell 
transfer is sufficient to prevent diabetes progression. Immunoregulatory DN T cells 
have been previously characterized by others [31, 32], where they must be activated 
by antigen to efficiently eliminate CD8 T cells carrying the same antigenic specificity 
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[33]. Indeed, these cells can prevent skin and heart allograft as well as heart xenograft 
rejection [31, 65, 66]. Using a different TCR transgenic model, where diabetes is 
induced upon peptide and anti-CD40 challenge, DN T cells were also shown to 
confer protection from autoimmune diabetes progression [67]. Our data thus support 
and add to the findings that DN T cells protect from diabetes progression. For one, 
we demonstrate that DN T cells can prevent diabetes onset in a spontaneous model of 
diabetes. Secondly, we perform a more extensive phenotypic characterization of this 
T cell subset and show that they exhibit a similar profile to naïve CD4 T cells. 
Thirdly, we associate low DN T cell number with diabetes susceptibility in TCR 
transgenic CD47-deficient BALB.K mice and NOD.H2k mice, as well as in non-
transgenic NOD mice. Finally, we demonstrate that DN T cell transfer associates with 
lower autoantibody levels. 
 
In summary, our observations have permitted the association of a defect in the CD47 
pathway with autoimmune diabetes progression and identify at least part of the 
mechanism by which the disruption of the CD47 pathway accelerates disease onset; 
through the regulation of DN T cell number. As TCR:insHEL NOD.H2k mice carry a 
low number of DN T cells and are highly susceptible to autoimmune diabetes, it 
would be expected that introgression of the Idd13 resistance allele, which contains 
SIRPα, in this transgenic model would restore DN T cell number and confer 
protection from diabetes progression. Alternatively, DN T cell proportion could be 
monitored in humans carrying either the resistance or susceptibility allele for the 
SIRP locus genetic marker rs2281808 [29], to determine the association between the 
genotype and phenotype. Such an association would identify a novel therapeutic 
target and lead the way for a potential cellular therapy approach, where expansion of 
DN T cell numbers may protect from autoimmune disease progression. 
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Figures and Tables: 
 
 
 
 
 
 
 
Figure 1: Diabetes incidence is increased in TCR:insHEL BALB.K CD47-
deficient mice. Diabetes incidence was monitored in CD47-sufficient (n = 11) and 
CD47-deficient (n = 18) TCR:insHEL BALB.K mice. 
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Figure 2: Tregs, CD4 and CD8 T cells are not influenced by the absence of CD47 
The proportion of T cells from the spleen and lymph nodes of TCR transgenic CD47-
sufficient and -deficient BALB.K mice was determined by staining for CD4, CD8, 
1G12 and Foxp3. A) The proportion of TCR transgenic CD4+ Foxp3+ T cells (n ≥ 5) 
and B) the ability of sorted CD4+CD25hi Tregs to suppress the proliferation of CFSE-
labeled CD4+CD25- effector T cells in vitro is shown for CD47-sufficient (white) and 
–deficient (grey) TCR transgenic BALB.K mice (n = 3). C) The proportion of TCR 
transgenic CD4 and CD8 T cells in the spleen and lymph nodes are shown for CD47-
sufficient (white) and –deficient (grey) BALB.K mice (n ≥ 5). * p < 0.01, ** p < 
0.001 
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Figure 3: Decreased proportion of an unconventional cell-type in CD47-deficient 
mice. Cells were prepared as in Figure 2. A) The gating strategy used to detect CD4-
CD8-1G12+ T cells is shown for spleen (left) and lymph nodes (right).  n ≥ 5. B). The 
proportion of CD4-CD8-1G12+ is presented for the spleen and lymph nodes of each 
mouse from the indicated strains. DN T cell proportion is significantly decreased in 
CD47-deficient TCR transgenic BALB.K mice (n ≥ 5). Student’s T test * p < 0.05.  
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Figure 4: Elevated DN T cell numbers are associated with diabetes resistance. 
Cells from lymphoid organs of transgenic BALB.K, B10.Br and NOD.H2k mice were 
harvested and stained for CD4, CD8 and 1G12 expression. A) DN T cell proportion 
in TCR transgenic CD47-deficient and -sufficient BALB.K compared to TCR 
transgenic diabetes-resistant B10.Br and –susceptible NOD.H2k mice. The data is 
representative of at least three independent experiments. The bar charts demonstrate 
B) the proportion of CD4+1G12+, CD8+1G12+ and CD4-CD8-1G12+ (DN) T cells 
in the spleen and lymph nodes of TCR transgenic B10.Br and NOD.H2k mice and C) 
the proportion of CD4-CD8-1G12+ (DN) T cells in the spleen and skin-draining 
lymph nodes (LN) of TCR:insHEL transgenic B10.Br and NOD.H2k mice. The mean 
and SD of more than five mice per group is shown. * p< 0.01, ** p < 0.001 
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Figure 5: DN T cells are anergic. CFSE-labeled CD4 and DN T cells were cultured 
for 3 days with APCs (shaded); APCs and anti-CD3 (thick); or APCs, anti-CD3 and 
IL-2 (dotted). The histograms indicate the level of CFSE dilution corresponding to 
cellular proliferation. Representative of 3 independent experiments. 
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Figure 6: Phenotypic characterization of DN T cells. Spleen cells of TCR 
transgenic B10.Br mice were stained with CD4, CD8, 1G12 and various other 
phenotypic markers, as indicated. The expression of cell surface markers is indicated 
for DN T cells (CD4-CD8-1G12+, thick), CD4 T cells (CD4+CD8-, dashed) and non 
T cells (CD4-CD8-1G12-), comprising mostly B cells, shaded) were analysed for 
various cell surface markers. Histograms show expression level of A) surface markers 
characterizing immunoregulatory DN T cells and B) naïve T cell markers. 
Representative of at least three independent experiments. 
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Figure 7: Non-transgenic autoimmune-prone NOD mice show a reduction in the 
number of DN T cells. A) Cells from spleen and lymph nodes of non-transgenic 
B10.Br and NOD (I-Ag7) mice were negatively selected for CD4, CD8, CD49b, 
B220 and TCRδ expression using magnetic separation. Top panels: Cells are gated 
for TCR+ expression. The percentage of CD1d tetramer negative cells is shown. 
Bottom panels: The histograms show the level of CD5 expression on B220+ (shaded), 
CD4+ (dotted) and DN (solid) T cells. Representative of at least three experiments. 
B) Proportion of DN T cells (B220- CD4- CD8- CD1d-tetramer- TCR+ CD5low) in 
the spleen and lymph nodes of non-transgenic B10.Br and NOD mice. Student’s T 
test. * p< 0.05, ** p < 0.01 
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Figure 8: DN T cells are sufficient to restore diabetes resistance. A) Diabetes 
incidence and B) HEL-specific antibody serum levels of IgM and C) IgG are shown 
for TCR:insHEL BALB.K CD47-/- mice injected (n = 9) or not (n = 14) with DN T 
cells. * p < 0.05. 
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Table 1: Absolute numbers of CD4 1G12+ and CD8 1G12+ cells found in TCR 
transgenic CD47-sufficient and -deficient BALB.K mice. Data represents mean ±SD 
n ≥ 5 
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Table 2: Total cellularity and absolute numbers of DN T cells found in TCR 
transgenic B10.Br, NOD.H2k and CD47-sufficient and -deficient BALB.K mice. Data 
represents mean ± SD n ≥ 4 
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Table 3: Description of diabetes incidence cohorts injected either with sorted DN T 
cells or with CD4 T cells. 
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APPENDIX 2 
 
 
 
 
 
 
 
Non-transgenic DN T cells exhibit a polyclonal Vβ TCR repertoire. The spleen 
was isolated from CD1d-deficient NOD mice. DN T cells were gated based on a 
CD4-CD8-CD19-TCRβ+ phenotype. The Vβ TCR repertoire of DN T cells from 
CD1d-deficient NOD mice was assessed by flow cytometry.  Representative of two 
independent experiments. 
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APPENDIX 3 
 
 
 
 
 
 
DN T cells from diabetes-susceptible mice express higher levels of IL-10R. DN T 
cells were enriched from the spleens of 3A9 TCR B10.Br and NOD. H2k  mice and 
activated in vitro for 3 days. The histograms depict the level of expression of IL-10R. 
n=3. 
IL-10R 
Unstimulated cells 
B10.Br TCR DN T cells 
NOD. H2k  TCR DN T cells 
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